Research Report - Nikolaus-Fiebiger-Zentrum für Molekulare Medizin
Research Report - Nikolaus-Fiebiger-Zentrum für Molekulare Medizin
Research Report - Nikolaus-Fiebiger-Zentrum für Molekulare Medizin
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Nikolaus</strong>-<strong>Fiebiger</strong>-<strong>Zentrum</strong><br />
<strong>für</strong><br />
<strong>Molekulare</strong> <strong>Medizin</strong><br />
<strong>Research</strong> <strong>Report</strong><br />
2011
Publisher<br />
<strong>Nikolaus</strong>-<strong>Fiebiger</strong>-Center for Molecular Medicine<br />
Glückstrasse 6<br />
D-91054 ERLANGEN<br />
Tel.: + 49 (9131) 85 29109<br />
Fax: + 49 (9131) 85 29111<br />
Acting Director: Prof. Dr. Jürgen Behrens<br />
Email: jbehrens@molmed.uni-erlangen.de<br />
Editing and Layout<br />
Dr. Jürgen Behrens and Angela Döbler<br />
Cover Layout<br />
Angela Döbler
PREFACE<br />
Our present report covers the period from 2009 to 2012 and documents the scientific<br />
achievements at the <strong>Nikolaus</strong>-<strong>Fiebiger</strong> Center which precipitated in a number of high<br />
impact publications in both basic and applied research. The report also highlights the<br />
personal turnover at our institution. In 2011, we were pleased to welcome Prof. Dr.<br />
Dominik Müller, expert in hypertension research as the successor of Prof. von der<br />
Mark at the chair of Experimental Medicine I. Also two new IZKF junior researchers,<br />
Dr. Beate Winner and Dr. Jens Titze who have their research focus in clinical neurobiology<br />
and kidney physiology, respectively, started in 2011. They replace Dr. Reinhard<br />
Voll, now Director of the Division of Rheumatology and Clinical Immunology, Freiburg,<br />
and Dr. Michael Wiesener, now Professor at the Medical Clinic 4, Erlangen. Several of<br />
the clinical research group leaders left to take up new positions, including Dr. Falk<br />
Nimmerjahn, now Professor of Genetics, Erlangen, Dr. Diana Dudziak, now professor<br />
of Dendritic Cell Biology, Dematology, Erlangen. We are grateful to all previous and<br />
current members for their cooperation, their assistance in the organisation of the<br />
house and most importantly for contributing to the high scientific standard of our centre<br />
by their outstanding publications.<br />
The goal of our centre is to promote scientific excellence and to foster interactions between<br />
clinical and basic researcher. A number of publications in internationally distinguished<br />
and high-impact journals can be found in the individual reference lists. Moreover,<br />
the center is a meeting place for students taking courses in Molecular Medicine,<br />
Medicine and Biology and remains attractive for a large number of PhD students and<br />
PostDocs, frequently from foreign countries. Core facilities in the house, in particular<br />
the state-of-the art cell sorting facility are used by many scientists from other institutions<br />
of the University Erlangen. Altogether these various interactions contribute to the<br />
lively atmosphere of the NFZ.<br />
On behalf of the steering committee of the NFZ I would like to take the opportunity to<br />
thank the University and University Clinics for their support, the Advisory Board of the<br />
NFZ for help in evaluation our research and the many research units from the Medical<br />
Faculty for their continued interest in our house.<br />
Erlangen, August 2012 Prof. Jürgen Behrens<br />
Acting chairman of the NFZ
TABLE OF CONTENTS<br />
SCIENTIFIC ADVISORY BOARD 1<br />
GENERAL OVERVIEW 2<br />
RESEARCH UNITS 5<br />
DEPARTMENT OF EXPERIMENTAL MEDICINE I 6<br />
DEPARTMENT OF EXPERIMENTAL MEDICINE II 26<br />
DIVISION OF MOLECULAR IMMUNOLOGY 37<br />
HEMATOPOIESIS UNIT 49<br />
JUNIOR RESEARCH GROUPS 62<br />
CLINICAL PROJECT GROUPS 80<br />
TEACHING ACTIVITIES 166<br />
SEMINARS 167
SCIENTIFIC ADVISORY BOARD<br />
The scientific standard, productivity and interactions within the <strong>Research</strong> Center for<br />
Molecular Medicine are evaluated by an International Scientific Advisory Board. The<br />
members of the Board are nominated by the Medical Faculty. The board monitors and<br />
judges the quality and stringency of current and future research projects within the<br />
Center. Furthermore the Advisory Board evaluates the proposals by young clinicians<br />
for research terms and makes recommendations to the Extended Steering Committee.<br />
Prof. Dr. C. Huber<br />
Medical Clinic III<br />
Div. of Hematology<br />
University of Mainz<br />
55101 Mainz, Germany<br />
Prof. Dr. K. Knight<br />
Professor and Chair<br />
Department of Microbiology<br />
& Immunology<br />
Loyola University of Chicago<br />
Maywood, IL 60153, U.S.A.<br />
Prof. Dr. D. Heinegard<br />
Dept. Of Cell and Molecular Biology<br />
University of Lund<br />
Box 94<br />
22100 Lund, Sweden<br />
Prof. Dr. F. Melchers<br />
Max-Planck-Institute<br />
Of Infection Biology<br />
Charitéplatz 1<br />
10117 Berlin<br />
1
GENERAL OVERVIEW<br />
Overall Structure<br />
The <strong>Nikolaus</strong>-<strong>Fiebiger</strong>-Center of Molecular Medicine is a research institution of the<br />
Medical Faculty at the Friedrich-Alexander University (FAU) of Erlangen-Nuremberg.<br />
The center harbours two chairs of Experimental Medicine I and II (Connective Tissue<br />
<strong>Research</strong> and Molecular Tumor <strong>Research</strong>, respectively), a division of Molecular<br />
Immunology as part of the Department of Internal Medicine III, a division of Genetics<br />
which belongs to the Department of Genetics of the Science Faculty, as well as two<br />
junior research groups of the Interdisciplinary Clinical <strong>Research</strong> Center (IZKF) of the<br />
Medical Faculty. The intention of the research center is to strengthen biomedical<br />
research in the Medical School by stimulating cooperations between basic and clinical<br />
researchers and by giving young clinicians the opportunity to carry out competitive<br />
biomedical research projects under the infrastructure of a modern research center.<br />
The <strong>Nikolaus</strong>-<strong>Fiebiger</strong>-Center of Molecular Medicine is well equipped with modern<br />
research facilities required for cell and molecular biological research and offers a<br />
variety of biochemical, immunological and cell biological seminars, guest lectures and<br />
common graduate student seminars. Central equipment such as DNA sequencing,<br />
fluorescence activated cell sorting, confocal laser microcopy, surface plasmon<br />
resonance are accessible to all scientists and technical personell. All scientists of the<br />
center are encouraged to seek interactions and cooperations with clinicians inside and<br />
outside the center, and to participate in the maintenance of the central facilities and<br />
equipment.<br />
Steering Committee<br />
The two full professors of Experimental Medicine, the associate professor and the<br />
Speaker of the Interdisciplinary Center for Clinical <strong>Research</strong> (IZKF) are members of<br />
the Steering Committee that is responsible for the scientific and administrative<br />
organization of the <strong>Research</strong> Center. The Steering Comittee elects a speaker every 2<br />
years. Young clinicians and scientists who are members of the Medical School or the<br />
University Hospital and whose research is supported by extramural grants are<br />
encouraged to apply for a maximum of up to 3 years for research space in the center.<br />
Decisions on their applications are made by the Extended Steering Committee (see<br />
Scheme) based on recommendations of the Scientific Advisory Board. These research<br />
groups have access to all central large equipment, library, computers, isotope<br />
laboratory and other central facilities; in turn, it is expected that they will participate in<br />
research seminars, journal clubs and teaching.<br />
2
Financial Concept (Running Costs)<br />
Running costs of the <strong>Research</strong> Center (electricity, water, heating, gas, cleaning,<br />
building maintenance, salaries for central administrative and technical personell etc.)<br />
are shared by the University and the University Hospital. Running cost for central large<br />
equipment, equipment maintenance and renewal, liquid nitrogen, carbon dioxide,<br />
central computer software, library, isotope waste, dish washing, animal costs will be<br />
shared among the users.<br />
♦ Library<br />
♦ Seminar rooms<br />
Facilities and Equipment<br />
Central laboratories and facilities<br />
♦ S2 Biological Safety Laboratory<br />
♦ Isotope laboratory (S2) for experiments with 125 Iodine, 51 Cr, 45 Ca etc<br />
♦ Temporary animal rooms<br />
♦ Confocal microscope<br />
Central major equipment<br />
♦ High-speed cell sorter, analytical fluorescence-activated cell sorters<br />
♦ DNA Sequencer<br />
♦ BIAcore Surface Plasmon Resonance<br />
♦ Phosphoimager<br />
♦ Luminoimager<br />
♦ Preparative liquid chromatography (BioPerseptive)<br />
♦ Microinjection unit<br />
♦ Liquid nitrogen cell storage system<br />
4
RESEARCH UNITS<br />
� Department of Experimental Medicine I<br />
Head: Prof. K. von der Mark until 3/2011<br />
Prof. D. Müller from 4/2011<br />
� Department of Experimental Medicine II<br />
(Molecular Tumor <strong>Research</strong>)<br />
Head: Prof. J. Behrens<br />
� Division of Molecular Immunology<br />
Department of Internal Medicine III<br />
Head: Prof. H.-M. Jäck<br />
� Hematopoiesis Unit, Chair of Genetics,<br />
Department of Biology<br />
Faculty of Natural Sciences II<br />
Head: Prof. T. Winkler<br />
� Junior <strong>Research</strong> Groups of the IZKF<br />
Heads: PD Dr. R. Voll*<br />
PD Dr. M. Wiesener*<br />
PD Dr. B. Winner #<br />
PD Dr. J. Titze #<br />
� Clinical <strong>Research</strong> Groups<br />
PD Dr. J. Distler* Prof. A. Bozec #<br />
Prof. D. Dudziak* PD Dr. K. Gelse #<br />
Prof. F. Nimmerjahn* PD Dr. U. Kneser #<br />
PD Dr. J. Titze* Dr. G. Krönke #<br />
Prof. R. Voll* Dr. M. Stock #<br />
Prof. H. Taubert #<br />
Prof. E. Ullrich #<br />
PD Dr. M. Wiesener #<br />
5<br />
* previous<br />
# current
DEPARTMENT OF EXPERIMENTAL MEDICINE I<br />
Matrix Biology/ Molecular Pathology<br />
Head Klaus von der Mark, Dr. rer.nat<br />
(till 3/2011) Prof. of Experimental Medicine<br />
Address: Department of Experimental Medicine I<br />
Glückstr. 6<br />
D-91054 Erlangen<br />
Phone: + 49 (9131) 85 29124<br />
Fax: + 49 (9131) 85 26341<br />
E-mail: kvdmark@molmed. uni-erlangen.de<br />
Homepage: www.em1.molmed.uni-erlangen.de<br />
Supporting Staff<br />
Irene Bielmeier, Secretary<br />
Postdoctoral Fellows<br />
.<br />
Jung Park, Dr,med. dent.<br />
Helga von der Mark, Dr.rer. nat<br />
Takako Sasaki, Ph.D.<br />
Michael Stock, Dr. rer. nat.<br />
Cordula Surman-Schmitt, Dr. rer. nat.<br />
Nicole Eitzinger<br />
( � 10(2008)<br />
(��9/2008<br />
(11/2008 �)<br />
(��10/2010<br />
(��9/2011<br />
Doctoral Students (Biology)<br />
6<br />
PhD 8/2011
.Svitlana Golovchenko<br />
Doctoral Students (Molecular Medicine)<br />
( 10/2011)<br />
Diploma Students<br />
Catharina Müller(2008)<br />
Svitlana Ryabova-Golovchenko (2010)<br />
MatthiasGebhard (2011)<br />
Eva Bauer<br />
Friederike Pausch<br />
Britta Schlund<br />
Technicians<br />
General<br />
The legal time as head of the department of Experimental Medicine I ended for Prof.<br />
K. von der Mark with his official retirement date at Oct. 1, 2008. Until the installment<br />
of the new head of the Department, Prof. Dominik Müller, in April 2011, K. von der<br />
Mark continued to conduct research and teaching in the Department, but with<br />
strongly reduced staff and student numbers. With retirement of Dr. Helga von der<br />
Mark, the integrin research project was terminated, but collaborative studies with Dr.<br />
Jung Park, now Childrens Hospital, FAU (Prof. Holm Schneider) and Prof. Schmuki,<br />
Dept. of Material Sciences, FAU, on translational aspects of Titandioxide nanotubes<br />
are still going on. The research work of K. von der Mark focuses on two topics: 1) the<br />
role of hypertrophic chondrocytes in controlling subchondral trabecular bone<br />
formation by deleting �-catenin with a BACCol10Cre –deleter mouse, and 2) cell<br />
fate tracing and transdifferentiation of hypertrophic chondrocytes to osteoblasts using<br />
a BAC Col10Cre;ROSA-YFP reporter mice. The research projects on the new<br />
cartilage-specific proteins UCMA and the Wnt –inhibitor Wif 1 were continued under<br />
the supervision of Dr. M. Stock, now as research staff member in Internal Medicine<br />
III (Prof. G.Schett).<br />
A new research project on the role of fibulin-4 was started by Dr. Takako Sasaki in<br />
Nov. 2008 who received an independent research grant from the DFG in 2010.<br />
7
<strong>Research</strong> projects:<br />
I. Analyzing the role of hypertrophic chondrocytes in endochondral bone<br />
formation using BACCol10Cre deleter mice (K.von der Mark)<br />
II. Cellular response to nanoscale patterns of Titandioxide surfaces (J.Park)<br />
III. Control of collagen crosslinking and connective tissue stability by fibulin-4<br />
(Takako Sasaki)<br />
IV. Characterization of new cartilage matrix proteins (Michael Stock)<br />
<strong>Research</strong><br />
I. Analyzing the role of hypertrophic chondrocytes in endochondral bone<br />
formation using BACCol10Cre deleter mice (P.I. :Klaus von der Mark)<br />
A) Deletion of �- catenin in hypertrophic growth plate chondrocytes impairs<br />
trabecular bone formation<br />
Svitlana Golovchenko, Sonja Gebhard, Britta Schlund, Matthias Gebhardt, Andreas<br />
Hess, Klaus von der Mark<br />
In numerous studies it has been shown that canonical Wnt signalling plays a central<br />
but complex role in the regulation of chondrogenic and osteogenic differentiation<br />
during skeletal development Continuous Wnt/ �-catenin signalling in nascent<br />
cartilaginous skeletal elements blocks chondrocyte hypertrophy and endochondral<br />
ossification, whereas �-catenin overexpression at later stages stimulates hypertrophy<br />
and Col10a1 expression, mediated by binding to the Runx2 promoter and activating<br />
thereby expression of Col10a1. Furthermore, activation of Wnt/ �-catenin signalling in<br />
mature chondrocytes stimulated the expression of markers of late hypertrophy<br />
including MMP13 and VEGF and the expression other MMP genes.<br />
The role of Wnt/ �-catenin signalling in bone development is even more complicated<br />
in light of report showing that Wnt signalling is also involved in the control of bone<br />
remodelling by regulating the expression RANKL and osteoprotegerin in osteoblasts,<br />
thereby controlling osteoclast differentiation. Since RANKL and OPG are also<br />
expressed in hypertrophic chondrocytes, we tested the hypothesis that inhibition of �catenin<br />
signalling in hypertrophic chondrocytes might interfere with the RANKL/OPG<br />
balance and thus affect trabecular bone formation in growing bones.<br />
For this purpose, we specifically deleted the �-catenin gene in hypertrophic<br />
chondrocytes by crossing a ctnnb1 fl/fl mouse with a BAC-Col10a1-Cre deleter<br />
mouse. Surprisingly, the Cre-positive, ctnnb1 -/- mice (BCat-ko mice) revealed<br />
morphologically normal growth plate cartilage, but a substantial deficiency in<br />
trabecular bone, with increasing loss during postnatal development. Collagen I<br />
immunostaining and Alcian Blue staining for proteoglycans showed that not only the<br />
osteoid seam of bone trabeculae was missing, but also the calcified cartilage core,<br />
indicating excess of osteoclast activity. This notion was confirmed by TRAP staining<br />
8
and in situ hybridisation analysis of MMP9 which revealed a dramatically enhanced<br />
concentration of osteoclasts at the cartilage-bone marrow border in BCat-ko mice.<br />
Quantitative analysis of mRNA isolated from hypertrophic chondrocytes or whole<br />
bones of BCat–ko mice and wt littermates indicated significantly enhanced RANKL<br />
mRNA levels in BCat ko samples. In light of recent reports indicating that not<br />
osteoblasts, but osteocytes and hypertrophic chondrocytes are the main sources for<br />
RANKL synthesis, our findings support the provocative concept that it is the �-catenin<br />
in hypertrophic chondrocytes which predominantly controls the extent of trabecular<br />
bone formation in postnatal and juvenile development by regulating RANKL<br />
expression.<br />
Fig.1a,b: In situ hybridization analysis of newborn wild type and BACCol10Cre; ctnnb1 -/-<br />
(= BCat-ko) embryonic littermates (2d) shows that ��catenin mRNA expression is<br />
substantially reduced in the BCat-ko hypertrophic zones (b) as compared to wt cartilage<br />
(a), but equal in proliferating chondrocytes and in the bone marrow zone. c,d: Alcian blue<br />
staining marks growth plate cartilage and the calcified cartilage in subchondral trabeculae of<br />
wt mice (c), and demonstrates substantial loss of trabeculae in BCat-ko (d). (P7 tibia). e,f:<br />
Staining for TRAP reveals a high concentration of osteoclasts (Blue arrows) at the erosion<br />
zone of hypertrophic cartilage in BCat-ko mice (f), while in the wt spongiosa osteoclasts are<br />
evenly distributed between cartilage erosion zone and bone trabeculae (e). (P17,<br />
humerus).g) Real Time PCR analysis mRNA levels of hypertrophic chondrocytes isolated<br />
from growth plates of wt and BCAT-ko mice (P5) confirm reduction of �-catenin mRNA and<br />
indicate enhanced RANKL expression in Cat-ko hypertrophic chondrocytes.<br />
B) Do trabecular osteoblasts originate from hypertrophic chondrocytes?<br />
Matthias Gebhardt, Cordula Surmann-Schmitt, Jung Park, Britta Schlund, Klaus von der<br />
Mark<br />
Although the above findings indicate that the lack of trabecular bone caused by<br />
inactivation of the �-catenin gene in hypertrophic chondrocytes is due to enhanced<br />
9
osteoclast activity, we cannot rule out the possibility that the deletion of �-catenin in<br />
hypertrophic chondrocytes also impairs the differentiation of osteoblasts. This would<br />
be in line with a hypothesis by H. Roach et al (1996) who proposed<br />
transdifferentiation of terminally differentiated hypertrophic chondrocytes at the<br />
cartilage-bone marrow interface into osteoblasts, although the general<br />
understanding is that terminally differentiated chondrocytes die by apoptosis. To test<br />
this hypothesis, our BAC-Col10Cre deleter mice were mated to ROSA26LacZ<br />
reporter mice, and LacZ expression was used to trace the cell fate of hypertrophic<br />
chondrocyte. In fact, while X-gal staining of BAC Col10cre; ROSA26LacZ embryos<br />
labeled exclusively hypertrophic chondrocytes as expected, in postnatal stages<br />
LacZ activity was also seen in bone marrow and even in osteoblasts-like cells lining<br />
endosteal bone trabeculae. In order to exclude unspecific expression of Cre in cells<br />
other than hypertrophic chondrocytes, e.g. in bone marrow cells or osteoblast<br />
precursors, resulting in unspecific recombination of the floxed ROSA;LacZ locus,<br />
Cre expression in BACCol10Cre;ROSALacZ mice was analyzed by in situ<br />
hybridization. Cre signals were only seen hypertrophic chondrocytes, but not in<br />
other cells or tissues of the mouse embryo.<br />
To confirm the osteogenic phenotype of the LacZ-positive cells in the bone marrow,<br />
BACCol10Cre;ROSAYFP mice were generated and analyzed for expression of YFP<br />
expression osteogenic markers such as collagen I, osteocalcin and osterix.<br />
Immunofluorescence analysis revealed YFP and collagen I positive cells lining<br />
subchondral trabeculae, confirming their osteogenic phenotype. Also the<br />
immunofluorescence analysis of endosteal cells obtained after flushing long bones<br />
of 2-3 wk old BACCol10Cre;ROSA-YFP mice with collagenase showed YFP<br />
positive cells staining for collagen I and osteocalcin. These results strongly support<br />
the notion that not all terminal differentiated hypertrophic chondrocytes die by<br />
apoptosis, but may – at least to some extent – transdifferentiate to trabecular<br />
osteoblasts.<br />
a b<br />
c<br />
d e<br />
Figure 2: X-gal staining detects LacZ reporter gene activity in BACCol10Cre; ROSA26-<br />
LacZ transgenic mice in hypertrophic chondrocytes in E14.5-E18.5 embryos (a), in<br />
postnatal stages (P6) also in bone marrow and trabecular osteoblasts (c,d, arrows). A<br />
similar reactivity is seen in vertebrae (D) and long bones (e) of BACCol10Cre; ROSA-YFP<br />
mice.<br />
10
The mechanism of this transdifferentiation process remains to be elucidated. We<br />
have preliminary evidence that after opening of the chondrocyte lacunae by<br />
osteoclasts hypertrophic chondrocytes de-differentiate to bone marrow stem cells<br />
which may then differentiate into osteoblasts precursor cells and other<br />
mesenchymal cells. Studies to confirm this hypothesis are under investigation.<br />
Fig.3 Fig. 4<br />
Figure 3. YFP positive endosteal and bone marrow cells express osteoblast marker<br />
gene mRNA. Adherent bone marrow and endosteal cells were isolated from long bones of<br />
P21 BAC Col10 Cre;Rosa26-YFP reporter mice by bone flushing with collagenase P and<br />
cultured for two weeks. (A) YFP positive cells were sorted by FACS. Gating for viable cells<br />
(89.5% of total cells) is illustrated in the upper panel (pink circle). Lower panel: analysis of<br />
viable cells for YFP fluorescence reveals a clearly defined population of positive cells<br />
(12.4%). (B) RT-PCR analysis of RNA isolated from YFP + and YFP - cells after sorting and<br />
reverse transcription. Expression of osteoblast markers was analyzed using specific primers<br />
for the marker genes osterix, Runx2, osteocalcin, and Col1a1). Ppia (cyclophilin a) was used<br />
as a housekeeping gene control. Gel electrophoresis of PCR products shows, that YFP<br />
positive cells express high message levels of all four osteoblast marker genes (green box).<br />
Cal.: calvarial cDNA.<br />
Figure 4: Hypertrophic chondrocytes are an additional source of osteoblasts<br />
<strong>Report</strong>er gene expression is initiated in hypertrophic chondrocytes (HCs). The progeny of<br />
HCs continues reporter gene expression and can be detected as YFP positive trabecular<br />
osteoblasts (OBs). Some HCs are eliminated from the growth plate by apoptosis.<br />
Additionally, osteoblast precursor cells (OBP) invade the cartilage template and give rise to<br />
trabecular osteoblasts. Grey: cartilage matrix. Brown: bone trabeculae. Sand: bone marrow.<br />
PCs: proliferating chondrocytes. RCs: resting chondrocytes<br />
II: Synergistic control of mesenchymal stem cell differentiation by<br />
nanoscale surface geometry and immobilized growth factors on TiO2<br />
nanotubes ( P.I.: Dr. Jung Park)<br />
Park J, Bauer S, Pittrof A, Killian MS, Schmuki P, von der Mark K.<br />
11
Previously we have shown that cellular responses of bone marrow mesenchymal<br />
stem cells including adhesion, proliferation, migration, differentiation and apoptosis<br />
on titandioxide nanotube surfaces are strictly dependent on the nanoscale diameter<br />
of the tubular surfaces, with an optimum response on 15 nm diameter TiO2<br />
nanotubes (Park et al, 2007). In subsequent studies we asked the question whether<br />
combined environmental signals provided by nanoscale topography and by growth<br />
factors control cell behavior of mesenchymal stem cells (MSCs) in a synergistic or<br />
simply additive manner. Differentiation of MSCs to osteoblasts, chondrocytes and<br />
endothelial cells was studied on vertically aligned TiO2 nanotubes of size 15 and 100<br />
nm with and without immobilized bone morphogenetic protein-2 (BMP-2) and other<br />
growth factors such as EGF. Covalent immobilization of these growth factors onto the<br />
oxide surfaces was achieved by N,N-carbonyldiimidazole (CDI) coupling via binding<br />
to amine groups of the proteins either directly or via a spacer, namely 11-hydroxyundecylphosphonic<br />
acid (PhoA). Although BMP-2 coating stimulates both<br />
chondrogenic and osteogenic differentiation of MSCs, the response strongly<br />
depended on the surface nanoscale geometry of the BMP-2-coated nanotubes.<br />
Chondrogenic differentiation was strongly supported on 100 nm BMP-2-coated<br />
nanotubes, but not on 15 nm nanotubes, which induce spreading and dedifferentiation<br />
of chondrocytes. A similar response was observed with primary<br />
chondrocytes, which maintained their chondrogenic phenotype on BMP-2-coated 100<br />
nm nanotubes, but de-differentiated on 15 nm nanotubes. In contrast, osteogenic<br />
differentiation was greatly enhanced on 15 nm but not on 100 nm BMP-2-coated<br />
nanotubes as shown previously. Furthermore, covalent immobilization of BMP-2<br />
rescued MSCs from apoptosis occurring on uncoated 100 nm TiO2 nanotube<br />
surfaces. Thus, combined signals provided by BMP-2 immobilized to a defined lateral<br />
nanoscale spacing geometry seem to contain environmental cues that are able to<br />
modulate a lineage-specific decision of MSC differentiation and cell survival in a<br />
synergistic manner.<br />
III. The role of fibulin-4 in development and homeostasis of elastic<br />
components of the skeletal connective tissue (P.I. Dr.Takako Sasaki)<br />
Takako Sasaki, Eva Bauer, K.von der Mark<br />
The goal of this project is to elucidate the role of fibulin-4, a component of fibrillin<br />
microfibrils, in skeletal development and homeostasis. A recent gene targeting study<br />
has revealed fibulin-4 to be an essential molecule for the elastic fiber assembly<br />
during embryonic development. Mice deficient in fibulin-4 die perinatally due to<br />
cardiovascular and lung abnormalities, and similar phenotypes were reported for<br />
fibrillin-1 and lysyl oxidase (LOX) deficient mice. It has been proposed that fibrillin-1<br />
and fibulin containing microfibrils have an important role in sequestering cytokines,<br />
since perturbation of this function contributes to the pathogenesis of the disease.<br />
Thus, a hypomorphic in-frame deletion in the fibrillin-1 mutant mice, an accepted<br />
model of Marfan syndrome, leads to dysregulation of TGF-� activation and signaling.<br />
12
Increased TGF-� signaling in the cardiovascular system has also been found in mice<br />
hypomorphic for fibulin-4 and in the patient positive FBLN4 mutation. Recently, we<br />
found fibulin-4 expression also in fetal growth plate cartilage. Preliminary data on<br />
Fbln4 null mice showing reduced bone mass and increased bone fragility, and<br />
mutations found in human patients indicate that fibulin-4 may be also involved in<br />
skeletal development. The goal of this study is to obtain further insight into molecular<br />
changes causing the observed of skeletal alterations in fibulin-4 deficient mice such<br />
as limb contracture, detached distal phalanges and reduced bone mass.<br />
Results:<br />
Biochemical analyses on bone revealed that collagen I from fibulin-4 null mice was<br />
less cross-linked compared with those from wild type and heterozygous mice.<br />
Reduction of proteolytic activation of lysyl oxidase (LOX) which is essential for<br />
collagen crosslinking was detected not only in osteoblast culture but also in<br />
chondrocyte and fibroblast culture from fibulin-4 null mice. The mechanism how<br />
fibulin-4 is involved in LOX activation will be elucidated in vitro. It is still necessary to<br />
quantify the crosslink markers hyroxylyslpyridinoline (HP)/lysylpyridinoline (LP) of<br />
some more samples.<br />
Fig.5 SDS Page of collagens extracted with<br />
acid form bones of fibulin-4 k.o. mice<br />
shows significantly enhanced amounts of<br />
soluble collagen chains (a1(I) and a2(I)) ,<br />
indicating impaired crosslink formation,<br />
while collagens from wild type or<br />
heterozygote bones remain mostly insoluble<br />
2) There is ample evidence in the literature for a role of fibulin-4 in extracellular<br />
assembly of collagen and elastin. Therefore, particular attention was paid to fibulin-4<br />
binding proteins such as LTBPs and lysyloxidases in order to elucidate the<br />
mechanisms by which the absence of fibulin-4 leads to abnormalities in mice and<br />
human. To this aim, four mutations in fibulin-4 found in human patients were<br />
introduced in recombinant fibulin-4. The C276Y mutant fibulin-4 was not secreted<br />
from transfected 293 cells indicating that this cysteine residue is important for the<br />
protein folding. Other mutants can be secreted and purified except R279C mutant.<br />
These data suggest that the homozygous missense mutation of C276Y and the<br />
compound heterozygosity resulted in null mutation of fibulin-4 therefore those<br />
patients died very early, similar to fibulin-4 null mice. It will be tested whether cells<br />
other than 293 cells can secrete mutant fibulin-4. Some of fibulin-4 mutants exhibited<br />
reduced binding activities with different ligands. The E57K and E126K mutants were<br />
more susceptible to the proteases tested, suggesting that these mutation resulted in<br />
loss of calcium, causing instability in the conformation of EGF-like domain .<br />
13
The proposed studies will provide novel insights into the role of fibulin-4 in skeletal<br />
system as well as in the development and homeostasis of cardiovascular tissue.<br />
IV. Characterization of new cartilage matrix proteins<br />
(P.I.: Dr .Michael Stock)<br />
1. mWif-1 is expressed at cartilage-mesenchyme interfaces and impedes<br />
Wnt3a-mediated inhibition of chondrogenesis<br />
Cordula Surmann-Schmitt, Nathalie Widmann, Uwe Dietz, Bernhard Saeger, Nicole<br />
Eitzinger, Yukio Nakamura, Marianne Rattel, Richard Latham, Christine Hartmann,<br />
Helga von der Mark, Georg Schett, Klaus von der Mark and Michael Stock<br />
Skeletal development is controlled by a complex network of growth factors. Important<br />
signalling cascades regulating chondrocyte differentiation and maturation include<br />
signals mediated by the TGFβ/BMP puderfamily of growth factors, fibroblast growth<br />
factors (FGF), the Ihh/PTHrp system and Wnt factors. Wnt proteins are involved in<br />
the regulation of all steps of cartilage development. Their activity to a large extent<br />
regulated at the extracellular level by factors like the Dkk family, sFRPs, Cerberus<br />
and Wnt inhibitory factor 1 (Wif-1).<br />
In this study we provide evidence that Wif-1 is highly expressed at cartilagemesenchyme<br />
interfaces of the early developing skeleton. In fetal and postnatal<br />
skeletal development, Wif-1 expression is mainly confined to a zone of only a few cell<br />
layers in the upper hyaline layer of epiphyseal and articular cartilage. Significant Wif-<br />
1 expression was also detected in trabecular bone. In order to identify cartilagerelated<br />
Wnt factors that Wif-1 might interact with in vivo, we performed<br />
coimmunoprecipitation and pull-down assays using recombinant Wif-1 and Wnt<br />
factors. Thereby, we could identify specific binding of Wif-1 to Wnt3a, Wnt4, Wnt5a,<br />
Wnt7a, Wnt9a and Wnt11. We could demonstrate that Wif-1 was able to block Wnt3a<br />
mediated activation of the canonical Wnt signalling pathway, probably mediated by<br />
14
Figure 6: Wif-1 blocks Wnt3a activity<br />
The chondrogenic cell line 4C6 was stimulated as indicated with 25 µl/ml or 100 µl/ml Wnt3aconditioned<br />
medium in the presence or absence (Ctrl.) of 10 µg/ml recombinant Wif-1.<br />
Wnt3a-dependent accumulation and nuclear translocation of β-catenin was detected by<br />
immunofluorescence 5 hours after stimulation.<br />
B: Mouse limb-bud cells were grown in micromass cultures and treated with Wnt3a and Wif-1<br />
as indicated. After RNA extraction, Col2a1 mRNA levels were determined by real-time PCR<br />
using cyclophilin A levels for normalisation. Values are means ± s.d.<br />
physical interaction of Wif-1 and Wnt3a. Consequently, Wif-1 impaired growth of<br />
mesenchymal precursor cells and neutralised Wnt3a-mediated inhibition of<br />
chondrogenesis in micromass cultures of embryonic chick limb bud cells.<br />
These results identify Wif-1 as a novel extracellular Wnt modulator in cartilage<br />
biology.<br />
2. The Wnt Antagonist Wif-1 interacts with CTGF and Inhibits CTGF<br />
Activity<br />
Cordula Surmann-Schmitt, Takako Sasaki, Takako Hattori, Nicole Eitzinger, Georg<br />
Schett, Klaus von der Mark, and Michael Stock<br />
A recent study showed that shifted, the Drosophila orthologue of Wif-1, is involved in<br />
the control of hedgehog signalling. Therefore, we hypothesized that in mammals Wif-<br />
1 may also be associated with signalling pathways other than the Wnt cascade.<br />
Since Wif-1 exerts its regulatory role in Wnt signalling by direct interaction with Wnt<br />
ligands, we searched for novel protein interaction partners of Wif-1, which are<br />
involved in signalling pathways other than Wnt signalling. Therefore, we performed a<br />
yeast-two-hybrid approach to identify such novel protein interactions. Thereby, we<br />
identified the matricellular signalling molecule connective tissue growth factor<br />
(CTGF/CCN2) as a potential Wif-1-interacting protein. We confirmed that Wif-1<br />
physically binds to connective tissue growth factor (CTGF/CCN2) in vitro,<br />
predominantly by interaction with the C-terminal cysteine knot domain of CTGF. In<br />
vivo such an interaction appears also likely since the expression patterns of these<br />
two secreted proteins overlap in peripheral zones of epiphyseal cartilage. In<br />
chondrocytes CTGF has been shown to induce the expression of cartilage matrix<br />
genes such as aggrecan (Acan) and collagen2a1 (Col2a1). Here we could<br />
demonstrate that Wif-1 is capable to interfere with CTGF-dependent induction of<br />
Acan and Col2a1 gene expression in primary murine chondrocytes. Conversely,<br />
CTGF does not interfere with Wif-1-dependent inhibition of Wnt signalling.<br />
These results indicate that Wif-1 may be a multifunctional modulator of signalling<br />
pathways in the cartilage compartment.<br />
3. Ucma is not Necessary for Normal Development of the Mouse Skeleton<br />
Nicole Eitzinger, Cordula Surmann-Schmitt, Michael Bösl, Georg Schett, Klaus<br />
Engelke, Andreas Hess, Klaus von der Mark, and Michael Stock<br />
15
We recently introduced Ucma (Upper zone of growth plate and Cartilage Matrix<br />
Associated protein), a highly conserved tyrosine,sulphated, secreted protein of Mw<br />
17 kDa, which is expressed by juvenile chondrocytes. Initial in vitro experiments<br />
indicated that Ucma may be involved in skeletal development by affecting<br />
differentiation of pre-osteoblasts. Here we present the generation and analysis of a<br />
Ucma-deficient mouse strain, which should help to identify the physiological role of<br />
Ucma. Ucma gene-deficient mice were generated by introducing a lacZ/neoRcassette<br />
into the first exon of the Ucma gene. This mutation results in the complete<br />
loss of Ucma mRNA and protein expression. As expected due to the cartilage-<br />
specific expression of Ucma, these mice are viable and fertile. Surprisingly, however,<br />
Ucma-deficient mice appear to develop normally. Neither ossification and calcification<br />
of the skeleton, nor cartilage development were affected by Ucma-deficiency. This is<br />
particularly surprising since in a recent study, the knockdown of Ucma in zebrafish<br />
resulted in a severely disturbed formation of craniofacial cartilage.<br />
Our earlier studies have shown that Ucma is most prominently expressed perinatally,<br />
a finding that supported our hypothesis that Ucma may play a role in skeletal<br />
development. In the study presented here we could show that Ucma is additionally<br />
expressed in the cartilage of ribs and growth plate in adult mice. This may indicate<br />
that Ucma might be involved in skeletal homeostasis and in the mechanical<br />
properties of the skeleton during challenging conditions such as ageing or disease.<br />
Publications<br />
2012<br />
Eitzinger N, Surmann-Schmitt C, Bösl M, Schett G, Engelke K, Hess A, von der<br />
Mark K, Stock M. Ucma is not necessary for normal development of the mouse<br />
skeleton. Bone. 2012 Mar;50(3):670-80. Epub 2011 Dec 2. PubMed PMID: 22155508.<br />
Park J, Bauer S, Pittrof A, Killian MS, Schmuki P, von der Mark K. Synergistic<br />
control of mesenchymal stem cell differentiation by nanoscale surface geometry<br />
and immobilized growth factors on TiO2 nanotubes. Small. 2012 Jan 9;8(1):98-107.<br />
doi: 10.1002/smll.201100790. Epub 2011 Nov 18. PubMed PMID: 22095845.<br />
Surmann-Schmitt C, Sasaki T, Hattori T, Eitzinger N, Schett G, von der Mark K,<br />
Stock M. The Wnt antagonist Wif-1 interacts with CTGF and inhibits CTGF activity.<br />
J Cell Physiol. 2012 May;227(5):2207-16. doi: 10.1002/jcp.22957. PubMed PMID:<br />
21928342.<br />
2011<br />
Bauer S, Park J, Pittrof A, Song YY, von der Mark K, Schmuki P. Covalent<br />
functionalization of TiO2 nanotube arrays with EGF and BMP-2 for modified<br />
behavior towards mesenchymal stem cells. Integr Biol (Camb). 2011<br />
Sep;3(9):927-36. Epub 2011 Aug 10. PubMed PMID: 21829821.<br />
Gelse K, Klinger P, Koch M, Surmann-Schmitt C, von der Mark K, Swoboda B,<br />
Hennig FF, Gusinde J. Thrombospondin-1 prevents excessive ossification in<br />
16
cartilage repair tissue induced by osteogenic protein-1. Tissue Eng Part A. 2011<br />
Aug;17(15-16):2101-12. Epub 2011 Jun 1. PubMed PMID: 21513464.<br />
Klinger P, Surmann-Schmitt C, Brem M, Swoboda B, Distler JH, Carl HD, von der<br />
Mark K, Hennig FF, Gelse K. Chondromodulin 1 stabilizes the chondrocyte phenotype and<br />
inhibits endochondral ossification of porcine cartilage repair tissue.<br />
Arthritis Rheum. 2011 Sep;63(9):2721-31. doi: 10.1002/art.30335. PubMed PMID:<br />
21391200.<br />
2010<br />
Hattori T, Müller C, Gebhard S, Bauer E, Pausch F, Schlund B, Bösl MR, Hess A,<br />
Surmann-Schmitt C, von der Mark H, de Crombrugghe B, von der Mark K. SOX9 is a<br />
major negative regulator of cartilage vascularization, bone marrow formation and<br />
endochondral ossification. Development. 2010 Mar;137(6):901-11. PubMed PMID:<br />
20179096.<br />
Dragu A, Schnürer S, Surmann-Schmitt C, von der Mark K, Stürzl M, Unglaub F,<br />
Wolf MB, Leffler M, Beier JP, Kneser U, Horch RE. Gene expression analysis of<br />
ischaemia and reperfusion in human microsurgical free muscle tissue transfer. J<br />
Cell Mol Med. 2011 Apr;15(4):983-93. doi: 10.1111/j.1582-4934.2010.01061.x.<br />
PubMed PMID: 20345846.<br />
Belluoccio D, Etich J, Rosenbaum S, Frie C, Grskovic I, Stermann J, Ehlen H,<br />
Vogel S, Zaucke F, von der Mark K, Bateman JF, Brachvogel B. Sorting of growth<br />
plate chondrocytes allows the isolation and characterization of cells of a<br />
defined differentiation status. J Bone Miner Res. 2010 Jun;25(6):1267-81. PubMed<br />
PMID: 20200945.<br />
Krönke G, Uderhardt S, Kim KA, Stock M, Scholtysek C, Zaiss MM, et al. R-spondin 1<br />
protects against inflammatory bone damage during murine arthritis by modulating the Wnt<br />
pathway. Arthritis Rheum. 2010 Aug; 62(8):2303-2312.<br />
2009<br />
Bauer S, Park J, Faltenbacher J, Berger S, von der Mark K, Schmuki P. Size<br />
selective behavior of mesenchymal stem cells on ZrO(2) and TiO(2) nanotube<br />
arrays. Integr Biol (Camb). 2009 Sep;1(8-9):525-32. Epub 2009 Jun 19. PubMed<br />
PMID: 20023767.<br />
Bruckner-Tuderman L, von der Mark K, Pihlajaniemi T, Unsicker K. Cell<br />
interactions with the extracellular matrix. Cell Tissue Res. 2010 Jan;339(1):1-5.<br />
PubMed PMID: 19902257.<br />
von der Mark K, Park J, Bauer S, Schmuki P. Nanoscale engineering of<br />
biomimetic surfaces: cues from the extracellular matrix. Cell Tissue Res. 2010<br />
Jan;339(1):131-53. Epub 2009 Nov 7. Review. PubMed PMID: 19898872.<br />
Surmann-Schmitt C, Widmann N, Mallein-Gerin F, von der Mark K, Stock M.<br />
Stable subclones of the chondrogenic murine cell line MC615 mimic distinct stages<br />
of chondrocyte differentiation. J Cell Biochem. 2009 Oct 15;108(3):589-99. PubMed<br />
PMID: 19670270.<br />
Park J, Bauer S, Schmuki P, von der Mark K. Narrow window in nanoscale<br />
dependent activation of endothelial cell growth and differentiation on TiO2<br />
nanotube surfaces. Nano Lett. 2009 Sep;9(9):3157-64. PubMed PMID: 19653637.<br />
17
Park J, Bauer S, Schlegel KA, Neukam FW, von der Mark K, Schmuki P. TiO2<br />
nanotube surfaces: 15 nm--an optimal length scale of surface topography for cell<br />
adhesion and differentiation. Small. 2009 Mar;5(6):666-71. PubMed PMID: 19235196.<br />
von der Mark K, Bauer S, Park J, Schmuki P. Another look at "Stem cell fate<br />
dictated solely by altered nanotube dimension". Proc Natl Acad Sci U S A. 2009<br />
Jun 16;106(24):E60; author reply E61. Epub 2009 Jun 8. PubMed PMID: 19506261;<br />
Surmann-Schmitt C, Widmann N, Dietz U, Saeger B, Eitzinger N, Nakamura Y,<br />
Rattel M, Latham R, Hartmann C, von der Mark H, Schett G, von der Mark K, Stock<br />
M. Wif-1 is expressed at cartilage-mesenchyme interfaces and impedes<br />
Wnt3a-mediated inhibition of chondrogenesis. J Cell Sci. 2009 Oct 15;122(Pt<br />
20):3627-37. Epub 2009 Sep.<br />
18
DEPARTMENT OF EXPERIMENTAL MEDICINE I<br />
(Hypertension-Induced Target Organ Damage)<br />
Head: Dominik N. Müller, Dr. rer. nat.<br />
Professor of Experimental Medicine<br />
Address: Department of Experimental Medicine I<br />
Glückstr. 6<br />
D-91054 Erlangen<br />
Telefone: + 49 (9131) 85 29100<br />
Fax: + 49 (9131) 85 26341<br />
E-mail: dmueller@molmed.uni-erlangen.de<br />
Homepage: http://www.molmed.uni-erlangen.de/<br />
Head<br />
Dominik N. Müller, Prof. Dr. rer. nat.<br />
Professor of Experimental Medicine<br />
Dr. rer. nat. Katrina Binger<br />
Dr. rer. nat. Kristina Tanneberger<br />
Dr. rer. nat. Agnes Schröder<br />
Eva Bauer<br />
Supporting Staff<br />
Irena Bielmeier, Secretary<br />
Postdoctoral Fellows<br />
Technicians<br />
19<br />
Dr. med. Anke Dahlmann<br />
Dr. med. Wolfgang Freisinger<br />
Britta Schlund
<strong>Research</strong><br />
Hypertension is the primary risk factor for cardiovascular disease, the major<br />
cause of death worldwide. Our group’s major research interests are the reninangiotensin<br />
system (RAS), the immune system and how both systems cause<br />
hypertension-induced target organ damage. In a translational approach, the Müller<br />
lab focuses on the vessels, hearts, kidneys with our recent work extending these<br />
concepts to analyze how epigenetic factors, such as high salt, influence immune cells<br />
and target organ damage.<br />
Projects<br />
The immune system, salt and hypertension-induced target organ damage<br />
Our research is aimed at better understanding the role of innate and adaptive<br />
immunity in hypertension-induced organ damage. T cells, macrophages, and<br />
dendritic cells all harbor the AT1 receptor. Ang II stimulates T cell proliferation and<br />
dendritic cell migration. We showed that mice lacking the transcription factor Id2, a<br />
pivotal factor for Langerhans dendritic cells, are resistant to Ang II-induced<br />
hypertension and sequelae. We also observed that regulatory T cells modulate Ang<br />
II-induced cardiac damage to a point of therapeutic utility. Since our data suggested<br />
an interaction of the renin-angiotensin system, immune system and target organ<br />
damage (Figure), we are investigating the role of angiotensin II in autoimmunity.<br />
In collaboration with Ralf Linker (Univ. Erlangen), we investigated whether blockade<br />
of the renin-angiotensin system improves non-cardiovascular autoimmunity. Our<br />
results suggest that by<br />
blocking the aspartyl<br />
protease renin, ACE<br />
and the AT1 receptor,<br />
autoimmune<br />
encephalitis in rodents<br />
can be effectively<br />
inhibited.<br />
We are now<br />
extending our<br />
immunological studies<br />
to the investigation of<br />
inflammatory<br />
activation in the<br />
interstitium by<br />
hyperosmolarity through sodium. This line of investigation was initiated with Jens<br />
Titze (Univ. Erlangen/ Vanderbilt Univ.), with whom we have an intensive<br />
collaboration. With dietary sodium excess, sodium accumulates in the skin and<br />
activates the osmotic stress gene tonicity-responsive enhancer binding protein<br />
(TonEBP/NFAT5) in macrophages. TonEBP activity in macrophages results in<br />
secretion of VEGF-C promoting the clearance of hypertonic fluid from the interstitium.<br />
This circuit is critically dependent on macrophages and their ability to ward off<br />
hypertension in case of excess sodium supply. We have initiated a program to<br />
determine how hypertonicity induced by deranged sodium chloride storage affects<br />
the differentiation of T cells and macrophages.<br />
20
Cardiovascular and non-cardiovascular functions of the (pro)renin receptor<br />
The (pro)renin receptor (PRR) is a relatively newly discovered member of the<br />
renin-angiotensin system (RAS). Initially, PRR was believed to directly contribute to<br />
cardiovascular disease by activating the RAS and several signaling cascades.<br />
However, recent publications in Science have shown that PRR plays an essential<br />
and non-RAS related role in the activation of Wnt signal transduction and cellular<br />
development. In light of this, our understanding of the role of the prorenin receptor<br />
(PRR) in physiology and pathology has changed dramatically and we are now<br />
focused on determining these non-RAS functions of PRR.<br />
In collaboration with Michael Bader (MDC), we have determined that complete<br />
knockout of PRR in mouse embryonic stem cells, fails to generate chimeras when<br />
injected into blastocysts, indicating an important role for this protein in cellular<br />
development. We have subsequently initiated several PRR tissue-specific conditional<br />
knockout models. Generation of podocyte-specific PRR knockout mice (cKO)<br />
resulted in the death of the animals ~2-3 weeks after birth. Within 14 days, these<br />
cKO animals developed nephrotic syndrome and albuminuria, due to podocyte foot<br />
process fusion (Figure) and cytoskeletal changes.<br />
Figure legend EM shows normal epithelial cells and foot processes in control animals (left). cKO mice<br />
(right) developed foot process fusion (c=capillary, p=podocyte).<br />
Our in vivo and in vitro findings indicated a functional block in autophagosomelysosome<br />
fusion and overload of the proteasome protein degradation machinery.<br />
These results suggest that the PRR is essential for podocyte function and survival by<br />
maintaining autophagy and protein turnover machinery. We are now investigating the<br />
effect of PRR deletion in other cell types, namely T cells, pancreatic b-cells and<br />
renin-producing cells.<br />
We are also focused on understanding the molecular mechanism by which<br />
PRR is important for cellular homeostasis and development. The PRR was initially<br />
proposed to have no homology to other proteins, however it is now apparent that the<br />
nucleotide sequence of PRR is identical to that of ATP6AP2; a gene identified as an<br />
21
accessory protein of the H+ vacuolar-ATPase (V-ATPase). The V-ATPase is<br />
responsible for establishing and maintaining intracellular pH gradients along the<br />
secretory and endocytic pathways in all cell types. Acidification of vacuoles along<br />
these pathways is essential for many cellular functions including the processing and<br />
secretion of proteins, receptor endocytosis and recycling, and membrane fusion<br />
events, which are essential for processes such as autophagy. We are undertaking<br />
experiments to determine the protein-protein interactions important for PRR to<br />
maintain this function, and its role in Wnt signal activation.<br />
Interestingly, the PRR also exists as a soluble receptor (sPRR), and it has<br />
been hypothesized that this sPRR may have an important biological role. We have<br />
developed a sensitive ELISA to quantitate sPRR in biological fluids, and we are<br />
currently investigating if sPRR levels may be an important biomarker for<br />
cardiovascular disease and cancer.<br />
CV<br />
Dominik N. Müller studied pharmacy at the Free University of Berlin (1991-1992).<br />
He completed his Ph.D. thesis in 1996 and achieved faculty rank (Habilitation) for<br />
Experimental Medicine in 2004. After his postdoctoral work at Franz-Volhard Clinic<br />
and Max-Delbrück-Center Berlin (1996-2004), he was appointed a Delbrück Fellow at<br />
the MDC (2004-2010). In 2011, Dominik N. Müller was recruited to a W3 (full)<br />
professorship for Experimental Medicine at the University of Erlangen.<br />
Publications (2010-2012)<br />
Original Articles<br />
Five most important publications since 2007<br />
Riediger, F., Quack, I., Qadri, F., Hartleben, B., Park, J.K., Potthoff, S.A., Sohn, D.,<br />
Sihn. G., Rousselle, A., Fokuhl, V., Maschke, U., Pur<strong>für</strong>st, B., Schneider, W., Rump,<br />
L.C., Luft, F.C., Dechend, R., Bader, M., Huber, T.B., Nguyen, G. and Müller, D.N.<br />
(2011) Prorenin receptor is essential for podocyte autophagy and survival. J Am Soc<br />
Nephrol. 22, 2193-2202.<br />
Stegbauer, J., Lee, D.H., Seubert, S., Ellrichmann, G., Manzel, A., Kvakan, H.,<br />
Müller, D.N., Gaupp, S., Rump, L.C., Gold, R.,Linker, R.A. (2009). Role of the reninangiotensin<br />
system in autoimmune inflammation of the central nervous system. Proc<br />
Natl Acad Sci U S A 106, 14942-14947.<br />
Machnik, A., Neuhofer, W., Jantsch, J., Dahlmann, A., Tammela, T., Machura, K.,<br />
Park, J.-K., Beck, F.-X., Müller, D.N., Derer, W., Goss, J., Ziomber, A., Dietsch, P.,<br />
Wagner, H., van Rooijen, N., Kurtz, A., Hilgers, K.F., Alitalo, K., Eckardt, K.U., Luft,<br />
22
F.C., Kerjaschki, D., Titze, J. (2009) Macrophages regulate salt-dependent volume<br />
and blood pressure by a VEGF-C dependent buffering mechanism. Nat Med 15, 545-<br />
52.<br />
Kvakan, H., Kleinewietfeld, M., Qadri, F., Park, J.-K., Fischer, R., Schwarz, I., Rahn,<br />
H.-P., Plehm, R., Wellner, M., Elitok, S., Gratze, P.., Dechend, R, Luft, F.C., and<br />
Müller, D.N. (2009) Regulatory T cells ameliorate angiotensin II-induced cardiac<br />
damage. Circulation. 119, 2904-2912.<br />
Henke, N., Schmidt-Ullrich, R., Dechend, R., Park, J.-K., Qadri, F., Wellner, M., Obst,<br />
M., Gross, V., Dietz, R., Luft, F.C., Scheidereit, C., Müller, D.N. Vascular endothelial<br />
cell-specific NF-kB suppression attenuates hypertension-induced renal damage. Circ<br />
Res. 2007; 101:268-76.<br />
Publications since 2010<br />
2012<br />
Markó L, Kvakan H, Park J-K, Qadri F, Spallek B, Binger KJ, Bowman EP,<br />
Kleinewietfeld M, Fokuhl V, Dechend R, Muller DN. Interferon gamma (IFN-γ)<br />
signaling inhibition ameliorates Ang II-induced cardiac damage Hypertension 2012<br />
(in press)<br />
Kopp, C., Linz, P., Wachsmuth, L., Dahlmann, A., Horbach, T., Schofl, C., Renz, W.,<br />
Santoro, D., Niendorf, T., Muller, D.N., Neininger, M., Cavallaro, A., Eckardt, K.-U.,<br />
Schmieder, R.E., Luft, F.C., Uder, M., Titze, J. (2012). 23Na Magnetic Resonance<br />
Imaging of Tissue Sodium. Hypertension 59 167-172<br />
Finckenberg, P., Eriksson, O., Baumann, M., Merasto, S., Lalowski, M.M., Levijoki,<br />
J., Haasio, K., Kyto, V., Muller, D.N., Luft, F.C., Oresic., M, Mervaala, E. (2012).<br />
Caloric Restriction Ameliorates Angiotensin II-Induced Mitochondrial Remodeling and<br />
Cardiac Hypertrophy. Hypertension 59:76-84.<br />
2011<br />
Riediger, F., Quack, I., Qadri, F., Hartleben, B., Park, J.K., Potthoff, S.A., Sohn, D.,<br />
Sihn, G., Rousselle, A., Fokuhl, V., Maschke, U., Pur<strong>für</strong>st, B., Schneider, W., Rump,<br />
L.C., Luft, F.C., Dechend, R., Bader, M., Huber, T.B., Nguyen, G., Müller D.N.<br />
(2011). Prorenin receptor is essential for podocyte autophagy and survival. J Am<br />
Soc Nephrol 22, 2193-2202.<br />
Park, J.B., Kim, B.K., Kwon, Y.W., Muller, D.N., Lee, H.C., Youn, S.W., Choi, Y.E.,<br />
Lee, S.W., Yang, H.M., Cho, H.J., Park, K.W., Kim, H.S. (2011). Peroxisome<br />
proliferator-activated receptor-gamma agonists suppress tissue factor overexpression<br />
in rat balloon injury model with Paclitaxel infusion. PLoS One 6, e28327.<br />
Batenburg, W.W., Lu, X., Leijten, F., Maschke, U., Muller, D.N., and Danser, A.H.<br />
(2011). Renin- and prorenin-induced effects in rat vascular smooth muscle cells<br />
overexpressing the human (pro)renin receptor: does (pro)renin-(pro)renin receptor<br />
interaction actually occur? Hypertension 58, 1111-1119.<br />
23
Searle, J., Mockel, M., Gwosc, S., Datwyler, S.A., Qadri, F., Albert, G.I., Holert, F.,<br />
Isbruch, A., Klug, L., Muller, D.N., Dechend, R., Muller, R., Vollert, J.O., Slagman, A.,<br />
Mueller, C., Herse, F. (2011). Heparin strongly induces soluble fms-like tyrosine<br />
kinase 1 release in vivo and in vitro--brief report. Arterioscler Thromb Vasc Biol 31,<br />
2972-2974.<br />
Falck, J.R., Wallukat, G., Puli, N., Goli, M., Arnold, C., Konkel, A., Rothe, M., Fischer,<br />
R., Muller, D.N., and Schunck, W.H. (2011). 17(R),18(S)-epoxyeicosatetraenoic acid,<br />
a potent eicosapentaenoic acid (EPA) derived regulator of cardiomyocyte<br />
contraction: structure-activity relationships and stable analogues. J Med Chem 54,<br />
4109-4118.<br />
Wenzel, K., Rajakumar, A., Haase, H., Geusens, N., Hubner, N., Schulz, H., Brewer,<br />
J., Roberts, L., Hubel, C.A., Herse, F., Hering, L., Qadri, F., Lindschau, C., Wallukat,<br />
G., Pijnenborg, R., Heidecke, H., Riemekasten, G., Luft, F.C., Müller, D.N., Lamarca,<br />
B., Dechend, R. (2011). Angiotensin II type 1 receptor antibodies and increased<br />
angiotensin II sensitivity in pregnant rats. Hypertension 58, 77-84.<br />
Herse, F., Fain, J.N., Janke, J., Engeli, S., Kuhn, C., Frey, N., Weich, H.A.,<br />
Bergmann, A., Kappert, K., Karumanchi, S.A., Luft, F.C., Müller, D.N., Staff, A.C.,<br />
Dechend, R. (2011). Adipose tissue-derived soluble fms-like tyrosine kinase 1 is an<br />
obesity-relevant endogenous paracrine adipokine. Hypertension 58, 37-42.<br />
Riemekasten, G., Philippe, A., Nather, M., Slowinski, T., Muller, D.N., Heidecke, H.,<br />
Matucci-Cerinic, M., Czirjak, L., Lukitsch, I., Becker, M., Kill, A., van Laar, J.M., Catar,<br />
R., Luft, F.C., Burmester, G.R., Hegner, B., Dragun, D. (2011). Involvement of<br />
functional autoantibodies against vascular receptors in systemic sclerosis. Ann<br />
Rheum Dis 70, 530-536.<br />
Hoff, U., Lukitsch, I., Chaykovska, L., Ladwig, M., Arnold, C., Manthati, V.L., Fuller,<br />
T.F., Schneider, W., Gollasch, M., Müller, D.N., Flemming, B., Seeliger, E., Luft,<br />
F.C., Falck, J.R., Dragun, D., Schunck, W.H. (2011). Inhibition of 20-HETE synthesis<br />
and action protects the kidney from ischemia/reperfusion injury. Kidney Int 79, 57-<br />
65.<br />
2010<br />
Schmerbach, K., Pfab, T., Zhao, Y., Culman, J., Mueller, S., Villringer, A., Müller,<br />
D.N., Hocher, B., Unger, T., and Thoene-Reineke, C. (2010). Effects of aliskiren on<br />
stroke in rats expressing human renin and angiotensinogen genes. PLoS One 5,<br />
e15052.<br />
Biala, A., Martonen, E., Kaheinen, P., Levijoki, J., Finckenberg, P., Merasto, S.,<br />
Louhelainen, M., Müller, D.N., Luft, F.C., and Mervaala, E. (2010a). Levosimendan<br />
improves cardiac function and survival in rats with angiotensin II-induced<br />
hypertensive heart failure. Hypertens Res 33, 1004-1011.<br />
Arnold, C., Markovic, M., Blossey, K., Wallukat, G., Fischer, R., Dechend, R., Konkel,<br />
A., von Schacky, C., Luft, F.C., Müller, D.N., Rothe, M., Schunck, W.H. (2010).<br />
24
Arachidonic acid-metabolizing cytochrome P450 enzymes are targets of {omega}-3<br />
fatty acids. J Biol Chem 285, 32720-32733.<br />
Verlohren, S., Geusens, N., Morton, J., Verhaegen, I., Hering, L., Herse, F.,<br />
Dudenhausen, J.W., Müller, D.N., Luft, F.C., Cartwright, J.E., Davidge, S.T.,<br />
Pijnenborg, R., Dechend, R. (2010). Inhibition of trophoblast-induced spiral artery<br />
remodeling reduces placental perfusion in rat pregnancy. Hypertension 56, 304-310.<br />
Hering, L., Herse, F., Geusens, N., Verlohren, S., Wenzel, K., Staff, A.C., Brosnihan,<br />
K.B., Huppertz, B., Luft, F.C., Müller, D.N., Pijnenborg, R., Cartwright, J., Dechend,<br />
R. (2010). Effects of circulating and local uteroplacental angiotensin II in rat<br />
pregnancy. Hypertension 56, 311-318.<br />
Wenzel, K., Wallukat, G., Qadri, F., Hubner, N., Schulz, H., Hummel, O., Herse, F.,<br />
Heuser, A., Fischer, R., Heidecke, H., Luft F.C., Müller, D.N., Dietz, R., Dechend, R.<br />
(2010). Alpha1A-adrenergic receptor-directed autoimmunity induces left ventricular<br />
damage and diastolic dysfunction in rats. PLoS One 5, e9409.<br />
Machnik, A., Dahlmann, A., Kopp, C., Goss, J., Wagner, H., van Rooijen, N., Eckardt,<br />
K.U., Müller, D.N., Park, J.K., Luft, F.C., Kerjaschki, D., Titze, J. (2010).<br />
Mononuclear phagocyte system depletion blocks interstitial tonicity-responsive<br />
enhancer binding protein/vascular endothelial growth factor C expression and<br />
induces salt-sensitive hypertension in rats. Hypertension 55, 755-761.<br />
Mervaala, E., Biala, A., Merasto, S., Lempiainen, J., Mattila, I., Martonen, E.,<br />
Eriksson, O., Louhelainen, M., Finckenberg, P., Kaheinen, P., Müller, D.N., Luft,<br />
F.C., Lapatto, R., Oresic, M. (2010). Metabolomics in angiotensin II-induced cardiac<br />
hypertrophy. Hypertension 55, 508-515.<br />
25
DEPARTMENT OF EXPERIMENTAL MEDICINE II<br />
(Molecular Tumour <strong>Research</strong>)<br />
Head: Jürgen Behrens, Dr. rer. nat.<br />
Professor of Experimental Medicine<br />
Address: Department of Experimental Medicine II<br />
Glückstr. 6<br />
D-91054 Erlangen<br />
Telefone: + 49 (9131) 85 29109<br />
Fax: + 49 (9131) 85 29111<br />
E-mail: jbehrens@molmed.uni-erlangen.de<br />
Homepage: www.em2.molmed.uni-erlangen.de<br />
Martin Sachs, Dr. rer. nat.<br />
Jean Schneikert, Dr. rer. nat.<br />
Head<br />
Jürgen Behrens, Prof. Dr. rer. nat.<br />
Professor of Experimental Medicine<br />
Supporting Staff<br />
Angela Döbler, Secretary<br />
Postdoctoral Fellows<br />
26<br />
Michel Hadjihannas, Dr. rer. nat.<br />
Ingrid Wacker, Dr. rer. nat.
Katharina Brauburger<br />
° PhD received<br />
° PhD received<br />
Doctoral Students (Biology)<br />
Sandra Mattauch°<br />
Astrid Pfister°<br />
Doctoral Students (Molecular Medicine)<br />
Martina Brückner<br />
Gabriele Daum<br />
* part of the time reported<br />
Dominic Bernkopf<br />
Kristina Tanneberger°<br />
Technicians<br />
27<br />
Shree Harsha Vijaya°<br />
Birgit Saffer<br />
Sabine Lukat*
<strong>Research</strong><br />
Our group analyses molecular mechanisms that control tumour development and<br />
progression, focussing on oncogenic Wnt and Activin signalling.<br />
Functional analysis of Wnt signaling components<br />
Wnts are a family of secreted glycoproteins that bind to frizzled seventransmembrane<br />
span receptors and LRP coreceptors. Intracellularly, the Wnt<br />
signaling cascade blocks degradation of β-catenin in proteasomes and thereby leads<br />
to accumulation of β-catenin in the cytoplasm. β-Catenin then enters the nucleus and<br />
activates the expression of Wnt-specific target genes by interacting with LEF-1/TCF<br />
transcription factors. Conductin (also named Axin2), and its relative axin act as<br />
scaffolding components that simultaneously bind to β-catenin, the serine/threonine<br />
kinases GSK3β and CK1ε, and APC. In this complex GSK3β and CK1ε<br />
phosphorylate β-catenin at serine and threonine residues, which leads to<br />
ubiquitination and subsequent proteasomal degradation of β-catenin. It is suggested<br />
that axin proteins block Wnt signaling by assembling the essential components of the<br />
β-catenin degradation pathway. In colorectal tumours mutations of the tumour<br />
suppressor APC (adenomatous polyposis coli) lead to stabilization of β-catenin and<br />
constitutive signaling to the nucleus independent of Wnts. APC is a co-factor<br />
indispensable for axin-mediated degradation of β-catenin. APC binds to β-catenin<br />
and axin/conductin via multiple interaction domains thereby supporting β-catenin<br />
degradation. Mutations of β-catenin have been observed that also lead to<br />
stabilization of β-catenin. Thus, aberrant activation of the Wnt signaling pathway is<br />
considered a major oncogenic mechanism for many tumour types.<br />
In the past years we have identified and functionally characterized several key<br />
components of the pathway using our highly efficient yeast two hybrid screening<br />
system. Among these are Lef-1 and conductin/axin2 as interaction partners of βcatenin,<br />
and more recently the Amer family of APC interactors, as well as EB1 as an<br />
interaction partner of Amer2.<br />
Role of conductin/axin2 in the cell cycle<br />
Michel Hadjihannas, Martina Brückner<br />
We found that conductin levels are regulated during the cell cycle with lowest levels<br />
present during the G1/S phase and highest during G2/M. Following exit from mitosis<br />
conductin expression levels decline in parallel with those of mitotic regulators, such<br />
as cyclin B1. In line, Wnt/β-catenin target genes are low at G2/M and high at G1/S,<br />
28
and β-catenin phosphorylation oscillates during the cell cycle in a conductindependent<br />
manner. Conductin is degraded by the anaphase-promoting<br />
complex/cyclosome cofactor CDC20. Knockdown of CDC20 blocks Wnt signalling<br />
through conductin. CDC20-resistant conductin inhibits Wnt signalling and attenuates<br />
colony formation of colorectal cancer cells. We propose that CDC20-mediated<br />
degradation of conductin regulates Wnt/β-catenin signalling for maximal activity<br />
during G1/S (Hadjihannas et al., 2012).<br />
We also found that conductin localizes at the centrosomes by binding to the centrioleassociated<br />
component C-Nap1. Knockout or knockdown of conductin leads to<br />
premature centrosome separation which is abolished by knockdown of β-catenin.<br />
Conductin promotes phosphorylation of the amino-terminal serine (Ser 33/37) and<br />
threonine (Thr 41) residues of centrosome-associated β-catenin. β-Catenin mutated<br />
at these residues causes centrosomal separation, whereas a phospho-mimicking<br />
mutant of β-catenin does not. Treatment with Wnts and inhibition of glycogen<br />
synthase kinase 3 block β-catenin phosphorylation and induce centrosomal splitting.<br />
These data indicate that Wnt signalling and conductin regulate centrosomal cohesion<br />
by altering the phosphorylation status of β-catenin at the centrosomes (Hadjihannas<br />
et al., 2010).<br />
Functional dissection of APC mutants truncated in colorectal cancer<br />
Jean Schneickert, Eva Kohler, Shree Harsha Vijaya Chandra<br />
The tumour suppressor Adenomatous Polyposis Coli (APC) is truncated in most<br />
colon cancers, but is not completely lost. It is not clear why colon cancer cells retain<br />
the truncated APC fragment. The mutations affecting both APC alleles are<br />
interdependent, the position of the first APC mutation determining where the second<br />
hit will occur. This results in a complex pattern of mutation distribution in the APC<br />
sequence that translates into the stabilization of β−catenin that in turn feeds the<br />
affected cells with a permanent mitogenic signal. We found a new APC domain, the<br />
β−catenin inhibitory domain (CID) of APC located between the second and third 20<br />
amino acid repeats and therefore present in many truncated APC products found in<br />
human tumours. In truncated APC, the CID is absolutely necessary to down-regulate<br />
the transcriptional activity and the level of β−catenin, even when an axin/conductin<br />
binding site is present (Kohler et al., 2009).<br />
The four 15 amino acid repeats (15R) and the seven 20 amino acid repeats (20R) of<br />
APC are beta-catenin-binding sites, but their role in beta-catenin degradation has<br />
remained unclear. We showed that binding of β-catenin to the 15R of APC is<br />
necessary and sufficient to target β-catenin for degradation. The first 15R displays<br />
the highest affinity for beta-catenin in the 15R-20R module. The analysis of the<br />
distribution of truncating mutations along the APC sequence in colorectal tumours<br />
from FAP patients revealed that the first 15R is one target of the positive selection of<br />
mutations that lead to tumour development (Kohler et al., 2010).<br />
29
We found that the transcriptional repressor C-terminal binding protein (CtBP)<br />
promotes the oligomerization of truncated APC through binding to the 15 amino acid<br />
repeats of truncated APC. CtBP can bind to either first, third or fourth 15 amino acid<br />
repeats, but not to the second. CtBP-mediated oligomerization requires both<br />
dimerization domains of truncated APC as well as CtBP dimerization. This suggests<br />
that the sensitivity of truncated APC to oligomerization by CtBP constitutes an<br />
essential facet of tumour development (Schneikert et al., 2011).<br />
RNA interference was used to down-regulate truncated APC in several colorectal<br />
cancer cell lines expressing truncated APCs of different lengths, thereby performing<br />
an analysis covering most of the mutation cluster region. The consequences on<br />
proliferation in vitro, tumour formation in vivo and the level and transcriptional activity<br />
of β-catenin were investigated. Down-regulation of truncated APC results in an<br />
inhibition of tumour cell population expansion in vitro in 6 cell lines out of 6 and<br />
inhibition of tumour outgrowth in vivo as analysed in one of these cell lines, HT29.<br />
Down-regulation of truncated APC is accompanied by an up-regulation of the<br />
transcriptional activity of β-catenin and in most cases β-catenin levels, indicating that<br />
truncated APC can still modulate wnt signalling through controlling the level of βcatenin.<br />
Thus, truncated APC is an essential component of colorectal cancer cells,<br />
required for cell proliferation, possibly by adjusting β-catenin signalling to the "just<br />
right" level (Vijaya Chandra et al., 2012).<br />
The AMER family of Wnt pathway regulators<br />
Kristina Tanneberger, Astrid Alzner, Katharina Brauburger, Martin Sachs<br />
Amer 1, Amer2 and Amer3 constitute a new family of Wnt pathway regulators that<br />
are characterized by the presence of conserved APC binding domains which interact<br />
with the armadillo repeats of APC. We have initially identified Amer1 in a yeast two<br />
hybrid screen for interaction partners of APC and have cloned the other family<br />
members as open reading frames from database information.<br />
Amer1<br />
We previously identified Amer1 (APC membrane recruitment 1) as a novel<br />
membrane-associated protein that interacts with APC and recruits it away from<br />
microtubule ends to the plasma membrane. The N-terminus of Amer1 contains two<br />
distinct phosphatidylinositol(4,5)-bisphosphate [PtdIns(4,5)P(2)]-binding domains<br />
composed of clusters of lysines, which mediate its localization to the plasma<br />
membrane.<br />
Amer1 is identical to the tumour suppressor WTX, which is mutated in a proportion of<br />
Wilms tumours. Amer1/WTX acts as an inhibitor of Wnt signaling by inducing βcatenin<br />
degradation. Amer1 directly interacts with the armadillo repeats of β-catenin<br />
30
via a domain consisting of repeated arginine-glutamic acid-alanine (REA) motifs, and<br />
assembles the β-catenin destruction complex at the plasma membrane by recruiting<br />
β-catenin, APC, and Axin/Conductin. Deletion or specific mutations of the membrane<br />
binding domain of Amer1 abolish its membrane localization and abrogate negative<br />
control of Wnt signaling. Knockdown of Amer1 leads to the activation of Wnt target<br />
genes, preferentially in dense compared with sparse cell cultures, suggesting that<br />
Amer1 function is regulated by cell contacts. Amer1 stabilizes Axin and counteracts<br />
Wnt-induced degradation of Axin, which requires membrane localization of Amer1.<br />
The data suggest that Amer1 exerts its negative regulatory role in Wnt signaling by<br />
acting as a scaffold protein for the β-catenin destruction complex and promoting<br />
stabilization of Axin at the plasma membrane (Tanneberger et al., 2011a).<br />
Phosphorylation of the Wnt receptor low-density lipoprotein receptor-related protein 6<br />
(LRP6) by glycogen synthase kinase 3β (GSK3β) and casein kinase 1γ (CK1γ) is a<br />
key step in Wnt/β-catenin signalling, which requires Wnt-induced formation of<br />
phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P(2)). We found that Amer1 is<br />
essential for the activation of Wnt signalling at the LRP6 receptor level. Knockdown<br />
of Amer1 reduced Wnt-induced LRP6 phosphorylation, Axin translocation to the<br />
plasma membrane and formation of LRP6 signalosomes. Overexpression of Amer1<br />
promotes LRP6 phosphorylation, which requires interaction of Amer1 with<br />
PtdIns(4,5)P(2). Amer1 translocates to the plasma membrane in a PtdIns(4,5)P(2)dependent<br />
manner after Wnt treatment and is required for LRP6 phosphorylation<br />
stimulated by application of PtdIns(4,5)P(2). Amer1 binds CK1γ, recruits Axin and<br />
GSK3β to the plasma membrane and promotes complex formation between Axin and<br />
LRP6. We propose a mechanism for Wnt receptor activation by which generation of<br />
PtdIns(4,5)P(2) leads to recruitment of Amer1 to the plasma membrane, which acts<br />
as a scaffold protein to stimulate phosphorylation of LRP6.<br />
Altogether our data show that Amer1 has a dual functional role in Wnt signalling<br />
acting as an activator at the level of the Frizzled/LRP receptor complex and as an<br />
inhibitor by assembling the β-catenin destruction complex (Fig. 1). Of note, Amer1<br />
makes use of similar interaction partners, namely axin and GSK3 for both activities<br />
(Tanneberger et al., 2011b).<br />
31
Fig. 1 Dual functional role of Amer1 in Wnt signalling. Amer1 recruits the b-catenin<br />
destruction complex to the plasma membrane by binding to PIP2 which promotes b-catenin<br />
degradation and blocks Wnt signalling. When Wnts bind to Frizzled/LRP6 receptors more<br />
PIP2 is generated probably in vicinity to the receptors, Amer1 becomes recruited and<br />
stimulates phosphorylation of LRP6 receptors through interaction with GSK3 and CK1γ.<br />
Thus, Amer1 can act both as a repressor and an activator of the pathway.<br />
Amer2<br />
Amer2 (APC membrane recruitment 2; FAM123A) is a direct interaction partner of<br />
APC, related to Amer1/WTX. We showed that Amer2 recruits APC to the plasma<br />
membrane by binding to phosphatidylinositol 4,5-bisphosphate lipids via lysine-rich<br />
motifs and that APC links β-catenin and the destruction complex components axin<br />
and conductin to Amer2. Knockdown of Amer2 increased Wnt target gene expression<br />
and reporter activity in cell lines, and overexpression reduced reporter activity, which<br />
required membrane association of Amer2. In Xenopus embryos, Amer2 is expressed<br />
mainly in the dorsal neuroectoderm and neural tissues. Down-regulation of Amer2 by<br />
specific morpholino oligonucleotides altered neuroectodermal patterning, which could<br />
be rescued by expression of a dominant-negative mutant of Lef1 that interferes with<br />
β-catenin-dependent transcription. Our data characterize Amer2 for the first time as a<br />
negative regulator of Wnt signaling both in cell lines and in vivo and define Amer<br />
proteins as a novel family of Wnt pathway regulators.<br />
In yeast two hybrid screen using a C-terminal fragment of Amer2 as a bait we found<br />
that Amer2 is a direct interaction partner of EB1, which is a key factor in the<br />
32
organisation of the microtubule cytoskeleton. Of note, EB1 interacts with APC to<br />
stabilise microtubules. Amer2 binds to EB1 via specific S/TxIP motifs and recruits it to<br />
the plasma membrane. Coexpression of Amer2 and EB1 generates stabilised<br />
microtubules whereas knockdown of Amer2 leads to destabilisation of microtubules.<br />
Knockdown of Amer2, APC, or EB1 reduces cell migration, and morpholino-mediated<br />
downregulation of Xenopus Amer2 blocks convergent extension cell movements<br />
suggesting that the Amer2/EB1/APC complex regulates cell migration by altering<br />
microtubule stability (Pfister et al., JBC in revision). The Amer2 knock-out in mice has<br />
recently been generated in our lab but shows no obvious phenotypes, possibly due to<br />
compensation by Amer2. We are currently generating double-knockout animals of<br />
Amer1 and Amer2 for further characterization.<br />
Fig. 2 Scheme of Amer2 interactions with APC and EB1 in microtubule stabilization.<br />
Amer3<br />
Amer3 does not interact with the plasma membrane and is mainly located in the<br />
cytoplasm and occasionally in the cell nucleus. Moreover, in contrast to Amer1 and<br />
Amer2 this protein acts as an activator rather than inhibitor of Wnt signalling.<br />
Ongoing work aims at identifying the precise function of Amer3 and its interplay with<br />
the other Amers in the Wnt pathway.<br />
33
HIF target gene expression in renal cell carcinomas<br />
A key role for Activin B in cellular transformation after loss of the von Hippel-<br />
Lindau (VHL) tumour suppressor<br />
Ingrid Wacker, Martin Sachs,<br />
Clear cell renal cell carcinoma (clear cell RCC) is the most frequent tumour disease<br />
in the kidney. Most of these tumours contain mutations in the VHL tumour suppressor<br />
gene, which leads to stabilization of HIF1α and Hif2α, and causes increased<br />
transcription of HIF target genes. We found that VHL suppresses key features of cell<br />
transformation solely through downregulation of the HIF-dependent expression of<br />
Activin B, a member of the TGFβ superfamily. Activin B expression is repressed by<br />
restoration of VHL in VHL-deficient RCC cells and upregulated by hypoxia. RCC<br />
tumour samples show increased expression of Activin B as compared to normal<br />
kidney. Importantly, knockdown of Activin B reduces tumour growth of RCC cell lines<br />
in nude mice. Our data indicate that Activin B is a key mediator of VHL/HIF induced<br />
transformation in RCC (Wacker et al., 2009). We are currently searching for ways to<br />
block Activin B signalling using biological reagents in order to prevent RCC<br />
tumourigenesis.<br />
Liprinα4 is a novel HIF1α target gene<br />
Sandra Mattauch<br />
Liprin-α1 to liprin-α4 constitute a family of cytoplasmic proteins, which have been<br />
found in various multiprotein complexes. For liprin-α1 roles in synapse formation and<br />
cell spreading were described but other liprin family members are not well<br />
characterized. We found that liprin-α4 is upregulated in human clear cell renal cell<br />
carcinomas as compared to normal kidney tissue and that it is regulated the VHL/HIF<br />
system. The liprin-α4 gene promoter is directly activated by binding of the hypoxiainducible<br />
factor 1α (HIF-1α) to HRE consensus binding sites as shown by reporter<br />
assays and chromatin immunoprecipitations. RNAi mediated knockdown of liprin-α4<br />
leads to reduced E-cadherin and β-catenin levels at cell junctions and to dissociation<br />
of epithelial cell contacts. Our data describe for the first time liprin-α4 as a hypoxiainduced<br />
gene potentially involved in cell-cell adhesion (Mattauch et al., 2010).<br />
34
2012<br />
Publications (2009-2012)<br />
Original Articles<br />
Vijaya Chandra, S.H., Wacker, I., Appelt, U.K., Behrens, J., and Schneikert, J.<br />
(2012). A common role for various human truncated adenomatous polyposis<br />
coli isoforms in the control of Beta-catenin activity and cell proliferation. PLoS<br />
One 7, e34479.<br />
Pfister, A.S., Tanneberger, K., Schambony, A., and Behrens, J. (2012). Amer2<br />
protein is a novel negative regulator of Wnt/beta-catenin signaling involved in<br />
neuroectodermal patterning. J Biol Chem 287, 1734-1741.<br />
Hadjihannas, M.V., Bernkopf, D.B., Bruckner, M., and Behrens, J. (2012). Cell cycle<br />
control of Wnt/beta-catenin signalling by conductin/axin2 through CDC20.<br />
EMBO Rep 13, 347-354.<br />
2011<br />
Tanneberger, K., Pfister, A.S., Kriz, V., Bryja, V., Schambony, A., and Behrens, J.<br />
(2011a). Structural and Functional Characterization of the Wnt Inhibitor APC<br />
Membrane Recruitment 1 (Amer1). J Biol Chem 286, 19204-19214.<br />
Tanneberger, K., Pfister, A.S., Brauburger, K., Schneikert, J., Hadjihannas, M.V.,<br />
Kriz, V., Schulte, G., Bryja, V., and Behrens, J. (2011b). Amer1/WTX couples<br />
Wnt-induced formation of PtdIns(4,5)P2 to LRP6 phosphorylation. EMBO J 30,<br />
1433-1443.<br />
Schneikert, J., Brauburger, K., and Behrens, J. (2011). APC mutations in colorectal<br />
tumours from FAP patients are selected for CtBP-mediated oligomerization of<br />
truncated APC. Hum Mol Genet 20, 3554-3564.<br />
2010<br />
Schietke, R., Warnecke, C., Wacker, I., Schodel, J., Mole, D.R., Campean, V.,<br />
Amann, K., Goppelt-Struebe, M., Behrens, J., Eckardt, K.U., et al. (2010). The<br />
lysyl oxidases LOX and LOXL2 are necessary and sufficient to repress Ecadherin<br />
in hypoxia: insights into cellular transformation processes mediated<br />
by HIF-1. J Biol Chem 285, 6658-6669.<br />
Mattauch, S., Sachs, M., and Behrens, J. (2010). Liprin-alpha4 is a new hypoxiainducible<br />
target gene required for maintenance of cell-cell contacts. Exp Cell<br />
Res 316, 2883-2892.<br />
Kohler, E.M., Brauburger, K., Behrens, J., and Schneikert, J. (2010). Contribution of<br />
the 15 amino acid repeats of truncated APC to beta-catenin degradation and<br />
selection of APC mutations in colorectal tumours from FAP patients.<br />
Oncogene 29, 1663-1671.<br />
Hadjihannas, M.V., Bruckner, M., and Behrens, J. (2010). Conductin/axin2 and Wnt<br />
signalling regulates centrosome cohesion. EMBO Rep 11, 317-324.<br />
35
2009<br />
Wacker, I., Sachs, M., Knaup, K., Wiesener, M., Weiske, J., Huber, O., Akcetin, Z.,<br />
and Behrens, J. (2009). Key role for activin B in cellular transformation after<br />
loss of the von Hippel-Lindau tumour suppressor. Mol Cell Biol 29, 1707-1718.<br />
Rotte, A., Bhandaru, M., Foller, M., Biswas, R., Mack, A.F., Friedrich, B., Rexhepaj,<br />
R., Nasir, O., Ackermann, T.F., Boini, K.M., et al. (2009). APC Sensitive<br />
Gastric Acid Secretion. Cell Physiol Biochem 23, 133-142.<br />
Nasir, O., Wang, K., Foller, M., Gu, S., Bhandaru, M., Ackermann, T.F., Boini, K.M.,<br />
Mack, A., Klingel, K., Amato, R., et al. (2009). Relative resistance of SGK1<br />
knockout mice against chemical carcinogenesis. IUBMB Life 61, 768-776.<br />
Kohler, E.M., Chandra, S.H., Behrens, J., and Schneikert, J. (2009). Beta-catenin<br />
degradation mediated by the CID domain of APC provides a model for the<br />
selection of APC mutations in colorectal, desmoid and duodenal tumours.<br />
Hum Mol Genet 18, 213-226.<br />
TRAINING OF GRADUATE AND MEDICAL STUDENTS<br />
Doctoral theses (Biology)<br />
Astrid Pfister<br />
Klonierung und funktionelle Charakterisierung von AMER2<br />
Katharina Brauburger<br />
<strong>Molekulare</strong> Funktionsanalyse von APC<br />
Sandra Mattauch<br />
Identifizierung und Charakterisierung von HIF-Zielgenen im Nierenzellkarzinom<br />
Shree Harsha Vijaya Chandra<br />
Blockade des Wachstums von Dickdarmkrebs durch RNA Interferenz<br />
Doctoral theses (Molecular Medicine)<br />
Dominic Bernkopf<br />
<strong>Molekulare</strong>r und funktioneller Vergleich von Axin und Conductin/Axin2<br />
Kristina Tanneberger<br />
<strong>Molekulare</strong> Charakterisierung des Tumoursuppressors AMER1/WTX<br />
36
DIVISION OF MOLECULAR IMMUNOLOGY<br />
(Department of Internal Medicine III)<br />
Head: Hans Martin Jäck, Dr. rer. nat.<br />
Professor of Immunology<br />
Address: Division of Molecular Immunology<br />
Glückstr. 6<br />
D-91054 Erlangen<br />
Telefone: + 49 (9131) 85 35912<br />
Fax: + 49 (9131) 85 39343<br />
E-mail: hjaeck@molmed.uni-erlangen.de<br />
Homepage: www.molim.uni-erlangen.de<br />
Dirk Mielenz, Dr. rer. nat.<br />
Jürgen Wittmann, Dr. rer. nat.<br />
Wolfgang Schuh, Dr. rer. nat.<br />
Head<br />
Hans-Martin Jäck, Prof. Dr. rer. nat.<br />
Professor of Immunology<br />
Supporting Staff<br />
Elisabeth Lang, Secretary<br />
Postdoctoral Fellows<br />
37<br />
Barbara Fürnrohr, Dr. rer. nat.<br />
Rebecca Winkelmann, Dr. rer. nat.<br />
Martina Porstner, Dr. rer. nat.
Andreas Brandl*<br />
Sebastian Dütting*<br />
Sandra Schreiber*<br />
* PhD received<br />
Doctoral Students (Biology)<br />
Pavitra Purohit<br />
Julia Schmid<br />
Sebastian Brachs<br />
Patrick Daum<br />
Carmen Kroczek*<br />
Stefanie Thiele*<br />
Anke Lang*<br />
Doctoral Students (Molecular Medicine & Medicine)<br />
Martina Porstner*<br />
Rebecca Winkelmann*<br />
* PhD received<br />
Edith Roth<br />
Christiane Lang<br />
Heike Danzer<br />
Sandra Hagen<br />
Technicians<br />
Manuela Hauke<br />
Lena Sandrock<br />
Katrin Weiß<br />
Professor Emeritus<br />
Prof. Dr. med. Dr.<br />
mult. h.c. Joachim R.<br />
Kalden<br />
38<br />
Alexandra Klej<br />
Uwe Appelt
<strong>Research</strong><br />
Our research concentrates on molecular mechanisms that guide the development of<br />
antibody-producing B cells and control the adaptive humoral immunity in healthy<br />
organisms. In addition, we are interested in strategies to target pathologic plasma<br />
cells in autoimmune disease and in patients with multiple myeloma.<br />
Nonsense-mediated mRNA decay in lymphocytes<br />
Jürgen Wittmann, Carmen Baumgarten, Manuela Hauke, Heike Danzer and Hans-<br />
Martin Jäck<br />
Identification of novel factors involved in nonsense-mediated mRNA decay in<br />
higher eukaryotes<br />
Nonsense-mediated mRNA decay (NMD) is an essential eukaryotic pathway that<br />
recognizes and degrades erroneous mRNAs that contain a premature termination<br />
codon (nonsense mRNAs). By doing so, a negative influence on physiologic<br />
functions within a cell by faulty mRNAs is prevented, and error-free gene expression<br />
is guaranteed. Three evolutionary conserved proteins, UPF1, UPF2 and UPF3, play<br />
important roles in NMD. In particular, UPF2 fulfils a central role as adaptor protein,<br />
because it interacts with UPF1 and UPF3. However, not much is known about the<br />
biochemical role of UPF2 and its precise function in the different effector arms of<br />
NMD. We are therefore planning to identify interaction partners of key NMD factors<br />
by immunoprecipitation followed by mass spectrometric analysis to shed some light<br />
on mechanistic details of UPF function during NMD.<br />
Collaboration with Henning Urlaub (Göttingen)<br />
Function of the nonsense-mediated mRNA decay pathway during murine<br />
lymphocyte development<br />
As a result of the programmed rearrangements that generate the diverse<br />
immunoglobulin repertoire, nonsense codons are frequently generated in B- and Tcell<br />
receptor genes. Therefore, during B- and T-cell-development, a large number of<br />
lymphoid precursors with non-functional mRNAs are produced, which have to be<br />
detected and degraded early by the NMD pathway to avoid the production of<br />
deleterious products. To start addressing the role of NMD during lymphocyte<br />
development, we have generated two different conditional knock-out mice for one of<br />
the key factors of NMD. Although NMD is predicted to be important during<br />
embryogenesis, our conditional knock-out strategy allows us to study the role of NMD<br />
not only in lymphocyte development, but also in disease prevention in pre-selected<br />
tissues in the adult. Therefore, we will address presently unanswered fundamental<br />
questions about the role of NMD in B cell development and the basic NMD<br />
mechanism.<br />
Collaboration with Bo Porse (Copenhagen)<br />
39
microRNAs in lymphocytes in health and disease<br />
Jürgen Wittmann, Markus Zwick, Ina Wirries, Sandra Schreiber, Patrick Daum,<br />
Andreas Brandl, Martina Porstner, Manuela Hauke, Heike Danzer and Hans-Martin<br />
Jäck<br />
Role of microRNAs in B cell development in health and disease<br />
MicroRNAs (miRNAs) are a class of small endogenous non-coding RNAs that<br />
regulate gene expression at the post-transcriptional level by targeting partially<br />
sequence-complementary mRNAs. To investigate the role of miRNAs in B cell<br />
development, we used deep sequencing analysis of sorted primary B cells of several<br />
developmental stages to profile their miRNome. These studies allowed us to<br />
determine a set of marker miRNAs characteristic of the respective developmental<br />
stage. In addition, stage-specific novel miRNAs and other small RNA classes were<br />
discovered, opening up new research avenues for elucidating the fine-tuning of gene<br />
expression in murine B cell development.<br />
To expand the known regulatory function of miRNAs in early hematopoiesis and to<br />
test the hypothesis that miRNAs play a role in the pre-B cell receptor (pre-BCR)mediated<br />
control of early B cell development, we used a tetracycline-inducible µ<br />
heavy chain mouse model to identify differently expressed miRNAs in pro- and pre-B<br />
cells by miRNA microarray- and deep sequencing analysis. Several miRNAs were<br />
found to be up- or downregulated after µ heavy chain induction. In silico analysis<br />
identified several potential mRNA targets of these miRNAs that are involved in early<br />
B cell development, BCR signal transduction, opening of the Ig light chain locus as<br />
well as proliferation and cancer development. Functional assays with overexpressed<br />
miRNAs and reporter gene assays revealed that they indeed regulate key processes<br />
in early B cell development.<br />
Role of microRNAs in rheumatic diseases<br />
Rheumatoid arthritis is a chronic, systemic, inflammatory autoimmune disease that<br />
has its primary target in synovial tissues. It principally attacks the joints, which<br />
produce an inflammatory reaction that often progresses to destruction of the articular<br />
cartilage and bones and may eventually result in ankylosis of the joints. The major<br />
goal of this project is to gain insights into the molecular circuits that control the<br />
development of rheumatoid- and autoimmune diseases. Our short-term aim is to<br />
identify prognostic, diagnostic and potentially therapeutic miRNA markers and to<br />
better understand the role miRNAs play in the development of rheumatoid diseases.<br />
Plasma cell homing and B cell homeostasis controlled by Krüppellike<br />
factor 2 (KLF2)<br />
Rebecca Winkelmann, Lena Sandrock, Wolfgang Schuh and Hans-Martin Jäck<br />
Plasma cells are powerful micro factories producing thousands of antibody molecules<br />
per second and thereby protecting the organism from harmful pathogens and<br />
infections. Once a B cell encounters its specific antigen, a fascinating differentiation<br />
program is initiated that leads to morphological cellular restructuring and converting<br />
40
the B cell into an antibody-producing cell, the so-called plasma cell. Plasma cells can<br />
be subdivided into short- and long-lived plasma cells. Short-lived plasma cells<br />
predominantly produce IgM and have a life-span of approximately one week; in<br />
contrast long-lived plasma cells continuously produce high affinity IgG or IgA<br />
molecules and survive for years. Long-lived plasma cells, which are generated in<br />
secondary lymphoid tissues, have to reach specialized survival niches formed by<br />
stromal and other cells in the bone marrow. Still, it is puzzling how migration, homing<br />
and survival of these cells are controlled.<br />
Krüppel-like factor 2 (KLF2/LKLF) belongs to the family of Krüppel-like transcription<br />
factors, which consists of at least 17 members in mammals. Krüppel-like<br />
transcription factors bind to GC rich DNA domains via three C-terminal zinc fingers<br />
and are involved in controlling proliferation and terminal differentiation of various cell<br />
types. KLF2 was originally discovered in lung tissue and was shown to be important<br />
for cardiovascular development. Apart from its role in lung and cardiovascular<br />
development, KLF2 plays an important role in activation and migration of T<br />
lymphocytes.<br />
Using mice with a B cell specific deletion of KLF2, we demonstrated that KLF2 is<br />
crucial for proper homing of antigen-specific plasma cells to the bone marrow and for<br />
B cell homeostasis. In KLF2 deficient animals all splenic B cell subsets including B1<br />
cells were present, but their numbers were increased with a clear bias for marginal<br />
zone (MZ) B cells. In contrast, less peyers patches harboring fewer B cells were<br />
found and B1 cells in the peritoneal cavity were almost absent. B cell specific deletion<br />
of KLF2 results in a clear reduction of plasma cells in the bone marrow, whereas<br />
plasma cell numbers in the spleen and the blood were fairly normal, indicating that<br />
KLF2 plays an important role in homing of plasma cells to the bone marrow (Fig. 1).<br />
Since we found diminished levels of ß7 Integrin and L-Selectin on KLF2-deficient B<br />
cells, we propose that KLF2 regulates plasma cell homing to the bone marrow via<br />
regulation of these two cell adhesion molecules. Future experiments using a plasma<br />
cell-specific GFP reporter mouse will clarify the role of KLF2 in humoral immunity and<br />
provide new ways to interfere with the generation of pathologic plasma cells in<br />
patients with multiple myeloma and autoimmune disease.<br />
Fig. 1 Elispot assay of TNP-specific IgG secreting cells in spleen and bone marrow 14 days after<br />
boost immunization with TNP-KLH. A triplicate of one representative experiment is shown to the left,<br />
and results of all analyzed littermates are summarized with one dot representing the mean value of<br />
triplicates of one mouse is shown to the right.<br />
41
Function of EFhd1 and EFhd2 in B cells and brain in vivo<br />
Pavitra Purohit, Sebastian Brachs, Sebastian Dütting, Carmen Kroczek, Christiane<br />
Lang and Dirk Mielenz<br />
Antigen-induced B cell activation depends on a subset of antigen-B cell receptor<br />
(BCR) complexes that partition into plasma membrane microdomains, thereby,<br />
controlling the BCR-elicited calcium (Ca 2+ ) efflux from the endoplasmatic reticulum.<br />
This, in turn, regulates the total cytosolic Ca 2+ concentration [Ca 2+ ]i after BCR<br />
stimulation. Amplitude and duration of [Ca 2+ ]i in response to BCR activation governs<br />
activity of pro- or anti-apoptotic transcription factors, NF-AT and NF-�B. To identify<br />
mechanisms mediating membrane microdomain association of the BCR, a couple of<br />
years ago we defined the membrane microdomain proteome of B cells by separating<br />
purified membrane microdomains on 2D gels, followed my mass spectrometry.<br />
Thereby, we identified the new Ca 2+ binding protein Swiprosin-1/EFhd2 (EFhd2).<br />
EFhd2 regulates proximal BCR signaling and [Ca 2+ ]i via a mechanism that involves<br />
low-affine (110 �M) and cooperative Ca 2+ binding to EFhd2 in a 2:1 molar ratio, as<br />
well as membrane microdomain association of EFhd2 and proximal BCR signaling<br />
proteins. In addition to enhancing proximal BCR signals, EFhd2 interferes with antiapoptotic<br />
NF-�B activation, thereby, acting pro-apoptotically in B cells. Thus, loss of<br />
EFhd2 was expected to affect B cell selection and activation. To elucidate the<br />
function of EFhd2 in vivo, we generated EFhd2 deficient mice (EFhd2 K.O.).<br />
Surprisingly, B cell development and basal immunoglobulin (Ig) titers of all<br />
subclasses were normal in EFhd2 K.O. mice. However, EFhd2 K.O. mice responded<br />
slightly better to T-independent and T-dependent immunizations. More clearly, EFhd2<br />
K.O. mice developed higher affine antibodies towards a T-dependent antigen after<br />
recall immunization. We tested whether that could be due to increased competition<br />
amongst B cells, which would favour selection of high-affine B cell clones by T cells.<br />
In fact, EFhd2 K.O. mice developed larger germinal centers after immunization with<br />
sheep red blood cells. Along these lines, EFhd2 K.O. mice develop anti double<br />
stranded DNA antibodies after 1 year of age, pointing to either a defect in negative B<br />
cell selection or enhanced polyclonal activation. We obtained evidence for the latter<br />
point through polyclonal stimulation of purified B cells in vitro with lipopolysaccharide,<br />
demonstrating that EFhd2 K.O. B cells are 1) pre-activated and 2) switch faster from<br />
this pre-activated state into the plasma cell differentiation programme. In summary,<br />
EFhd2 is a negative regulator of B cell activation through an as yet to be defined<br />
mechanism.<br />
In contrast to EFhd2 that is expressed in all B cell stages, the related EFhd1<br />
becomes down-regulated during early B cell development by the pre-BCR. Activity of<br />
the transcription factor Foxo1, that controls stress responses, senescence and<br />
expression of recombinase activating genes (rag), is controlled by the pre-BCR as<br />
well as Interleukin-7 (IL-7). Interestingly we found a physical interaction of<br />
endogenous EFhd1 with endogenous Foxo1 in the cytoplasm of the pro B cell line<br />
38B9, as well as in 293 cells transfected with EFhd1. EFhd2 does not interact with<br />
Foxo1. To circumvent down-regulation of EFhd1 by the pre-BCR we generated<br />
transgenic mice which ectopically express EFhd1 (EFhd1tg) both in B as well as in T<br />
cells. In contrast to data obtained with an in vitro differentiation system, ectopic<br />
expression of EFhd1 did not affect steady state early B cell development in vivo.<br />
However, transgenic B and T cells expressed more CD62L, a Foxo1 target gene, and<br />
revealed increased Foxo1 expression on the protein level. We hypothesize that<br />
EFhd1 regulates Foxo1 function positively. This interaction should contribute to<br />
42
Foxo1 activity in early B cells in the context of IL-7 and pre-BCR signaling. Loss of<br />
EFhd1 should induce loss of function of Foxo1, thereby, reducing rag expression and<br />
slowing down early B cell development. Both gain and loss of function of EFhd1 may<br />
only be revealed under competitive conditions. Thus, we will create mixed bone<br />
marrow chimeras of wt and EFhd1tg bone marrow as well as wt and EFhd1 K.O.<br />
bone marrow and analyze the putative contribution of EFhd1 to early B cell<br />
development<br />
Since there was evidence that EFhd2 might be involved in neurodegeneration<br />
mediated by the microtubule-stabilizing protein tau we tested whether EFhd2<br />
modulates tau function. Surprisingly, we observed that co-expression of EFhd2 with<br />
mutant tau proteins (tau P301S and tau �K280), that cause frontotemporal dementia<br />
associated with parkinsonism (FTDP), but not with wildtype tau, caused degradation<br />
of EFhd2, but not of the co-expressed GFP. We are currently elucidating the<br />
proteolytic pathway underlying this degradation process. In line with a putative<br />
interaction of tau and EFhd2, we detected EFhd2 with newly generated monoclonal<br />
antibodies in ordered presynaptic complexes in murine as well as human brain<br />
sections. Interestingly, the presynaptic, ordered expression of EFhd2 was completely<br />
abolished in barins of Alzheimer’s patients. Likewise, EFhd2 co-localized with tau and<br />
with tau tangles in brains of Alzheimer’s patients. Finally we observed that the<br />
presynaptic marker Bassoon was largely absent from synaptic structures in brains of<br />
EFhd2 K.O. mice whereas tau expression was stronger and more confined to<br />
presynaptic complexes than in wildtype mice. Taken together we hypothesize that<br />
EFhd2 modulates tau function to control the composition of pre-synaptic complexes.<br />
This might be important during onset and progression of tau-mediated<br />
neurodegenerative diseases and for learning or rewarding processes.<br />
Genetic and functional analysis of Lupus-associated risk alleles<br />
Katrin Weiß and Barbara Fürnrohr<br />
Systemic Lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease<br />
involving multiple organs including skin, joints, kidneys, brains, the cardiovascular<br />
system and serosal membranes. Immunologically, SLE is characterised by the<br />
presence of antinuclear autoantibodies, especially against double stranded (ds) DNA<br />
and nucleosomes, activation of the complement system during flares and type I<br />
interferon secretion. The etiology of SLE remains elusive, however, an interplay of<br />
genetic and environmental factors is considered to ultimately cause immune<br />
dysregulation, resulting in clinical symptoms. Twin studies have reported a<br />
concordance of 24-57% and 2-5% in monozygotic and dizygotic twins, respectively,<br />
therefore SLE has an estimated heritability of 66%. Recent genome-wide association<br />
studies together with candidate gene studies have uncovered four major candidate<br />
gene loci, namely the MHC class II locus IKZF1, STAT4 and ITGAM which are most<br />
probably of functional relevance in SLE.<br />
Genetic variation at the ITGAM gene has been identified as a key genetic<br />
susceptibility effect in human systemic lupus erythematosus (SLE). It is one of the<br />
strongest known genetic risk factors in SLE, and is common (minor allele frequency<br />
approximately 10%) in all except East Asian populations. Interest has specifically<br />
focussed on the rs1143679 variant, which encodes an arginine to histidine amino<br />
acid change at position 77 in the �-propeller of the extracellular domain in CD11b<br />
which is encoded by ITGAM. As part of the complement receptor CR3, CD11b is<br />
43
mainly expressed on phagocytes, functioning as an adhesion molecule and a<br />
phagocytic receptor.<br />
At the Department of Medical and Molecular Genetics at King’s College in London in<br />
the group of Professor Timothy Vyse we have studied together with Dr. Benjamin<br />
Rhodes ex vivo monocytes/monocyte-derived macrophages from healthy volunteers<br />
homozygous for the 77H variant compared with homozygous wild-type (WT) controls.<br />
In cells isolated from donors homozygous for 77H we observed a reduction in the<br />
phagocytosis of iC3b opsonised sheep erythrocytes (sRBCiC3b) in comparison to WT<br />
cells.<br />
1160<br />
Ch04 Ch02/C h05 Ch05<br />
Fig. 1 Phagocytic Assay with red-fluorescent labelled iC3b-opsonised sheep red blood cells<br />
internalised by green-fluorescent labelled human macrophages.<br />
In addition, the adhesion of 77H monocytes was reduced to a range of CR3 ligands,<br />
such as iC3b, fibrinogen, fibronectin and DC-SIGN. To confirm the functionality of<br />
R77H specific ITGAM variants were transfected into COS7 cells and defective<br />
phagocytosis was observed in COS7 cells expression the 77H variant. We could also<br />
demonstrate differences in the release of Toll-like receptor-induced pro-inflammatory<br />
cytokines from monocytes of donors with different ITGAM genotypes following preengagement<br />
of CR3 using sRBCiC3b. The R77H variant therefore impairs a broad<br />
range of CR3 effector functions in human monocytes.<br />
CR3 ligation is likely to be important in immune complex and apoptotic cell clearance,<br />
both of which may contribute to the pathogenesis of SLE. Our future experiments will<br />
include phagocytic assays with monocytes from donors with different ITGAM<br />
genotype using fluorescent labelled apoptotic cells. Protein purification and structural<br />
analysis of the individual CD11b variants will hopefully unravel the functional<br />
differences observed in adhesion and phagocytosis.<br />
Collaboration with Prof. Timothy Vyse and Dr. Ben Rhodes (King’s College London)<br />
44
2009<br />
Publications (2009-2012)<br />
Original Articles (members are underlined)<br />
Trageser, D., Iacobucci, I., Nahar, R., Duy, C., Von Levetzow, G., Klemm, L., Park,<br />
E., Schuh, W., Gruber, T., Herzog, S., Kim, Y.M., Hofmann, W.K., Li, A.,<br />
Storlazzi, C.T., Jäck, H.M., Groffen, J., Martinelli, G., Heisterkamp, N., Jumaa,<br />
H., and Müschen, M. (2009). Pre-B cell receptor-mediated cell cycle arrest in<br />
Philadelphia chromosome-positive acute lymphoblastic leukemia requires<br />
IKAROS function. J Exp Med, 206 (8): 1739-1753.<br />
Urbonaviciute, V., Meister, S., Fürnrohr, B.G., Frey, B., Gückel, W., Schett, G.,<br />
Herrmann, M., and Voll, R.E. (2009). Oxidation of the alarmin high-mobility<br />
group box 1 protein (HMGB1) during apoptosis. Autoimmunity. 42 (4):305-7.<br />
2010<br />
Danke, C., Grünz, X., Wittmann, J., Schmidt, A., Agha-Mohammadi, S., Kutsch, O.,<br />
Jäck, H. M., Hillen, W., and Berens, C. (2010). Adjusting transgene expression<br />
levels in lymphocytes with a set of inducible promoters. J Gene Med, 12:501-<br />
515.<br />
Duy, C., Yu, J.J., Nahar, R., Swaminathan, S. , Kweon, S.M., Polo, J.M., Valls, E.,<br />
Klemm, L., Shojaee, S., Cerchietti, L., Schuh, W., Jäck, H.M., Hurtz, C.,<br />
Ramezani-Rad, P., Herzog, S., Jumaa, H., Koeffler, H.P., De Alborán, I.M.,<br />
Melnick, A.M., Ye, B.H., and Müschen, M. (2010). BCL6 is critical for the<br />
development of a diverse primary B cell repertoire. J Exp Med, 207 (6), pp.<br />
1209-1221.<br />
Fürnrohr, B.G., Wach, S., Haslbeck, M., Weber, C.K., Stach, C.M., Hueber, A., Graef,<br />
D., Spriewald, B., Manger, K., Herrmann, M., Kaufmann, K.M., Summer, G.F.,<br />
James, J.A., Goodmon, E., Kelly, J.A., Schett, G., Winkler, T., Harley, J.B.,<br />
and Voll, R.E. (2010). Hsp70 polymorphisms are genetically associated with<br />
systemic lupus erythematosous. Ann Rheum Dis, 69 (11):1983-9.<br />
Hakkim, A., Fürnrohr, B.G., Amann, K., Laube, B., Abu Abed, U., Brinkmann, V.,<br />
Herrmann, M., Voll, R.E., and Zychlinsky, A. (2010). Impairment of neutrophil<br />
extracellular trap degradation is associated with lupus nephritis. PNAS, 107<br />
(21):9813-8.<br />
Kroczek, C., Lang, C., Brachs, S., Grohmann, M., Dutting, S., Schweizer, A.,<br />
Nitschke, L., Feller, H. M., Jäck, H.M. and Mielenz, D. (2010). Swiprosin-<br />
1/EFhd2 controls B cell receptor signaling through the assembly of the B cell<br />
receptor, Syk, and phospholipase C gamma2 in membrane rafts. J Immunol,<br />
184:3665-3676.<br />
45
Lang, V. R., Mielenz, D., Neubert, K., Bohm, C., Schett, G., Jäck, H.M., Voll, R.E.,<br />
and Meister, S. (2010). The early marginal zone B cell-initiated T-independent<br />
type 2 response resists the proteasome inhibitor bortezomib. J Immunol,<br />
185:5637-5647.<br />
Metzner, M., Schuh, W., Roth, E., Jäck, H.M., and Wabl, M. (2010). Two forms of<br />
activation-induced cytidine deaminase differing in their ability to bind agarose.<br />
PloS one, 5 (1).<br />
Weber, C. K., Haslbeck, M., Englbrecht, M., Sehnert, B., Mielenz, D., Graef, D.,<br />
Distler, J. H., Mueller, R. B., Burkhardt, H., Schett, G., Voll, R. E., and<br />
Fürnrohr, B. G. (2010). Antibodies to the endoplasmic reticulum-resident<br />
chaperones calnexin, BiP and Grp94 in patients with rheumatoid arthritis and<br />
systemic lupus erythematosus. Rheumatology (Oxford), (12):2255-63.<br />
2011<br />
Avouac, J., Fürnrohr, B.G., Tomcik, M., Palumbo, K., Zerr, P., Horn, A., Dees, C.,<br />
Akhmetshina, A., Beyer, C., Distler, O., Schett, G., Allanore, Y., Distler, J.H.<br />
(2011). Inactivation of the transcription factor STAT4 prevents inflammationdriven<br />
fibrosis in systemic sclerosis animal models. Arthritis Rheum, 63<br />
(3):800-9.<br />
Brandl, A., Wittmann, J., and Jäck, H. M. (2011). Increased retroviral titers of miRNAencoding<br />
retroviruses by inhibition of the RNaseIII enzyme Drosha. Eur J<br />
Immunol, 41:549-551.<br />
Dedman, A. M., Majeed, Y., Tumova, S., Zeng, F., Kumar, B., Munsch, C., Bateson,<br />
A. N., Wittmann, J., Jäck, H. M., Porter, K. E., and Beech, D. J.. (2011).<br />
TRPC1 transcript variants, inefficient nonsense-mediated decay and low upframeshift-1<br />
in vascular smooth muscle cells. BMC Mol Biol, 12:30.<br />
Marschall, J.S., Wilhelm, T., Schuh, W., and Huber, M. (2011). MEK/Erk-based<br />
negative feedback mechanism involved in control of Steel Factor-triggered<br />
production of Krüppel-like factor 2 in mast cells. Cell Signal, (4):879-88.<br />
Rosenbaum, S., Kreft, S., Etich, J., Frie, C., Stermann, J., Grskovic, I., Frey, B.,<br />
Mielenz, D., Pöschl, E., Gaipl, U., Paulsson, M., and Brachvogel, B. (2011).<br />
Identification of novel binding partners (annexins) for the cell death signal<br />
phosphatidylserine and definition of their recognition motif. J Biol Chem,<br />
286:5708-5716.<br />
Weber, C.K., Mielenz, D., Voll, R.E., and Fürnrohr, B.G. (2011). Comment on:<br />
Antibodies to the endoplasmic reticulum-resident chaperones calnexin, BiP<br />
and Grp94 in patients with rheumatoid arthritis and systemic lupus<br />
erythematosus: Reply. Rheumatology (Oxford), 50:629-631.<br />
46
Winkelmann, R., Sandrock, L., Porstner, M., Roth, E., Mathews, M., Hobeika, E.,<br />
Reth, M., Kahn, M.L., Schuh, W., and Jäck, H.M. (2011). B cell homeostasis<br />
and plasma cell homing controlled by Krüppel-like factor 2. PNAS, 108 (2), pp.<br />
710-715.<br />
2012<br />
Buettner, M., Lang, A., Tudor, C.S., Meyer, B., Cruchley, A., Barros, M.H., Farrell, P.,<br />
Jäck, H.M., Schuh, W., and Niedobitek, G. (2012). Lytic EBV infection in<br />
epithelial cells but not in B lymphocytes is dependent on Blimp1. J Gen Virol,<br />
[Epub ahead of print].<br />
Hagen, S., Brachs, S., Kroczek, C., Fürnrohr, B.G., Lang, C., and Mielenz, D. (2012).<br />
The B cell receptor-induced calcium flux involves a calcium mediated positive<br />
feedback loop. Cell Calcium, [ePub 06Feb].<br />
Preußner, M., Schreiner, S., Hung, L.H., Porstner, M., Jäck, H.M., Benes, V., Rätsch,<br />
G., and Bindereif, A. (2012). HnRNP L and L-like cooperate in multiple-exon<br />
regulation of CD45 alternative splicing. Nucleic Acids Res. 2012 Mar 8. [Epub<br />
ahead of print]<br />
Books and Reviews<br />
Dütting, S., Brachs, S., and Mielenz, D. (2011). Fraternal twins: Swiprosin-1/EFhd2<br />
and Swiprosin-2/EFhd1, two homologous EF-hand containing calcium binding<br />
adaptor proteins with distinct functions. Cell Commun Signal, 9:2.<br />
Wittmann, J., and Jäck, H.M. (2011). microRNAs in rheumatoid arthritis: midget<br />
RNAs with a giant impact. Ann Rheum Dis, 70:Suppl 1:i92-i96.<br />
Wittmann, J., Jäck H.M., and Mashreghi, M.F. (2011). microRNAs in B- and T cells<br />
as regulators of inflammation. Z Rheumatol, 70:507-510.<br />
Rhodes B., Fürnrohr B.G., and Vyse, T.J. (2011). C-reactive protein in rheumatology:<br />
biology and genetics. Nat Rev Rheumatol. 7 (5):282-9.<br />
Sestak, A.L., Fürnrohr, B.G., Harley J.B., Merrill, J.T., and Namjou, B. (2011). The<br />
genetics of systemic lupus erythematosus and implications for targeted<br />
therapy. Ann Rheum Dis, 70 Suppl 1:i37-43.<br />
Wittmann, J., and Jäck, H.M. (2010). Serum microRNAs as powerful biomarkers in<br />
disease. Biochim Biophys Acta – Reviews on Cancer, 1806:200-207.<br />
Wittmann, J., and Jäck, H.M. (2010). New surprises from the deep - The family of<br />
small regulatory RNAs increases. ScientificWorldJournal, 10:1239-1243.<br />
47
TRAINING OF GRADUATE AND MEDICAL STUDENTS<br />
Doctoral theses (Biology)<br />
Andreas Brandl<br />
MicroRNA-vermittelte Kontrolle der Antigen-induzierten B-Zell-Differenzierung und<br />
deren Rolle in der B-Zell-Entwicklung<br />
Sebastian Dütting<br />
Charakterisierung von Swiprosin-2/EFHD1 und dessen Funktion während der frühen<br />
B-Zellentwicklung<br />
Carmen Kroczek<br />
Funktionelle Analyse von Swiprosin-1/EFhd2 im proximalen B-Zellrezeptor Signalweg<br />
Anke Lang<br />
Mechanismen der lytischen Reaktivierung des Epstein-Barr Virus<br />
Sandra Schreiber<br />
Die Rolle von microRNAs in der frühen B-Zellentwicklung<br />
Stefanie Thiele<br />
Die Rolle der microRNAs und Dicer in Entzündungszellen von<br />
Atemwegserkrankungen<br />
Doctoral theses (Molecular Medicine)<br />
Rebecca Winkelmann<br />
The function of Krüppel-like factor 2 in B cell development<br />
Martina Porstner<br />
Untersuchungen zur Rolle von microRNAs in der Plasmazelldifferenzierung und dem<br />
Multiplen Myelom<br />
48
Hematopoiesis Unit<br />
Chair of Genetics – Department Biology<br />
Head: Thomas Winkler, Dr. rer. nat.<br />
Professor for Genetics<br />
Address: Hematopoiesis Unit<br />
Glückstr. 6<br />
D-91054 ERLANGEN<br />
Telefone: + 49 (9131) 85 29136<br />
Fax: + 49 (9131) 85 29106<br />
E-mail: thomas.winkler@molmed.rz.uni-erlangen.de<br />
Homepage: http://www.genetik.nat.uni-erlangen.de<br />
Ute Wellmann, Dr. rer. nat. *<br />
* part of the time reported<br />
Sven Brenner °<br />
Agnes Giniewski<br />
Kristin Schröder<br />
° PhD received<br />
Tanja Fisch*<br />
Markus Mroz*<br />
* part of the time reported<br />
Head<br />
Thomas Winkler, Prof. Dr. rer. nat.<br />
Professor for Genetics<br />
Postdoctoral Fellows<br />
Doctoral Students (Biology)<br />
Sonja Pötzsch °<br />
Martina Seefried<br />
Technicians<br />
49<br />
Sabrina Sell<br />
Florian Weisel °<br />
Andrea Schneider<br />
Hannes Tittlbach*
<strong>Research</strong><br />
Our research focus lies on the selection processes at different stages of the<br />
development of B-lymphocytes. We investigate the genetic mechanisms for the early<br />
development of B-lymphocytes, the mechanisms for the loss of self-tolerance in the<br />
autoimmune disease systemic lupus erythematosus and antibody-mediated<br />
protection against cytomegalovirus. In our research we predominantly work with<br />
mouse models that we also create in our laboratory by the techniques of gene<br />
targeting (knock-out mice, knock-in mice, transgenic mice).<br />
B cell development and regulation of VDJ-recombination<br />
During the differentiation of B-lymphocytes the genes for the antibody molecules are<br />
assembled in a unique process called VDJ-recombination. VDJ-recombination is<br />
responsible for the enormous diversity of antibody molecules. This diversity is<br />
necessary to defend all possible invaders of our body. Whereas the molecular<br />
mechanism of the VDJ-recombination is understood in very much detail today, the<br />
regulation of this process is less well understood. All 7 different antigen-receptor<br />
gene loci (3 for immunoglobulins and 4 for T-cell-receptors) use the same VDJrecombination<br />
machinery, but still the expression of the different genes is tighly<br />
regulated. Antibody receptors are expressed only on B-lymphocytes and T-cell<br />
receptors only on T-lymphocytes. In addition, during development of B-lymphocytes<br />
the genes for the heavy chain of the immunoglobulin is recombined before the genes<br />
for the light chain and additional regulation exists that only one antigen-receptor is<br />
expressed on each B-lymphocyte.<br />
Our research focus is to investigate the accessibility of the immunoglobulin heavy<br />
chain genes for the VDJ-recombinase. The epigenetic mechanisms for the regulation<br />
of the chromatin state at the immunoglobulin loci is analyzed by modern methods<br />
(ChIP-on-ChiP, ChIP-Seq). In addition we try to identify the essential regulatory<br />
sequences at the immunoglobulin locus by gene-targeting.<br />
Regulation of VDJ-recombination in precursor B-lymphocytes<br />
Agnes Giniewski and Thomas Winkler<br />
VDJ recombination is strictly confined to the early precursors of T- and B-cells, where<br />
only T-cells recombine the T-cell-receptor loci and only B-cells recombine the B-cellreceptor<br />
loci. The differential regulation of VDJ recombination remains unknown as<br />
the Rag1 and Rag2 enzymes that are critical for this reaction are expressed in early<br />
B-cells as well as in early T-cells. It has been proposed, that the differentially<br />
regulated accessibility of the T- and B-cell receptor loci is the basis of this regulation.<br />
As chromatin accessibility is regulated by histone modifications, we generated a high<br />
50
esolution map of histone modifications at the complete IgH-locus (app. 2.8 Mb) from<br />
early B-cell progenitors. Chromatin immunoprecipitation (ChIP) experiments using<br />
primary pro-B cells from Rag -/- mice and specific antibodies for acetylated histone H3<br />
and several different histone H3 methylations were performed. For the quantification<br />
of the results we use custom-made high-density arrays for a high-resolution analysis<br />
of histone modifications of the complete IgH locus (ChIP-on Chip analysis). The IgH<br />
Eµ intron enhancer region from the switch region to the first D segment (DQ52) is<br />
found to be enriched for the two activating histone modifications H3Ac and<br />
H3K4Me2. We also have indications that within the VH gene cluster histone<br />
acetylation and histone H3 K4 methylation is limited to the VH gene segments.<br />
In the ChIP-on Chip analysis we discovered three new regions in the intergenic part<br />
of the distal VH cluster (we call them IVARs), which are associated with high levels of<br />
active chromatin marks (H3Ac and H3K4Me2/3) only in pro B cells but not in pro T<br />
cells.<br />
To elucidate the role of the IVARs in VH -> DJH recombination we were generating a<br />
knock out mouse, which is lacking the IVAR #3 element. By analyzing the VDJrecombination<br />
repertoire using high-throughput next generation sequencing we found<br />
that the usage of distal VH gene segments is altered in mutant mice, supporting our<br />
hypothesis that the IVAR elements are involved in the VDJ-recombination of distal<br />
VH-elements.<br />
A hypomorph mutation of the B cell receptor<br />
Sven Brenner and Thomas Winkler<br />
As a result from a gene targeting experiment in which we wanted to introduce a GFPreporter<br />
gene into the immunoglobulin locus, we incidentally created a hypomorphic<br />
IgH-gene allele. Due to a poly-adenylation site introduced into the enhancer intron<br />
the levels of Igµ heavy chain mRNA and protein are reduced approximately 5-fold. In<br />
heterozygous mice B cells expressing the targeted IgH allele are undetectable,<br />
although VDJ recombination at the targeted allele is normal.<br />
We could show for these novel gene-targeted mice that hypomorphic expression of<br />
µHC leads to augmented selection processes at all stages of B-cell development,<br />
noticeably at the expansion of pre-B cells, the positive selection of immature B<br />
lymphocytes in the bone marrow and the selection into the follicular, marginal zone<br />
and B1 B lymphocyte compartments in peripheral lymphoid organs. Immature as well<br />
as mature follicular and marginal zone B lymphocytes in the peripheral lymphoid<br />
organs express lower levels of the receptor for B-cell activating factor (BAFF). In<br />
addition, hypomorphic expression of the BCR favors receptor editing. Together, our<br />
results highlight the critical importance of pre-BCR and BCR receptor levels for the<br />
normal development of B-lymphocyte-subpopulations in the context of intact VDJ<br />
recombination and a diverse antibody repertoire.<br />
51
During the last 3 years we had successful collaborations with Dr. Lars Nitschke (Dep.<br />
Biology, Genetics, Erlangen).<br />
The role of B lymphocytes in the chronic autoimmune disease<br />
systemic Lupus erythematosus<br />
SLE is a multisystem autoimmune disease characterized by autoantibodies against<br />
nuclear antigens, particularly antibodies against native (double-stranded) DNA (antidsDNA).<br />
Glomerulonephritis is one of the most serious manifestations of the disease.<br />
The incidence of glomerulonephritis in SLE patients is about 40-60%. The nephritis<br />
that accompanies SLE is mediated by immune complexes that deposit in the kidney<br />
and initiate an inflammatory response leading to organ damage and failure. The<br />
presence of anti-dsDNA antibodies correlates with nephritis in both human patients<br />
and mice with a spontaneous lupus like disease. Our research focus is on both the<br />
mechanisms of the generation of anti-dsDNA antibodies and on the role of antidsDNA<br />
antibodies in the pathogenesis of lupus nephritis.<br />
Molecular mechanisms of glomerular deposition of autoantibodies and<br />
pathogenesis of lupus nephritis<br />
Ute Wellmann, and Thomas Winkler, Technician: Markus Mroz<br />
A monoclonal anti-dsDNA antibody from a SLE patient binds in vivo to the<br />
mesangium upon injection in mice. Recently we have identified a crossreactivity of<br />
this antibody with nucleolin, a multifunctional protein that had been shown to be<br />
displayed on the cell surface of endothelial cells. We can show that nucleolin-specific<br />
rabbit antisera also bind specifically in the glomerulus of mice upon injection<br />
supporting the notion that nucleolin is accessible for autoantibodies in the<br />
glomerulus. Furthermore, we found a strong correlation of anti-nucleolin<br />
autoantibodies with more severe glomerulonephritis in several mouse models for<br />
SLE. In addition sera from SLE patients with severe glomerulonephritis contain antinucleolin<br />
autoantibodies in elevated titres.<br />
To further elucidate the potential pathogenetic role of anti-nucleolin (crossreactive)<br />
autoantibodies we eluted immune complexes from kidneys from proteinuric SLE mice<br />
(NZB/W mice). The eluted antibodies were highly enriched for anti-nucleolin reactivity<br />
further supporting the pathogenic role of these autoantibodies.<br />
(Collaborations with Dr. Ole-Petter Rekvig, University Tromsö, Norway)<br />
The evolution of anti-dsDNA autoantibodies in germinal centers<br />
Kristin Kruse, Ute Wellmann and Thomas Winkler, Technician: Andrea Schneider<br />
and Markus Mroz<br />
52
It has been proposed that the anti-double-stranded DNA (dsDNA) response in<br />
patients with systemic lupus erythematosus (SLE) is antigen driven and that DNA or<br />
nucleosomes select anti-DNA reactive, somatically mutated B cells. Recently we<br />
showed that high-affinity binding to dsDNA and nucleosomes is acquired by somatic<br />
replacement mutations in a stepwise manner, presumably in germinal center<br />
reactions. Importantly, autoreactivity seems to by acquired de novo as antibodies that<br />
have been backmutated to the germline sequence lack any autoreactivity towards<br />
DNA (Wellmann et al. 2005, PNAS 102: 9258-63). Nucleosomes accumulating due to<br />
defects in clearing of apoptotic debris, might positively select high affinity anti-DNA B<br />
cells.<br />
To directly test this hypothesis we were generating knock-in mice expressing a<br />
backmutated, non-autoreactive, lupus autoantibody. Only 3 somatic mutations are<br />
necessary and sufficient to create high affinity anti-dsDNA reactivity in this antibody.<br />
We targeted the BCR heavy- and light chain loci to obtain 33.C9gl heavy chain and<br />
33.C9gl light chain double knockin mice. As expected, B cells expressing the<br />
revertant B-cell receptor are developing normally and show no evidence for<br />
tolerization. Upon immunization with a surrogate phage antigen the transgenic B cells<br />
form germinal centers and undergo somatic hypermutation. The three critical somatic<br />
hypermutations, which are necessary and sufficient for the acquisition of high affinity<br />
anti-dsDNA binding, were not observed in a large collection of sequences analyzed.<br />
In accordance with this, anti-DNA autoantibodies do not develop, even after repetitive<br />
immunizations and when FDCs were MFG-E8 deficient. These results strongly<br />
suggest a self-tolerance checkpoint by deletion of autoreactive clones during or after<br />
the germinal center reaction.<br />
(Collaboration with Dr. Martin Herrmann, Med. Dept. III, Erlangen)<br />
We had further successful collaborations with Dr. Reinhard Voll at the NFZ on the<br />
role of plasma cells in SLE (Starke et al., 2011).<br />
Antibody-based immune protection against Cytomegalovirus<br />
Infections with Cytomegalovirus are usually asymptomatic and 50 – 90 % of the<br />
human population is persistently infected with this herpes virus. Severe disease<br />
becomes apparent when the immune system of the infected individual is suppressed,<br />
for example after transplantation. In addition, human cytomegalovirus is an important<br />
congenital infection.<br />
We aim at the better understanding of humoral immune-responses against the virus<br />
to develop new therapeutic concepts and potential therapeutic antibodies for<br />
treatment. We carry out all research in this field in close collaboration with the group<br />
of Prof. Michael Mach at the Virology Institute.<br />
For our research we use the human cytomegalovirus (HCMV) as well as its close<br />
relative in the mouse, the murine cytomegalovirus (MCMV).<br />
53
Adoptive transfer of memory B cells as a new cell based therapy for infection<br />
with Cytomegalovirus after transplantation<br />
Florian Weisel, Martina Seefried, Anna Bootz*, Monika Dietz*, Astrid Karbach*, Julia<br />
Winkler # , Andreas Mackensen # , Michael Mach*, Thomas Winkler, Technicians:<br />
Andrea Schneider, Hannes Tittlbach<br />
* Institute for Clinical and Molecular Virology<br />
# Department of Internal Medicine 5, Hematology and Oncology<br />
Severe disease associated with cytomegalovirus (CMV) infection is still a major<br />
problem in transplant patients. Support of the patient’s immune defense against the<br />
virus is therefore a major goal in transplantation medicine. We use the murine model<br />
of CMV (MCMV) to investigate the potential of a cell-based strategy to support the<br />
humoral antiviral immune response. We have previously shown that a transfer of<br />
memory B cells was effective in protecting from an ongoing viral infection indicating a<br />
therapeutic potential of virus specific memory B cells. In the recent period for this<br />
report we analyzed the effector mechanisms for the protective effect of anti-CMV<br />
antibodies. We have clear data that Fc-receptor (FcR) mediated mechanisms,<br />
presumably antibody dependent cellular cytotoxicity (ADCC) play a major role in the<br />
protective effect of antibodies in this viral disease. Determination of viral load in<br />
organs (Fig. 1A, B) and analysis of survival (Fig. 1C) after serotherapy confirmed that<br />
FcγR-deficient mice are not protected by administration of serum from MCMVimmune<br />
donors. Further experiments with individual FcγRs revealed a complex and<br />
partly redundant function of the different FcγRs. Whereas genetic deletion or antibody<br />
blockade of either FcγRIII or FcγRIV alone have any measurable effect on antibody<br />
protection, a combined defect of FcγRIII and FcγRIV had strong effects on protective<br />
function of antibodies. With regard to effector cells we have the surprising finding that<br />
NK cells, which are believed to be efficient effectors for ADCC, have surprisingly no<br />
major role in antibody-mediated protection in CMV-infection as NK cell-depleted<br />
animals were fully protected by serum therapy. Preliminary results indicate that<br />
certain monocyte subpopulations that can be specifically depleted by clodronate<br />
liposomes are important for antibody protection. We are currently studying the<br />
function of these monocyte subpopulation and the role of FcγRI in antibody-mediated<br />
protection in CMV-infection.<br />
54
Fig. 1 Fc_Rs are essential for antibody-mediated protection from MCMV infection.<br />
Mice were infected with 10 5 plaque forming units MCMV157luc and treated with 100µl serum from<br />
naïve or MCMV-immune donors. (A) Bioluminescence imaging of mice 10 days after serum treatment.<br />
The pseudocolor scale indicates viral load. (B) Relative viral load in organs in mice 14days after<br />
serotherapy. Luciferase activity was measured in organ homogenates and relative light units (RLU)/15<br />
µg protein are shown. (C) Survival curve of 5 mice/group after serotherapy.<br />
Our data provide evidence that a cell based strategy using memory B-lymphocytes to<br />
support the humoral immune response can be effective to combat infectious<br />
pathogens in severely immunodeficient hosts, like patients after stem cell<br />
transplantation. To bring this strategy into the clinics, the preclinical technology<br />
development including registration and implementation according to AMG –<br />
guidelines were mandatory prerequisites for the initiation of a phase I/II clinical trial,<br />
particularly as no experience was available for the GMP-qualified production of Blymphocytes.<br />
We therefore developed protocols for the production of a GMP-qualified<br />
B-lymphocyte product from leukapheresis material during the last 2 years by using<br />
the CliniMacs-technology in cooperation with Miltenyi-Biotec. A two-step separation<br />
strategy was developed and validated under GMP-conditions in a validated GMPlaboratory<br />
(Department of Transfusion Medicine). The manufacturing license for the<br />
B-cell product will soon be obtained.<br />
As a second prerequisite for the initiation of a first-in-human phase I/IIa clinical trial<br />
we developed a clinical protocol for a phase I/II study in accordance with GCP<br />
guidelines. An adoptive transfer of B-lymphocytes after allogeneic stem cell<br />
55
transplantation represents a novel, world-wide first-in-man cellular therapy.<br />
Therefore, this therapy has to be evaluated in a Phase I/IIa clinical trial primarily for<br />
safety and feasibility. The B-lymphocyte product will be the investigational medicinal<br />
product (IMP) in this trial. After extensive discussion with stem cell transplantation<br />
specialists we considered that a phase I/II trial with patients at risk for HCMVreactivation<br />
shortly after stem cell transplantation would potentially provide<br />
inconclusive data, especially regarding safety, which has to be the primary endpoint<br />
of the study. We therefore intend a transfer of the B-lymphocyte product<br />
approximately 4-5 months after transplantation when B-lymphocyte numbers are still<br />
significantly reduced in patients receiving matched-unrelated grafts and revaccination<br />
of the patient is routinely performed in the clinic. For the patient, a<br />
significant benefit for the reconstitution of the humoral immune function would be<br />
expected by the transfer of the B-lymphocyte product. At the same time, routinely<br />
performed re-vaccinations would offer the unique possibility to assess the function of<br />
the transferred B-lymphocytes from the donor. For the immune monitoring of patients<br />
in the clinical trial we already developed methods for the analysis of the frequencies<br />
of antigen-specific memory B-lymphocytes and plasma-blasts for various viral<br />
antigens and vaccine antigens.<br />
Currently we complete the documents for the trial protocol, the investigator brochure<br />
and the IMP dossier for the application to Paul-Ehrlich-Institure with the help of the<br />
Center of Clinical Studies (CCS) of the University hospital. These preclinical and<br />
clinical aspects of our research are performed in close collaboration with Dr. Julia<br />
Winkler and Dr. Andreas Mackensen, Department of Internal Medicine 5 and Miltenyi<br />
Biotec and are supported by the BayImmuNet.<br />
Furthermore, we refined our murine model further including viral reactivation from<br />
latency as well as induction of graft-versus-host disease (GVHD) after bone marrow<br />
transplantation to adopt it as close as possible to the clinical situation. Using this<br />
model, we were able to demonstrate a vital importance of antibodies in prevention of<br />
virus reactivation following bone marrow transplantation. When B-cell deficient mice<br />
unable to produce antibodies in the serum were infected with MCMV, a rapid<br />
clearance of the virus was observed in the B-cell deficient mice, as expected,<br />
because these mice contain a normal T-cell compartment being able to control<br />
infection to latency. When these recipients were treated by irradiation and<br />
transplanted with autologous or allogeneic bone marrow a massive reactivation of<br />
MCMV was observed in B-cell deficient bone marrow recipient mice whereas mice<br />
with serum antibodies only showed a low level of reactivation of the virus Fig. 2). By<br />
day 30 after transplantation the virus in surviving B-cell deficient animals was under<br />
control, due to the newly formed immune system derived from the bone marrow<br />
transplant.<br />
When a graft-versus-host reaction was induced in this transplant setting we observed<br />
a massive and uncontrolled reactivation of MCMV, even in the presence of antibodies<br />
(data not shown). These preliminary data demonstrate a major clinical problem in<br />
56
stem cell transplantations for the first time in the mouse model and will enable us to<br />
refine our therapy concepts under these clinically relevant conditions.<br />
Fig. 2 Antibodies are important for prevention of MCMV reactivation after bone marrow<br />
transplantation<br />
C57Bl/6 mice and B-cell deficient JH -/- were infected with 10 5 plaque forming units of MCMV157luc<br />
and transplanted with bone marrow after lethal irradiation. Bioluminescence imaging of mice after<br />
primary infection, latency (d24) and after bone marrow transplantation.<br />
These experiments were in part (GVHD-model) performed in close collaboration with<br />
the group of Dr. Evelyn Ulrich, Department of Internal Medicine 5.<br />
Neutralizing human antibodies against HCMV<br />
Sonja Pötzsch and Thomas Winkler, Technicians: Tanja Fisch, Hannes Tittlbach and<br />
Uwe Appelt<br />
Human cytomegalovirus (HCMV) infections can lead to clinically manifested, often<br />
life-threatening disease among immunocompromised hosts, in particular solid organ<br />
or bone marrow transplant recipients. Owing to lack of immune response in these<br />
patients, virus replication and dissemination occurs uncontrollably. Therefore,<br />
57
passive immunization for prevention or amelioration of CMV disease in high-risk<br />
individuals is a major goal not only in transplant medicine. The administration of CMV<br />
neutralizing monoclonal antibodies could be a feasible approach and has shown to<br />
be very effective in the mouse model.<br />
In addition, infection during pregnancy has been recognized as a major problem for<br />
the newborn. Congenital (present at birth) CMV infection causes more long-term<br />
problems and childhood deaths than Down syndrome, fetal alcohol syndrome, and<br />
neural tube defects. Antibodies delivered to pregnant mothers at risk would have the<br />
potential to prevent severe sequelae, such as hearing loss and other CNS defects in<br />
about 30,000 children which are born with congenital CMV infection each year<br />
(numbers from CDC for the USA, http://www.cdc.gov/cmv/trends-stats.html).<br />
Target antigens of CMV neutralizing antibodies usually are glycoproteins in the viral<br />
membrane, the most immunogenic being glycoprotein B (gB). Glycoprotein B (gB) is<br />
a well conserved protein among herpesviruses. In the case of HCMV, gB is a major<br />
target for the virus neutralizing humoral immune response. Two antigenic domains<br />
(AD) on gB which are targets of neutralizing antibodies have been identified and<br />
characterized in some detail. AD-1 is located between aa 552-635 and AD-2 between<br />
aa 68-77 of gB strain AD169. A third antigenic domain (AD-3) which is located<br />
intravirally and which is not target of neutralizing antibodies has also been identified.<br />
We have used data from the recently<br />
established 3D structure of HSV-1 gB for<br />
molecular modelling of HCMV gB and<br />
based on the model we have identified<br />
two domains on HCMV gB which<br />
resemble structural compact domains on<br />
the protein surface that could be targets of<br />
antibodies. Domain 1 comprises aa 132-<br />
343 and domain 2, a discontinuous<br />
sequence, comprises aa 116-132 + 344-<br />
440 of gB strain AD169 (Fig. 3)<br />
Fig. 3 Antigenic domains (ADs) on HCMV<br />
glycoprotein B<br />
(3D model generated by H. Sticht)<br />
In a comprehensive screening of over 800<br />
human monoclonal antibodies binding to<br />
gB derived from normal blood donors we identified several strongly neutralizing<br />
antibodies reacting against newly defined epitopes on domain 1 and domain 2 (AD-5<br />
and AD-4, respectively. These new antibodies certainly represent lead candidates for<br />
further preclinical and clinical development for therapeutic applications in prenatal<br />
HCMV infections and HCMV reactivation in transplant patients.<br />
(Collaboration with Dr. Michael Mach, Institute for Virology, Erlangen, Dr. Heinrich<br />
Sticht, Bioinformatics, Erlangen and 4-Antibody AG, Basel, Switzerland).<br />
58
2011/12<br />
Publications (2009-2012)<br />
Original Articles<br />
Schietke, R.E., T. Hackenbeck, M. Tran, R. Gunther, B. Klanke, C.L. Warnecke, K.X.<br />
Knaup, D. Shukla, C. Rosenberger, R. Koesters, S. Bachmann, P. Betz, G. Schley, J.<br />
Schodel, C. Willam, T. Winkler, K. Amann, K.U. Eckardt, P. Maxwell, and M.S.<br />
Wiesener. 2012. Renal Tubular HIF-2alpha Expression Requires VHL Inactivation<br />
and Causes Fibrosis and Cysts. PLoS ONE 7:e31034.<br />
Sitte, S., J. Glasner, J. Jellusova, F. Weisel, M. Panattoni, R. Pardi, and A. Gessner.<br />
2012. JAB1 is essential for B cell development and germinal center formation and<br />
inversely regulates Fas ligand and Bcl6 expression. J Immunol 188:2677-2686<br />
Pötzsch, S., N. Spindler, A.K. Wiegers, T. Fisch, P. Rucker, H. Sticht, N. Grieb, T.<br />
Baroti, F. Weisel, T. Stamminger, L. Martin-Parras, M. Mach, and T.H. Winkler. 2011.<br />
B Cell Repertoire Analysis Identifies New Antigenic Domains on Glycoprotein B of<br />
Human Cytomegalovirus which Are Target of Neutralizing Antibodies. PLoS Pathog<br />
7:e1002172.<br />
Brenner, S., D. Drewel, T. Steinbart, F. Weisel, E. Hartel, S. Pötzsch, H. Welzel, A.<br />
Brandl, P. Yu, G.C. Mudde, A. Schweizer, L. Nitschke, and T.H. Winkler. 2011. A<br />
hypomorphic IgH-chain allele affects development of B-cell subsets and favours<br />
receptor editing. Embo J 30:2705-2718.<br />
Ackermann, J.A., D. Radtke, A. Maurberger, T.H. Winkler, and L. Nitschke. 2011.<br />
Grb2 regulates B-cell maturation, B-cell memory responses and inhibits B-cell Ca(2+)<br />
signalling. Embo J 30:1621-1633.<br />
Starke, C., S. Frey, U. Wellmann, V. Urbonaviciute, M. Herrmann, K. Amann, G.<br />
Schett, T. Winkler, and R.E. Voll. 2011. High frequency of autoantibody-secreting<br />
cells and long-lived plasma cells within inflamed kidneys of NZB/W F1 lupus mice.<br />
Eur J Immunol 41:2107-2112<br />
2010<br />
Furnrohr, B.G., S. Wach, J.A. Kelly, M. Haslbeck, C.K. Weber, C.M. Stach, A.J.<br />
Hueber, D. Graef, B.M. Spriewald, K. Manger, M. Herrmann, K.M. Kaufman, S.G.<br />
Frank, E. Goodmon, J.A. James, G. Schett, T.H. Winkler, J.B. Harley, and R.E. Voll.<br />
2010. Polymorphisms in the Hsp70 gene locus are genetically associated with<br />
systemic lupus erythematosus. Ann Rheum Dis 69:1983-1989.<br />
Jellusova, J., U. Wellmann, K. Amann, T.H. Winkler, and L. Nitschke. 2010. CD22 x<br />
Siglec-G double-deficient mice have massively increased B1 cell numbers and<br />
develop systemic autoimmunity. J Immunol 184:3618-3627.<br />
59
Weisel, F.J., U.K. Appelt, A.M. Schneider, J.U. Horlitz, N. van Rooijen, H. Korner, M.<br />
Mach, and T.H. Winkler. 2010. Unique Requirements for Reactivation of Virus-<br />
Specific Memory B Lymphocytes. J Immunol 185:4011-4021.<br />
2009<br />
Burkhardt, C., S. Himmelein, W. Britt, T. Winkler, and M. Mach. 2009. Glycoprotein N<br />
subtypes of human cytomegalovirus induce a strain-specific antibody response<br />
during natural infection. J Gen Virol 90:1951-1961.<br />
Books and Reviews<br />
Almqvist, N., T.H. Winkler, and I.L. Martensson. 2011. Autoantibodies: Focus on anti-<br />
DNA antibodies. Self Nonself 2:11-18.<br />
Kruse, K., C. Janko, V. Urbonaviciute, C.T. Mierke, T.H. Winkler, R.E. Voll, G. Schett,<br />
L.E. Munoz, and M. Herrmann. 2010. Inefficient clearance of dying cells in patients<br />
with SLE: anti-dsDNA autoantibodies, MFG-E8, HMGB-1 and other players.<br />
Apoptosis 15:1098-1113.<br />
60
TRAINING OF GRADUATE AND MEDICAL STUDENTS<br />
Doctoral theses (Biology)<br />
Florian Weisel<br />
Reaktivierung Virus-spezifischer Gedächnis B Zellen<br />
Sven Brenner<br />
Selection processes guided by B-cell receptor signal strength<br />
Sonja Pötzsch<br />
Neutralizing human monoclonal antibodies against Cytomegalovirus<br />
Kristin Kruse<br />
Die Evolution von anti-DNA Autoantikörpern in Keimzentren<br />
Agnes Giniewski<br />
Charakterisierung eines neuen regulatorischen Elementes im IgH-Genlokus<br />
Martina Seefried<br />
Immunological mechanisms of reactivation of murine CMV after bone marrow<br />
transplantion<br />
Sabrina Sell<br />
The protective role of γ/δ T-lymphocytes in murine CMV infection<br />
61
IZKF Junior Group III<br />
BMBF <strong>Research</strong> Group Neurosciences<br />
Head: Beate Winner, PD Dr. med.<br />
Address: IZKF Junior Group III<br />
Glückstr. 6<br />
D-91054 Erlangen<br />
Telefone: + 49 (9131) 85 39301<br />
Fax: + 49 (9131) 85 39311<br />
E-mail: beate.winner@med.uni-erlangen.de<br />
Homepage:<br />
http://www.izkf.uk-erlangen.de/e37/e38/e87/e1593/index_ger.html<br />
Head<br />
Beate Winner, PD Dr. med.<br />
<strong>Research</strong> associates Doctoral students (Biology)<br />
Francesc Perez-Branguli, PhD*<br />
Iryna Prots, Dr. rer. nat.<br />
Haixin Zhang, MD/ PhD*<br />
Master Students (M)/<br />
Student helpers (S)<br />
Stefanie Brey (M) *<br />
Naime Denguir (S)<br />
Theresa Halder (S)<br />
* part of the time reported<br />
62<br />
Steven Havlicek<br />
Himanshu Mishra<br />
Technicians<br />
Daniela Gräf*<br />
Domenika Saul*<br />
Holger Wend
<strong>Research</strong><br />
The overall goal of research in our laboratory is to model neurodegenerative<br />
diseases in stem cell based models. Specifically we investigate neurodegeneration<br />
and regeneration in neurites. The two diseases studied are Parkinson’s disease (PD)<br />
and hereditary spastic paraplegia (HSP), a specific genetic form of motor neuron<br />
disease.<br />
Hereditary spastic paraplegia (HSP) and other motor neuron diseases<br />
We are specifically interested in understanding the involvement of selected hereditary<br />
spastic paraplegia (HSP) proteins in axonal degeneration. HSP is a genetic condition<br />
leading to corticospinal tract degeneration. HSPs selectively involve a lengthdependent<br />
axonopathy from long projecting corticospinal motorneurons (CSMN),<br />
while sparing the neuronal cell bodies. We study CSMN to understand the molecular<br />
mechanisms crucial for axonal maintenance and degeneration. The models we use<br />
are human induced pluripotent stem cell (hiPSC)-derived neurons generated from<br />
HSP patient’s fibroblasts (SPG4 and SPG11). The overall aim is to understand the<br />
normal function of selected HSP proteins, to determine how abnormality of these<br />
functions lead to the disease and to use this knowledge to rationally design new<br />
therapeutic strategies for the disorder.<br />
63
Figure 1: Induced pluripotent stem cells (iPSC) to model neurodegenerative<br />
diseases. Human iPSC from patients (e.g. HSP) and controls are generated after<br />
reprogramming of somatic tissue into iPSCs. Neural progenitor cells (NPC) are<br />
generated from these iPSCs and are further differentiated into neurons and/or glial<br />
cells. The neuronal phenotype is analyzed. Once a distinct disease-related<br />
phenotype is identified, drug-screening platforms can be developed to test<br />
compounds. Therapeutic compounds could emerge from the screenings, potentially<br />
benefiting neurologic patients.<br />
Understanding aggregation in Parkinson’s disease (PD)<br />
Protein aggregation of mis-folded proteins is associated with several<br />
synucleinopathies. Lewy bodies, an aggregated fibrillar form of multiple proteins<br />
(among them α-synuclein), are the major pathological hallmark in PD. During the<br />
recent year we have shown in vivo that small oligomeric species of the protein, rather<br />
than its aggregated fibrillar counterpart, are the toxic culprit in a rat model of<br />
synucleinopathies. We are investigating the impact of oligomerisation of α-synuclein<br />
in human in vitro models. Specifically, we are interested in studying the mechanism<br />
and functional consequences of oligomerization for neurite degeneration, axonal<br />
transport, and cellular membranes.<br />
Important results<br />
In vivo demonstration that oligomers are toxic<br />
We tested, whether Glu -> Lys mutations in the core area of α-synuclein interfere<br />
with the formation of α-synuclein fibrils and form oligomers instead. Several single<br />
point mutations in the core region (30-110) of α-synuclein have been investigated for<br />
their tendency to form fibrils and oligomers when compared with wild-type (WT) α-<br />
synuclein. In collaboration with Roland Riek, ETH Zürich, these results were obtained<br />
by incubating the different (artificial) variants of α-synuclein in a cell-free system. α-<br />
synuclein variants were analyzed by electron microscopy (EM), which indicated that<br />
these artificial mutants in the core region (30-110) were able to form oligomers but<br />
did not form fibrils. Interestingly, some preparations of these artificial mutants did not<br />
show amyloid fibrils even after long-term incubation, but formed very pronounced,<br />
ring/pore-like structures resembling large oligomers. We found two α-synuclein single<br />
point mutations, E35K and E57K, that showed a strongly decreased tendency of fibril<br />
formation when compared with WT α-synuclein, as evidenced by time-resolved<br />
amyloid formation. Neither variant E35K nor E57K showed amyloid fibrils under<br />
64
certain conditions, but they formed very pronounced ring/pore-like structures. In<br />
contrast, human WT and familial α-synuclein variants formed amyloid fibrils as<br />
expected. We injected lentiviral vectors of the artificial mutants into the rat substantia<br />
nigra and examined survival of dopaminergic neurons after 3 weeks. Our data<br />
indicate, that an enormous loss of dopaminergic cells in the substantia nigra of rats<br />
upon 3 weeks of lentiviral infection is observed for the artificial α-synuclein variants<br />
that form large quantities of oligomers, whereas the variant that forms fibrils very<br />
quickly is less toxic.<br />
The correlation between the extent of oligomer formation in vitro and toxicity in vivo is<br />
apparent. Furthermore, there is a lack of correlation between the tendency of amyloid<br />
fibril formation in vitro and toxicity in vivo and between the amount of monomer in<br />
vitro and toxicity in vivo. Combining the in vitro and in vivo experiments, we suggest<br />
that the in vivo-derived SDS-stable oligomers may be the building blocks for a larger<br />
alpha-synuclein oligomer that causes toxicity. In conclusion, this structure-toxicity<br />
relationship study of human α-synuclein strongly supports the notion that α-synuclein<br />
oligomers are the toxic species in PD and that the amyloid fibrils are not directly toxic,<br />
despite being present in the Lewy bodies, which are the pathological hallmark of PD<br />
(published in PNAS 2011).<br />
We are currently investigating the role of α-synuclein oligomers for axonal transport,<br />
membrane stability and the effect of α-synuclein on dendrites in stem cell based<br />
rodent and human models.<br />
Figure 2: In vitro aggregation of wild-type α-synuclein (B) compared to artificial<br />
oligomer-forming mutants (e.g. A) in a cell-free system. EM shows an abundance of<br />
fibrils in the wild-type α-synuclein (B), whereas only pore-like oligomers are found in<br />
the artificial oligomerizing mutant (A). Lentivirus injection into the rat substantia nigra<br />
of adult rats (C: paradigm): decrease in TH-positive cells following injection with the<br />
65
oligomerizing mutant (α-syn mut, F) compared to wild-type α-synuclein (α-syn, E)<br />
and GFP control (D, PNAS 2011).<br />
Figure 3: Neuronal differentiation of dopaminergic neurons from human embryonic<br />
stem cell (hESC)-derived neural precursor cells (NPCs). (A) Neurons were<br />
differentiated from NPCs over 6 weeks using neurotrophic factors and characterized<br />
by immunofluorescence for neuronal markers (B) and by electrophysiology (C,<br />
collaboration with Dr. Tobias Huth, Institute of Physiology and Pathophysiology,<br />
Head: Prof. Dr. Christian Alzheimer).<br />
Publications (2010-current)<br />
Bracko O, Singer T, Aigner S, Knobloch M, Winner B, Ray J, Clemenson GD Jr, Suh<br />
H, Couillard-Despres S, Aigner L, Gage FH, Jessberger S (2012). Gene expression<br />
profiling of neural stem cells and their neuronal progeny reveals IGF2 as a regulator<br />
of adult hippocampal neurogenesis. J Neurosci. 32(10):3376-87.<br />
Kohl Z, Winner B, Ubhi K, Rockenstein E, Mante M, Münch M, Barlow C, Carter T,<br />
Masliah E, Winkler J (2012) Fluoxetine rescues impaired hippocampal neurogenesis<br />
in a transgenic A53T synuclein mouse model. Eur J Neurosci. 35(1):10-9.<br />
Winner B, Kohl Z, Gage FH. (2011) Neurodegenerative disease and adult<br />
neurogenesis. Eur J Neurosci. 33(6):1139-51.<br />
Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S, Hetzer C, Loher T,<br />
Vilar M, Campioni S, Tzitzilonis C, Soragni A, Jessberger S, Mira H, Consiglio A,<br />
Pham E, Masliah E, Gage FH, Riek R. (2011) In vivo demonstration that alphasynuclein<br />
oligomers are toxic. Proc Natl Acad Sci U S A. 108(10):4194-9.<br />
McCrone P, Payan CA, Knapp M, Ludolph A, Agid Y, Leigh PN, Bensimon G;<br />
NNIPPS Study Group (2011) The economic costs of progressive supranuclear palsy<br />
and multiple system atrophy in France, Germany and the United Kingdom. PLoS<br />
One. 6(9):e24369.<br />
Payan CA, Viallet F, Landwehrmeyer BG, Bonnet AM, Borg M, Durif F, Lacomblez L,<br />
Bloch F, Verny M, Fermanian J, Agid Y, Ludolph AC, Leigh PN, Bensimon G;<br />
NNIPPS Study Group (2011), Disease severity and progression in progressive<br />
supranuclear palsy and multiple system atrophy: validation of the NNIPPS—<br />
Parkinson Plus Scale. PLoS One. 6(8):e22293.<br />
Rolland Y, Vérin M, Payan CA, Duchesne S, Kraft E, Hauser TK, Jarosz J, Deasy N,<br />
Defevbre L, Delmaire C, Dormont D, Ludolph AC, Bensimon G, Leigh PN; NNIPPS<br />
66
Study Group (2011). A new MRI rating scale for progressive supranuclear palsy and<br />
multiple system atrophy: validity and reliability. J Neurol Neurosurg Psychiatry.<br />
82(9):1025-32.<br />
Winner B, Melrose HL, Zhao C, Hinkle KM, Yue M, Kent C, Braithwaite AT,<br />
Ogholikhan S, Aigner R, Winkler J, Farrer MJ, Gage FH (2011). Adult neurogenesis<br />
and neurite outgrowth are impaired in LRRK2 G2019S mice. Neurobiol Dis.,<br />
41(3):706-16.<br />
Marchetto MC, Winner B, Gage FH (2010). Pluripotent stem cells in<br />
neurodegenerative and neurodevelopmental diseases. Hum Mol Genet. R71–R76.<br />
Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH (2010). Mechanism<br />
underlying inflammation in neurodegeneration. Cell. 19;140(6):918-34.<br />
Kohl Z, Regensburger M, Aigner R, Kandasamy M, Winner B, Aigner L, Winkler J.<br />
(2010) Impaired adult olfactory bulb neurogenesis in the R6/2 mouse model of<br />
Huntington’s disease. BMC Neurosci. 11:114.<br />
Kandasamy M, Couillard-Despres S, Raber KA, Stephan M, Lehner B, Winner B,<br />
Kohl Z, Rivera FJ, Nguyen HP, Riess O, Bogdahn U, Winkler J, von Hörsten S,<br />
Aigner L (2010). Stem cell quiescence in the hippocampal neurogenic niche is<br />
associated with elevated transforming growth factor-beta signaling in an animal<br />
model of Huntington disease. J Neuropathol Exp Neurol. 69(7):717-28.<br />
Doctoral (Biology)<br />
TRAINING OF GRADUATE AND MASTER STUDENTS<br />
Steven Havlicek<br />
Modeling familial motor neuron disease (SPG4) by the use of induced pluripotent<br />
stem cells<br />
Himanshu Mishra<br />
Modeling familial motor neuron disease (SPG11) by the use of induced pluripotent<br />
stem cells<br />
Master (Molecular Medicine)<br />
Stefanie Brey<br />
Impact of oligomerisation of α-synuclein on membranes in human neural in vitro<br />
models<br />
67
INTERDISCILINARY CENTER OF CLINICAL<br />
RESEARCH<br />
Junior <strong>Research</strong> Group 2 (IZKF – N2)<br />
Head: Jens Titze, Prof. Dr. med.<br />
Address: IZKF – N2<br />
Glückstr. 6<br />
D-91054 Erlangen<br />
Telefone: + 49 (9131) 85 39300<br />
Fax: + 49 (9131) 85 36386<br />
E-mail: jens.titze@uk-erlangen.de<br />
jens.m.titze@vanderbilt.edu<br />
Homepage: http://www.izkf.ukerlangen.de/e1615/inhalt1880/IZKF_JB11_05.2012.pdf<br />
Agnes Schröder, Dr. rer. nat.<br />
Peter Linz, Dr. rer. nat.<br />
Natalia Rakova, Dr.<br />
* part of the time reported<br />
Head<br />
Jens Titze, Prof. Dr. med.<br />
Supporting Staff<br />
Doris Bittner, Secretary<br />
Postdoctoral Fellows<br />
68<br />
Anke Dahlmann, Dr. med.<br />
Christoph Kopp, Dr. med.<br />
Sven Brenner, Dr. rer. nat.
Kathrin Jüttner<br />
° PhD received<br />
Florian Eicher<br />
° PhD received<br />
Ulrike Goller<br />
Jenny Goß<br />
* part of the time reported<br />
Doctoral Students (Biology)<br />
Diana Friedrich<br />
Doctoral Students (Medicine)<br />
Kathrin Dörfelt<br />
Technicians<br />
Sabrina Cabric<br />
69
<strong>Research</strong><br />
Primary essential hypertension is the major cardiovascular disease risk factor.<br />
Dietary salt intake is a putative driving force of blood pressure elevation; however,<br />
the mechanisms of this effect remain unclear. The central nervous system, heart and<br />
blood vessels, and kidney are primary participants and the kidney is the putative<br />
grand regulator of salt disposition and blood pressure. The overall goal of this work is<br />
to address whether or not local regulation of skin electrolyte metabolism is important<br />
for blood pressure control. Clinical evidence from pilot studies in humans and<br />
preliminary experimental data accumulated in our laboratory, support this hypothesis.<br />
Our data point to macrophage-derived vascular endothelial growth factor C (VEGF-C)<br />
as a crucial factor controlling skin electrolyte homeostasis. VEGF-C promotes<br />
interstitial electrolyte clearance through the cutaneous lymph capillary network.<br />
Macrophages induce hyperplasia of subcutaneous lymph capillaries after sensing<br />
local Na + or Cl - overload in the interstitium. The sensing function is accomplished by<br />
binding of the transcription factor tonicity-enhancer binding protein (TonEBP) to the<br />
promoter region of the VEGF-C gene. The cells exert their regulatory function by<br />
increasing VEGF-C expression and secretion. Blockade of this VEGF-C response<br />
from macrophages leads to skin electrolyte accumulation and arterial hypertension.<br />
Significance and Background<br />
The importance of a constant milieu intérieur, maintained through extracellular<br />
electrolyte and water content, has long been appreciated for blood pressure control.<br />
The underlying concept is that extracellular fluids readily equilibrate, resulting in a<br />
homogenous and uniform composition of the extracellular fluid space. The<br />
predominant role of the kidney for internal environment composition and blood<br />
pressure control relies on the idea that renal regulation of blood composition is<br />
sufficient for concomitant maintenance of interstitial fluid composition. Any inability of<br />
the body to excrete Na + is thus regarded as a major pathophysiological component<br />
for development of hypertension – and traditionally considered due to perturbations<br />
of renal function (Fig. 1A).<br />
We have previously shown that Na + is stored independent of water in the skin. This<br />
finding resulted in a hypothesis-driven research program in which we searched for<br />
extrarenal mechanisms for regulation of local interstitial electrolyte and water<br />
homeostasis. Approximately 70-80% of the extracellular fluids are interstitial and<br />
thereby not directly controlled by renal salt and water excretion. Therefore,<br />
identification of novel local extrarenal regulatory mechanisms for interstitial fluid<br />
70
homeostasis at the skin tissue level would provide a novel research avenue towards<br />
maintenance of electrolyte and water homeostasis and introduce new potential<br />
therapeutic targets for salt, water, and blood pressure disorders.<br />
We first identified a potential mechanism for storage and release of Na + from the<br />
skin. We have shown that a high-salt diet results in specific changes in the negative<br />
charge density of the extracellular matrix in the skin interstitium. Dietary salt led to<br />
increased glycosaminoglycan (GAG) polymerization and sulfatation in the skin<br />
interstitium. The resulting increase in the negative interstitial charge density was<br />
paralleled with Na + storage in the skin. In reverse, a low-salt diet led to reduced GAG<br />
polymerization and sulfatation, and the resulting decrease in the negative GAG<br />
charge density was paralleled by release of Na + from the skin. We interpreted these<br />
findings in a way that the skin interstitium actively modulated its extracellular GAG<br />
charge density in order to store or release Na + from an interstitial reservoir. Because<br />
Na + would electrostatically interact with GAGs, this storage process could result in<br />
water-free, osmotically inactive Na + storage in the skin. We concluded that the skin<br />
interstitium holds the capacity to locally control its electrolyte composition via<br />
extrarenal regulatory mechanisms.<br />
We then found that Na + storage was additionally paralleled by macrophage infiltration<br />
into the Na + -loaded interstitium (Fig. 1B), where the cells exert an important<br />
extrarenal regulatory cascade for interstitial electrolyte homeostasis and systemic<br />
blood pressure control. In the Na + -loaded skin, macrophages express the<br />
osmoprotective transcription factor TonEBP, suggesting that Na + storage results in<br />
A B<br />
Fig. 1 (A) Traditional research approach for body electrolyte balance and blood pressure<br />
homeostasis, based on the oversimplified concept of passive body fluid equilibrium in closed<br />
systems where known forces are balanced and electrolyte concentrations are not remarkably<br />
different between blood volume and interstitial volume (equilibrium). Suggesting that blood<br />
purification is sufficient for interstitial clearance of electrolytes and water, this research relies on<br />
investigation of renal electrolyte and water clearance mechanisms. (B) Novel research approach for<br />
body electrolyte balance and blood pressure homeostasis, based on the finding that interstitial<br />
electrolyte concentrations are higher than in blood (“skin Na + storage”). Interstitial electrolyte<br />
balance is not achieved by renal blood purification alone, but relies on additional extrarenal<br />
regulatory mechanisms within the skin interstitium. Macrophages act as local osmosensors that<br />
regulate local interstitial electrolyte composition via a TonEBP/VEGF-C dependent mechanism,<br />
enhancing electrolyte clearance via VEGF-C/VEGFR3 mediated modulation of the lymph capillary<br />
network in the skin. We are aware that peripheral vascular resistance in hypertension is increased<br />
throughout the entire body, including obviously the kidneys. Our skin storage mechanism implies an<br />
additional compartment that clearly impacts on general vascular resistance, and does not contradict<br />
the infinite-gain theory that links internal environment composition with blood pressure control.<br />
71
hypertonic interstitial fluid accumulation. TonEBP binds to the promoter of the VEGF-<br />
C gene in macrophages, resulting in gene expression and secretion of VEGF-C into<br />
the interstitial Na + reservoir. VEGF-C binds to vascular endothelial growth factor<br />
receptor 2 (VEGFR2) and increases eNOS expression in blood vessels. VEGF-C<br />
also binds to VEGFR3 on lymph endothelial cells, resulting in hyperplasia of<br />
interstitial lymph capillaries. When we blocked the physiologic macrophage-driven<br />
VEGF-C response experimentally, eNOS expression in blood vessels did not<br />
increase, the lymph capillary network showed no hyperplasia, and blood pressure<br />
was increased. These findings suggest that interstitial skin macrophages regulate<br />
blood pressure via a TonEBP/VEGF-C-dependent mechanism, either by increasing<br />
NO production in small blood vessels, or by enhancing local interstitial electrolyte<br />
clearance in the skin through the lymph capillary network (Fig. 1B).<br />
Our findings have added a new and unexpected research field for hypertension<br />
research. They suggest that skin electrolyte and water homeostasis is important for<br />
blood pressure regulation. We furthermore suggest that macrophages can modulate<br />
skin electrolyte and water metabolism via a TonEBP/VEGF-C regulatory axis, and we<br />
have identified the lymph capillary system in the skin as a new target for modulation<br />
of interstitial electrolyte composition and blood pressure.<br />
Macrophages regulate interstitial electrolyte composition via<br />
TonEBP/VEGF-C driven modulation of lymph capillaries<br />
We have shown that rats, in which we blocked de-novo infiltration of MPS cells into<br />
the skin interstitium with clodronate liposome treatment, were unable to increase<br />
VEGF-C in skin in response to a high-salt diet, and developed salt-sensitive<br />
hypertension. Clodronate liposomes are phagocytized by blood circulatory<br />
macrophages / MPS cells and induce apoptosis. We concluded that increased<br />
TonEBP / VEGF-C expression in skin in response to high salt was induced by<br />
circulatory monocytes/macrophages which entered the Na + overloaded<br />
subcutaneous interstitium. This finding was corroborated by cell culture experiments,<br />
where we showed that macrophages express VEGF-C in response to osmotic stress<br />
by TonEBP binding to the VEGF-C promoter. In additional in-vitro experiments in<br />
cells with TonEBP overexpression or silencing, we furthermore demonstrated that<br />
TonEBP promoter binding was essential for VEGF-C secretion in macrophages in<br />
response to osmotic stress. However, we have so far not yet demonstrated in vivo<br />
that TonEBP is essential for VEGF-C driven modulation of interstitial electrolyte<br />
composition and blood pressure.<br />
To test the hypothesis that TonEBP deficiency results in reduced skin VEGF-C<br />
levels, reduced lymph capillary density, electrolyte accumulation, and blood pressure<br />
increase in vivo, we have designed experiments with TonEBP (gene name: Nfat5)<br />
deficient mice. TonEBP-null mouse embryos die prenatally or late in gestation and<br />
have pronounced renal medullary atrophy and impaired cardiac development. In<br />
72
contrast, studies utilizing haploinsufficient TonEBP mice report normal development.<br />
TonEBP +/- lymphocytes proliferate normal at 330-350 mosmol/kg osmotic stress, and<br />
only when osmolality in cell culture media is >350 mosmol/kg is their proliferation<br />
impaired. No data on renal function in TonEBP +/- mice are available to the best of<br />
our knowledge. Our preliminary data on skin electrolyte composition suggest that<br />
reduced TonEBP expression in skin in TonEBP +/- mice fed a high-salt diet (Fig. 2A)<br />
is paralleled by reduced VEGF-C gene expression and reduced lymph capillary<br />
density in skin (Fig. 2B), which should lead to impaired skin electrolyte clearance.<br />
Indeed, TonEBP mice with high-salt diet were characterized by an almost two-fold<br />
increase in skin Na + and Cl - content<br />
(Fig. 2C), while the ratio of skin<br />
(Na + +K + )-to-water ratio was<br />
unchanged in the mice (Fig. 2D).<br />
We interpret these preliminary<br />
findings that the skin interstitium in<br />
mice is characterized by hypertonic<br />
interstitial fluid accumulation<br />
([Na + +K + ] = 180 mmol/L; Fig. 2D),<br />
and that immune cells are exposed<br />
to osmotic stress when leaving blood<br />
vessels and entering the interstitial<br />
Fig. 2. VEGF-C expression and skin electrolytes in<br />
TonEBP +/- mice. (A) TonEBP mRNA expression in<br />
skin in wild type (wt; n=6) and TonEBP -/+ (n=5)<br />
mice. (B) VEGF-C mRNA expression and average<br />
lymph capillary diameter in wt (n=3) and TonEBP -/+<br />
(n=3) mice fed a high-salt diet. (C & D) Skin Na +<br />
and Cl - content, and skin (Na + +K + )-to-water ratio in<br />
the same mice. * P
its soluble receptor sVEGFR3). This systemic depletion of VEGF-C resulted in<br />
increased skin electrolyte accumulation and blood pressure. We concluded that a<br />
loss of lymph capillary clearance function for skin electrolytes might lead to saltsensitive<br />
hypertension, and that VEGF-C initiates electrolyte clearance from skin<br />
tissue. We tested in an animal model with selective depletion of VEGF-C driven<br />
lymphangiogenesis in the skin whether primary disorders in skin electrolyte and water<br />
metabolism result in experimental arterial hypertension.<br />
We reasoned that mice with over-expression of soluble VEGFR3 (sVEGFR-3)<br />
receptor (gene name: flt-4) under the control of the keratinocyte promoter K14 (K14-<br />
FLT4 mice) may serve as a model to study the effect of targeted overexpression of<br />
sVEGFR3 in the skin on skin electrolyte metabolism and systemic blood pressure.<br />
High-dose overexpression of sVEGFR3 in keratinocytes in mice homozygous for the<br />
transgene leads to<br />
embryonic death. In<br />
contrast, K14 FLT4<br />
mice with<br />
heterozygous<br />
overexpression of<br />
the sVEGFR3 breed<br />
well and show<br />
selective hypoplasia<br />
of subdermal lymph<br />
capillaries with only<br />
discrete skin edema.<br />
In our preliminary<br />
experiments, we<br />
found that a high-salt<br />
diet induced lymph<br />
capillary hyperplasia<br />
in wt mice, while<br />
subdermal lymph<br />
Fig. 3. Selective blockade of the MPS/VEGF-C regulatory axis in the<br />
skin by over-expression of sVEGFR3 by skin keratinocytes (VEGF-C<br />
trap) in K14-FLT4 mice results in exaggerated salt-sensitive<br />
hypertension. (A-D) Subcutaneous lymph capillaries, visualized with a<br />
LYVE-1 specific antibody (green) in wt (n=14) and K14-FLT4 mice<br />
(n=12) fed a low-salt (LSD) or a high-salt (HSD) diet for two weeks. (E)<br />
CD68 and VEGF-C expression in skin in the same mice. β-actin<br />
expression was used as a loading control. (F) eNOS and p eNOS<br />
expression in mouse skin. (G) Lymph capillary density in ear and mean<br />
arterial blood pressure in the mice. * P < 0.05 versus wt/LSD; † P <<br />
0.05 versus K14 Flt4/LSD; ‡ P < 0.05 versus wt/HSD.<br />
capillaries remained hypoplastic in heterozygous K14-FLT4 mice (Fig. 3 A-D),<br />
because increased VEGF-C protein expression by macrophages (Fig. 3E) was<br />
blocked by sVEGFR3 from skin keratinocytes which acted as a skin-specific VEGF-C<br />
trap. In support of this skin specificity, renal macrophage count, VEGF-C mRNA and<br />
protein expression, and lymph capillary density was unchanged in the same animals.<br />
Targeted depletion of subdermal lymphcapillaries resulted in Na + , Cl - , and water<br />
accumulation in skin in K14-FLT4 mice, even with low salt diet. Salt-sensitive<br />
hypertension was augmented in K14-FLT4 mice, and blood pressure tended to be<br />
higher in K14-FLT4 than in wt mice with low-salt diet (Fig. 3G).<br />
We conclude that targeted depletion of skin VEGF-C with hypoplasia of intradermal<br />
lymph capillaries result in skin electrolyte and water retention and blood pressure.<br />
This hypertension comes about an external regulatory mechanism within the skin,<br />
presumably because of reduced electrolyte and water clearance by hypoplastic skin<br />
74
vessels. This animal model underscores the importance of skin lymph capillaries for<br />
skin electrolyte homeostasis and systemic blood pressure control. Perhaps more<br />
importantly, this animal model provides a valuable model that is complementary to<br />
our animal model with pharmacological blockade of VEGF-C/VEGFR3 driven lymph<br />
capillary hyperplasia.<br />
Macrophages control skin electrolyte composition via VEGF-C<br />
driven electrolyte clearance by lymph capillaries<br />
As predicted by our model (Fig. 1B), we have shown previously that blockade of the<br />
macrophage driven VEGF-C response in rats prevents hyperplasia of the<br />
lymphcapillary network with electrolyte accumulation in the skin, inhibits an increase<br />
in eNOS expression in blood vessels, and leads to salt-sensitive hypertension.<br />
However, it has been unclear whether macrophages exert this blood-pressure<br />
buffering effect in response to high-salt diet by VEGF-C/VEGFR2-driven modulation<br />
of vascular eNOS expression (vasodilation), or by VEGF-C/VEGFR3-driven<br />
hyperplasia of interstitial skin lymph capillaries (enhanced electrolyte clearance).<br />
Other investigators have shown previously that selective VEGFR-2 blockade reduces<br />
vascular eNOS expression and increases blood pressure independently of salt<br />
intake.<br />
We have data suggesting that VEGF-C/VEGFR3-driven modulation of the lymph<br />
capillary bed is<br />
decisive for the blood<br />
pressure buffering<br />
mechanism of<br />
macrophages (Fig. 4).<br />
We fed mice<br />
(background: FVB) a<br />
low or a high-salt diet<br />
for 2 consecutive<br />
weeks and also treated<br />
Fig. 4. Selective blockade of the VEGF-C/VEGFR-3 regulatory axis in<br />
the skin by systemic treatment with anti-VEGFR-3 antibody (mF4-<br />
31c1) blocks lymph capillary hyperplasia and results in exaggerated<br />
salt-sensitive arterial hypertension. (A-D) Subcutaneous lymph<br />
capillaries, visualized with a LYVE-1 specific antibody (green) in<br />
untreated (n=20) and mF4-31c1-treated mice (n=24) fed a low-salt<br />
(LSD) or a high-salt (HSD) diet for two weeks. (E) CD68 (macrophage<br />
surface marker) and VEGF-C expression in skin in the same mice. βactin<br />
expression was used as a loading control. (F) eNOS and p<br />
eNOS expression in mouse skin. (G) Lymph capillary density in ear<br />
and mean arterial blood pressure in the mice. * P < 0.05 versus<br />
wt/LSD; † P < 0.05 versus K14 Flt4/LSD; ‡ P < 0.05 versus wt/HSD.<br />
the mice with an anti-<br />
VEGFR3 antibody<br />
(mF4-31c1, 45 μg/g<br />
body weight i.p. every<br />
48 hours). The<br />
resulting blockade of<br />
VEGF-C/VEGFR3driven<br />
lymph capillary<br />
hyperplasia allowed us<br />
to specifically<br />
investigate the role of lymph capillaries for macrophage/VEGF-C-driven blood<br />
75
Fig. 5. Selective blockade of the VEGF-<br />
C/VEGFR-3 regulatory axis in the skin by<br />
systemic treatment with anti-VEGFR-3 antibody<br />
(mF4-31c1) blocks lymph capillary hyperplasia<br />
and results in tissue Cl - retention, which parallels<br />
salt-sensitive hypertension. (A): Relationship<br />
between lymphcapillary density and skin Na +<br />
content relative to tissue dry weight (rSKNa + ).<br />
(B): Relationship between lymphcapillary density<br />
and skin water content relative to tissue dry<br />
weight (rSKW). (C): Relationship between<br />
lymphcapillary density and skin Cl - content<br />
relative to tissue dry weight (rSKCl - ). (D):<br />
Relationship between lymph capillary density in<br />
skin and mean arterial blood pressure (MAP,<br />
intra-arterial measurement and the end of the<br />
experiment). LSD: low-salt diet, HSD: high-salt<br />
diet.<br />
pressure control. We found that mF4-<br />
31c1 did not change lymph capillary<br />
density in low-salt diet (LSD) mice;<br />
however, skin lymph capillary<br />
hyperplasia with high-salt diet (HSD)<br />
was completely prevented with anti-<br />
VEGFR-3 treatment (Fig. 4A-D).<br />
VEGFR-3 blockade was characterized<br />
by increased macrophage recruitment<br />
and increased VEGF-C production in<br />
the skin (Fig. 4E), presumably by a<br />
compensatory effect of the<br />
marcophages to overcome VEGFR3<br />
blockade. As expected, high VEGF-C<br />
levels in both untreated and mF4-<br />
31c1-treated mice with HSD diet<br />
resulted in increased p-eNOS<br />
expression (Fig. 4F). We conclude<br />
that mF4-31c1 treatment selectively<br />
eliminates the macrophage/VEGF-Cdriven<br />
hyperplastic response of<br />
cutaneous lymph capillaries, while<br />
VEGF-C/VEGFR2-driven increase in<br />
eNOS expression in blood vessels<br />
remains intact. This selective<br />
blockade of the hyperplastic response<br />
of lymph capillaries to HSD diet increased mean arterial blood pressure by 19 mmHg<br />
within two weeks (Fig. 4G), despite normal p-eNOS expression (Fig. 4F). The<br />
findings support the idea that macrophages exert their blood-pressure buffering effect<br />
by VEGF-C driven lymphatic regulation of blood pressure.<br />
Lymph capillaries serve as a transit system for rapid movement of interstitial immune<br />
cells into secondary lymphatic tissue, such as lymph nodes. They also serve as a<br />
drainage system of interstitial fluid into the blood stream. Having shown that saltsensitive<br />
hypertension “goes” with subcutaneous lymph capillaries in the skin, we<br />
next tested whether or not blockade VEGF-C/VEGFR3-driven hyperplasia of the<br />
lymph capillary system resulted in increased Na + , K + , Cl - , and water content in the<br />
skin. This finding would support the hypothesis that macrophages induce interstitial<br />
electrolyte clearance via an unknown clearance process within the subcutaneous<br />
lymph capillary system (Fig. 1B). Therefore, we chemically analyzed electrolyte<br />
composition in the skin in the same mice. We found that VEGFR-3 blockade in HSD<br />
mice neither increased Na + (Fig. 5A), nor water content in skin tissue (Fig. 5B).<br />
Instead, VEGFR-3 blockade resulted in a selective increase in skin Cl - content (Fig.<br />
5C). This finding suggests that macrophages selectively influence Cl - metabolism in<br />
the skin via VEGF-C/VEGFR3-driven modulation of lymph capillary function. In<br />
76
Tab. 1. Skin electrolyte and water composition in comparison to<br />
serum electrolyte composition in the same animals. Note that<br />
selective blockade of the VEGF-C/VEGFR-3 regulatory axis in<br />
the skin by systemic treatment with anti-VEGFR-3 antibody<br />
(mF4-31c1) tissue led to Cl - retention and increased Cl -<br />
concentration at the skin tissue level, but not in serum. Skin Na +<br />
content was more stable compared with Cl - . Depending on<br />
intervention, skin Na + content was 2-4 fold higher than Cl -<br />
content, while serum Na + content was exactly 1.2-fold higher<br />
than serum Cl - .<br />
parallel with increased<br />
tissue Cl - content, blood<br />
pressure was elevated<br />
(Fig. 5D), suggesting that<br />
Cl - metabolism is of major<br />
importance for saltsensitive<br />
hypertension.<br />
This finding is in line with<br />
data from humans, where<br />
salt-sensitive<br />
hypertension is mainly<br />
linked with NaCl<br />
ingestion, while similar<br />
NaHCO3 loading does not<br />
increase blood pressure.<br />
Our results bring saltsensitive<br />
hypertension<br />
into a novel biological<br />
context, as we suggest<br />
that hyperplastic lymph capillaries specifically control Cl - clearance from<br />
subcutaneous skin tissue, while hyperplasia of an otherwise intact lymph capillary<br />
system is not coupled with Na + or water clearance. We interpret our data in a way<br />
that skin lymph capillaries apparently do not only collect and pump interstitial fluid,<br />
but also actively modulate its electrolyte concentration. The unknown underlying<br />
concentration mechanism is controlled by VEGF-C from skin macrophages: we found<br />
that modulation of lymph capillary density by anti-VEGFR3 treatment resulted in<br />
increased Cl - concentration in skin tissue, but not in blood (Tab. 1).<br />
2012<br />
Publications (2008-2012)<br />
Original Articles<br />
Kopp C, Linz P, Wachsmuth L, Dahlmann A, Horbach T, Schofl C, Renz W, Santoro D,<br />
Niendorf T, Muller DN, Neininger M, Cavallaro A, Eckardt KU, Schmieder RE, Luft FC, Uder<br />
M, Titze J. (23)Na magnetic resonance imaging of tissue sodium. Hypertension.<br />
2012;59:167-172<br />
77
2011<br />
Slagman MC, Kwakernaak AJ, Yazdani S, Laverman GD, van den Born J, Titze J, Navis G.<br />
Vascular endothelial growth factor c levels are modulated by dietary salt intake in proteinuric<br />
chronic kidney disease patients and in healthy subjects. Nephrol Dial Transplant.<br />
2011;27:978-982.<br />
2010<br />
Machnik A, Dahlmann A, Kopp C, Goss J, Wagner H, van Rooijen N, Eckardt KU, Muller DN,<br />
Park JK, Luft FC, Kerjaschki D, Titze J. Mononuclear phagocyte system depletion blocks<br />
interstitial tonicity-responsive enhance binding protein/vascular endothelial growth factor c<br />
expression and induces salt-sensitive hypertension in rats. Hypertension. 2010;55:755-761.<br />
2009<br />
Machnik A, Neuhofer W, Jantsch J, Dahlmann A, Tammela T, Machura K, Park JK, Beck FX,<br />
Muller DN, Derer W, Goss J, Ziomber A, Dietsch P, Wagner H, van Rooijen N, Kurtz A,<br />
Hilgers KF, Alitalo K, Eckardt KU, Luft FC, Kerjaschki D, Titze J. Macrophages regulate saltdependent<br />
volume and blood pressure by a vascular endothelial growth factor-c-dependent<br />
buffering mechanism. Nat Med. 2009;15:545-552<br />
Heer M, Frings-Meuthen P, Titze J, Boschmann M, Frisch S, Baecker N, Beck L. Increasing<br />
sodium intake from a previous low or high intake affects water. Br J Nutr. 2009;101:1286-<br />
1294.<br />
2008<br />
Gratze P, Dechend R, Stocker C, Park JK, Feldt S, Shagdarsuren E, Wellner M, Gueler F,<br />
Rong S, Gross V, Obst M, Plehm R, Alenina N, Zenclussen A, Titze J, Small K, Yokota Y,<br />
Zenke M, Luft FC, Muller DN. Novel role for inhibitor of differentiation 2 in the genesis of<br />
angiotensin ii-induced hypertension. Circulation. 2008;117:2645-2656<br />
Ziomber A, Machnik A, Dahlmann A, Dietsch P, Beck FX, Wagner H, Hilgers KF, Luft FC,<br />
Eckardt KU, Titze J. Sodium-, potassium-, chloride-, and bicarbonate-related effects on blood<br />
pressure and electrolyte homeostasis in deoxycorticosterone acetate-treated rats. Am J<br />
Physiol Renal Physiol. 2008;295:F1752-1763<br />
78
2012<br />
Reviews/Comments<br />
Harrison DG, Marvar PJ, Titze JM. Vascular inflammatory cells in hypertension. Front<br />
Physiol. 2012;3:128.<br />
2010<br />
Titze J, Machnik A. Sodium sensing in the interstitium and relationship to hypertension. Curr<br />
Opin Nephrol Hypertens. 2010 Jul;19(4):385-92.<br />
Titze, J., Muller, D. N., Luft, F. C. Response to Blood Pressure Control: A Facelift for<br />
Macrophages? Hypertension. 2010;56(2): E24-E24<br />
2009<br />
Titze J. “Water-free sodium accumulation”. Semin Dial. 2009 May-Jun;22(3):253-5.<br />
Titze J, Ritz E. Salt and its effect on blood pressure and target organ damage: New pieces in<br />
an old puzzle. J Nephrol. 2009;22:177-189<br />
Titze J. Salz- und Wasserhaushalt: Neue Salzspeicher. Der Nephrologe. 2009;4:488–496<br />
TRAINING OF GRADUATE AND MEDICAL STUDENTS<br />
Doctoral theses (Biology)<br />
Agnes Schröder (2009)<br />
Macrophages as regulators of volume and blood pressure homeostasis.<br />
Doctoral theses (Medical Students)<br />
Markus Schafflhuber (2009)<br />
Gycosaminoglycan polymerization and Na + storage in the skin<br />
Christoph Ilies (2010)<br />
Osmotically inactive Na + storage in the skin<br />
Katharina Bauer (2010)<br />
Internal Na + balance in desoxycorticosterone acetate-treated rats<br />
79
Matrix Biology Group<br />
(Dpt. Of Internal Medicine III)<br />
Head: PD Dr. med. Jörg Distler<br />
Address: Department of Internal Medicine III<br />
Krankenhausstr. 12<br />
D-91054 Erlangen<br />
Telefone: + 49 (9131) 85 39226<br />
Fax: + 49 (9131) 85 35467<br />
E-mail: joerg.distler@uk-erlangen.de<br />
Christian Beyer, Dr. med. *<br />
* part of the time reported<br />
Head<br />
PD Dr. med. Jörg Distler<br />
Supporting Staff<br />
--<br />
Postdoctoral Fellows<br />
80<br />
Alfiya Akhmetshina, Dr. rer. nat. *
Nicole Reich°<br />
Pawel Zerr<br />
Katrin Palumbo<br />
° PhD received<br />
Maria Halter<br />
Anna Maria Herrmann*<br />
Julia Gebhardt*<br />
* part of the time reported<br />
Jerome Avouac, Dr.<br />
med., Paris<br />
Doctoral Students (Biology)<br />
Clara Dees<br />
Alfiya Akhmetshina°<br />
Ekatherina Skirtladze<br />
Technicians<br />
Guest Scientists<br />
Michal Tomcik, Dr.<br />
med., Prag<br />
81
<strong>Research</strong><br />
Our group is mainly interested in mechanisms of fibroblast activation and in the<br />
development of novel anti-fibrotic approaches. Tissue fibrosis can affect virtually<br />
every organ system and represents a major medicinal problem, because effective<br />
therapies are currently not available. During our time in the <strong>Nikolaus</strong>-<strong>Fiebiger</strong> Center<br />
from 2009 to 2010, we used systemic sclerosis (SSc), a prototypic systemic fibrotic<br />
disease, to investigate the role of the following pathways for fibroblast activation and<br />
fibrosis. We very particularly interested (i) in AP-1 signaling as a downstream<br />
mediator of the pro-fibrotic effects of TGFβ, (ii) in the role of morphogenic pathways<br />
such as hedgehog and notch-signaling in fibrosis and (iii) in cannabinoid receptors as<br />
potential targets for therapeutic approaches in fibrotic diseases.<br />
AP-1 signaling<br />
Transforming growth factor-β (TGF-β) is a key-player in fibrotic diseases. However,<br />
the molecular mechanisms by which TGF-β activates fibroblasts are incompletely<br />
understood. We have previously shown that the expression of the AP-1 transcription<br />
factor Fra-2 is upregulated in SSc and that Fra-2 stimulates the release of<br />
extracellular matrix. We hypothesized that other members of the AP-1 family may<br />
also contribute to the aberrant release of collagen in SSc. Indeed, we observed that<br />
the mRNA as well as the protein levels of three other members of the AP-1 family, c-<br />
Jun, JunD and cFos were strongly increased in fibrotic skin of SSc patients compared<br />
to healthy individuals. The overexpression persisted in cultured fibroblasts from SSc<br />
patients. c-Jun, JunD and cFos were induced by TGF-β in a time- and dosedependent<br />
manner. Moreover, the expression of those AP-1 family members colocalized<br />
with nuclear pSmad 3 in cultured fibroblasts and in fibrotic skin. Inhibition of<br />
canonical Smad signaling by siRNA mediated knockdown of either Smad3 or Smad4<br />
prevented the stimulatory effects of TGF-β and normalized the expression of c-Jun,<br />
JunD and cFos in SSc fibroblasts. To further evaluate the role of AP-1 signaling as a<br />
downstream mediator of the pro-fibrotic effects of TGF-β in vitro and in vivo, we<br />
employed knockout and knockdown strategies as well as selective chemical<br />
82
inhibitors. The small molecule inhibitor T-5224 abrogated the stimulatory effects of<br />
TGF-β on collagen synthesis and differentiation of resting fibroblasts into<br />
metabolically active myofibroblasts. Similar results were obtained upon siRNA<br />
mediated knockdown of cJun, JunD and cFos and in JunD deficient murine<br />
fibroblasts. Moreover, JunD -/- mice were protected from bleomycin induced fibrosis<br />
with reduced dermal thickening, decreased myofibroblast counts and lower collagen<br />
content of lesional skin. AP-1 signaling may also be a potential target for therapeutic<br />
intervention. T-5224, which is currently evaluated in clinical trials for rheumatoid<br />
arthritis, exerted potent anti-fibrotic effects in murine models of SSc in well tolerated,<br />
pharmacologically relevant doses. T-5224 prevented fibrosis in the mouse models of<br />
bleomycin-induced dermal fibrosis and fibrosis induced by overexpression of a<br />
constitutively active TGF-β receptor 1. Treatment with T-5224 dose-dependently<br />
reduced dermal thickening, myofibroblast counts and the collagen content in those<br />
models without toxic effect. Given the central role of AP-1 signaling as a downstream<br />
mediator of TGF- β signaling and the availability of well tolerated, selective inhibitors<br />
such as T-5224, AP-1 signaling might be a promising molecular target for the<br />
treatment of SSc and other fibrotic diseases.<br />
Hedgehog and Notch signaling<br />
Hedgehog and Notch signaling are so-called morphogenic pathways that do not only<br />
play major roles during embryonic development, but that are also essential to<br />
maintain tissue homeostasis in the adult. Aberrant activation of hedgehog- or notch<br />
signaling has both been implicated in the pathogenesis of various diseases in adults,<br />
including a variety of different malignancies. Given their important role in cellular<br />
differentiation, we hypothesized that hedgehog- and notch signaling may contribute<br />
to the activation of fibroblasts and may play a role in tissue fibrosis.<br />
For hedgehog signaling, we demonstrated an overexpression of the ligand sonic<br />
hedgehog (Shh) with accumulation of the downstream transcription factors Gli-1 and<br />
Gli-2 in SSc. The expression of hedgehog target genes such as ptch-1, ptch-2 and<br />
cyclin D were also upregulated, confirming the activation of hedgehog signaling in<br />
SSc. Stimulation of cultured fibroblasts with recombinant Shh induced an activated<br />
phenotype with differentiation of resting fibroblasts into myofibroblasts and increased<br />
release of collagen. Overexpression of Shh in the skin of mice induced fibrosis with<br />
83
accumulation of collagen, dermal thickening and myofibroblast differentiation,<br />
demonstrating that activation of hedgehog signaling alone is sufficient to induce<br />
fibrosis in vivo. Consistent with these findings, mice lacking one allele of the inhibitory<br />
receptor ptch-1 were more sensitive to experimental fibrosis. Conversely, inhibition of<br />
the activating receptor smoothened (Smo) either pharmacologically by the selective<br />
inhibitor LDE223 or by siRNA prevented bleomycin induced dermal fibrosis. Inhibition<br />
of the hedgehog pathway also exerted potent anti-fibrotic effects in the tight skin 1<br />
mouse model.<br />
We also demonstrated a role of aberrant notch signaling in the pathogenesis of SSc.<br />
Notch signaling was activated in SSc in vivo as well as in cultured SSc fibroblasts in<br />
vitro as shown by overexpression of the notch ligand Jagged-1 (Jag-1) and by<br />
elevated transcription of notch target genes such as hes-1. Stimulation of healthy<br />
dermal fibroblasts with the Jag-1-Fc induced an SSc-like phenotype with expression<br />
of contractile proteins and increased release of collagen. Inhibition of Notch signaling<br />
by the γ-secretase inhibitor DAPT or by siRNA mediated knockdown of Notch-1<br />
efficiently reduced the release of collagen from SSc fibroblasts. Overexpression of a<br />
Notch antisense construct or treatment with DAPT also prevented bleomycin-induced<br />
fibrosis and fibrosis in tight-skin 1 mice. Moreover, targeting Notch signaling resulted<br />
in almost complete regression of pre-established experimental fibrosis. Thus, we<br />
demonstrated that Notch signaling plays an important role in fibroblast activation and<br />
tissue fibrosis.<br />
Collectively, our results describe a central role of hedgehog and notch signaling for<br />
fibroblast activation in fibrosis. These findings might have direct translational<br />
implications because inhibitors of Smo as well as γ-secretase inhibitors are available<br />
and were well tolerated in clinical trials of cancer patients.<br />
Cannabinoid receptors<br />
Cannabinoids are derivates of the marijuana component Δ 9 -tetrahydrocannabinol that<br />
exert their effects via CB1 and CB2 receptors. Cannabinoids can be subdivided into<br />
three different groups according to their origin. The family of cannabinoids includes<br />
plant derived cannabinoids, synthetic cannabinoids and endogenous cannabinoids<br />
(endocannabinoids) that are synthesized within the human body. Besides their<br />
effects in the CNS, endocannabinoids regulate physiological and pathophysiological<br />
processes in non-neuronal tissues. Recent data demonstrated that cannabinoids<br />
84
egulate the activation of hepatic stellate cells, which contribute to the pathogenesis<br />
of liver fibrosis. We therefore aimed to evaluate the role of cannabinoids and their<br />
receptors in fibroblast activation and evaluate targeting of cannabinoid receptors as a<br />
therapeutic approach in fibrotic diseases.<br />
We demonstrated that mice deficient for CB1 (CB1 -/- ) were protected from<br />
bleomycin-induced dermal fibrosis with reduced dermal thickening, hydroxyproline<br />
content and myofibroblast counts. Inactivation of CB1 decreased the number of<br />
infiltrating T cells and macrophages in lesional skin. In contrast, activation of CB1<br />
with the selective small molecule inhibitor ACEA increased leukocyte infiltration and<br />
enhanced the fibrotic response to bleomycin. The phenotype of CB1 -/- mice was<br />
mimicked by transplantation of CB1 -/- bone marrow into CB1 +/+ mice, demonstrating<br />
that leukocytes mediate the pro-fibrotic effects of CB1. Consistently, knockdown of<br />
CB1 did not prevent fibrosis in the inflammation-independent Tsk-1 model.<br />
In contrast to CB1 -/- mice, CB2 -/- mice were more sensitive to bleomycin induced<br />
dermal fibrosis. Leukocytes counts were significantly higher in lesional skin of CB2 -/-+<br />
mice than CB2 +/+ mice. Treatment with the CB2 antagonist AM-630 also increased<br />
dermal fibrosis, whereas the CB2 agonist JWH-133 reduced leukocyte infiltration and<br />
dermal fibrosis. As for CB1, the altered sensitivity of CB2 -/- mice to fibrosis was<br />
mediated by bone marrow derived cells rather than by resident fibroblasts, because<br />
the phenotype of CB2 -/- mice was mimicked by transplantation of CB2 -/- bone<br />
marrow into CB2 +/+ mice, but not by CB2 -/- mice transplanted with bone marrow from<br />
CB2 +/+ mice. Consistent with this hypothesis, neither knockdown or inhibition, nor<br />
activation of CB1 or CB2 in cultured fibroblasts altered fibroblast activation or the<br />
release of collagen.<br />
We demonstrated that CB1 and CB2 have opposing effects in fibrosis. CB1<br />
stimulates leukocyte infiltration and enhances tissue fibrosis, whereas CB2 limits<br />
leukocyte influx and ameliorates experimental dermal fibrosis. Since selective CB1<br />
antagonists as well as selective CB2 agonists are available, the endocannabiod<br />
system and both of its receptors might be interesting molecular targets for the<br />
treatment of early inflammatory stages of fibrotic diseases, whereas they are unlikely<br />
to be effective in later, less inflammatory stages with predominant endogenous<br />
activation of fibroblasts.<br />
85
Original Articles<br />
Publications (2009-2010)<br />
1. Balistreri E, Garcia-Gonzalez E, Selvi E, Akhmetshina A, Palumbo K,<br />
Lorenzini S, Maggio R, Lucatelli M, Galeazzi M, Distler J. The cannabinoid<br />
WIN55, 212-2 abrogates dermal fibrosis in scleroderma bleomycin model. Ann<br />
Rheum Dis. 2010 Dec 21.<br />
2. Dieudé P, Guedj M, Truchetet ME, Wipff J, Revillod L, Riemekasten G,<br />
Matucci-Cerinic M, Melchers I, Hachulla E, Airo P, Diot E, Hunzelmann N,<br />
Mouthon L, Cabane J, Cracowski JL, Riccieri V, Distler J, Amoura Z, Valentini<br />
G, Camaraschi P, Tarner I, Frances C, Carpentier P, Brembilla NC, Meyer O,<br />
Kahan A, Chizzolini C, Boileau C, Allanore Y. Association of the CD226<br />
307Ser variant with systemic sclerosis: Evidence for a contribution of costimulation<br />
pathways in SSc pathogenesis. Arthritis Rheum. 2010 Dec 15.<br />
3. Dieudé P, Guedj M, Wipff J, Ruiz B, Riemekasten G, Airo P, Melchers I,<br />
Hachulla E, Cerinic MM, Diot E, Hunzelmann N, Caramaschi P, Sibilia J, Tiev<br />
K, Mouthon L, Riccieri V, Cracowski JL, Carpentier PH, Distler J, Amoura Z,<br />
Tarner I, Avouac J, Meyer O, Kahan A, Boileau C, Allanore Y. NLRP1<br />
influences the systemic sclerosis phenotype: a new clue for the contribution of<br />
innate immunity in systemic sclerosis-related fibrosing alveolitis pathogenesis.<br />
Ann Rheum Dis. 2010 Dec 13.<br />
4. Polzer K, Neubert K, Meister S, Frey B, Baum W, Distler JH, Gückel E, Schett<br />
G, Voll RE, Zwerina J. Proteasome inhibition aggravates TNF-mediated bone<br />
resorption. Arthritis Rheum. 2010 Dec 6.<br />
5. Avouac J, Fürnrohr BG, Tomcik M, Palumbo K, Zerr P, Horn A, Dees C,<br />
Akhmetshina A, Beyer C, Distler O, Schett G, Allanore Y, Distler JH.<br />
Inactivation of the transcription factor STAT4 prevents inflammation-driven<br />
fibrosis in systemic sclerosis animal models. Arthritis Rheum. 2010 Nov 30.<br />
6. Heiland GR, Zwerina K, Baum W, Kireva T, Distler JH, Grisanti M, Asuncion F,<br />
Li X, Ominsky M, Richards W, Schett G, Zwerina J. Neutralisation of Dkk-1<br />
protects from systemic bone loss during inflammation and reduces sclerostin<br />
expression. Ann Rheum Dis. 2010 Sep 21.<br />
7. Weber CK, Haslbeck M, Englbrecht M, Sehnert B, Mielenz D, Graef D, Distler<br />
JH, Mueller RB, Burkhardt H, Schett G, Voll RE, Fürnrohr BG. Antibodies to<br />
the endoplasmic reticulum-resident chaperones calnexin, BiP and Grp94 in<br />
patients with rheumatoid arthritis and systemic lupus erythematosus.<br />
Rheumatology (Oxford). 2010 Aug 17.<br />
8. Dallos T, Heiland GR, Strehl J, Karonitsch T, Gross W, Moosig F, Holl-Ulrich<br />
C, Distler JH, Manger B, Schett G, Zwerina J. Chemokine CCL17/TARC in<br />
Churg-Strauss syndrome. Arthritis Rheum. 2010 Jul 28.<br />
86
9. Marquart S, Zerr P, Akhmetshina A, Palumbo K, Reich N, Tomcik M, Horn A,<br />
Dees C, Engel M, Zwerina J, Distler O, Schett G, Distler JH. Inactivation of the<br />
cannabinoid receptor CB1 prevents leukocyte infiltration and experimental<br />
fibrosis. Arthritis Rheum. 2010 Jul 8.<br />
10. Wipff J, Dieudé P, Guedj M, Ruiz B, Riemekasten G, Cracowski J, Matucci-<br />
Cerinic M, Melchers I, Humbert M, Hachulla E, Airo P, Diot E, Hunzelmann N,<br />
Caramaschi P, Sibilia J, Valentini G, Tiev K, Girerd B, Mouthon L, Riccieri V,<br />
Carpentier P, Distler JH, Amoura Z, Tarner I, Degano B, Avouac J, Meyer O,<br />
Kahan A, Boileau C, Allanore Y. Association of KCNA5 gene polymorphism<br />
with systemic sclerosis-associated pulmonary arterial hypertension in the<br />
European Caucasian population. Arthritis Rheum. 2010 Jun 15.<br />
11. Avouac J, Walker U, Tyndall A, Kahan A, Matucci-Cerinic M, Allanore Y;<br />
EUSTAR, Miniati I, Muller A, Iannone F, Distler O, Becvar R, Sierakowsky S,<br />
Kowal-Bielecka O, Coelho P, Cabane J, Cutolo M, Shoenfeld Y, Valentini G,<br />
Rovensky J, Riemekasten G, Vlachoyiannopoulos P, Caporali R, Jiri S, Inanc<br />
M, Zimmermann Gorska I, Carreira P, Novak S, Czirjak L, Oliveira Ramos F,<br />
Jendro M, Chizzolini C, Kucharz EJ, Richter J, Cozzi F, Rozman B, Mallia CM,<br />
Gabrielli A, Farge D, Kiener HP, Schöffel D, Airo P, Wollheim F, Martinovic D,<br />
Trotta F, Jablonska S, Reich K, Bombardieri S, Siakka P, Pellerito R, Bambara<br />
LM, Morovic-Vergles J, Denton C, Hinrichs R, Van den Hoogen F, Damjanov<br />
N, Kötter I, Ortiz V, Heitmann S, Krasowska D, Seidel M, Hasler P, Van Laar<br />
JM, Kaltwasser JP, Foeldvari I, Juan Mas A, Bajocchi G, Wislowska M,<br />
Pereira Da Silva JA, Jacobsen S, Worm M, Graniger W, Kuhn A, Stankovic A,<br />
Cossutta R, Majdan M, Damjanovska Rajcevska L, Tikly M, Nasonov EL,<br />
Steinbrink K, Herrick A, Müller-Ladner U, Dinc A, Scorza R, Sondergaard K,<br />
Indiveri F, Nielsen H, Szekanecz Z, Silver RM, Antivalle M, Espinosa IB,<br />
García de la Pena Lefebvre P, Midtvedt O, Launay D, Valesini F, Tuvik P,<br />
Ionescu RM, Del Papa N, Pinto S, Wigley F, Mihai C, Sinziana Capranu M,<br />
Sunderkötter C, Jun JB, Alhasani S, Distler JH, Ton E, Soukup T, Seibold J,<br />
Zeni S, Nash P, Mouthon L, De Keyser F, Duruöz MT, Cantatore FP, Strauss<br />
G, von Mülhen CA, Pozzi MR, Eyerich K, Szechinski J, Keiserman M,<br />
Houssiau FA, Román-Ivorra JA, Krummel-Lorenz B, Aringer M, Westhovens<br />
R, Bellisai F, Mayer M, Stoeckl F, Uprus M, Volpe A, Buslau M, Yavuz S,<br />
Granel B, Valderílio Feijó A, Del Galdo F, Popa S, Zenone T, Ricardo<br />
Machado X, Pileckyte M, Stebbings S, Mathieu A, Tulli A, Tourinho T, Souza<br />
R, Acayaba de Toledo R, Stamp L, Solanki K, Veale D, Francisco Marques<br />
Neto J, Bagnato GF, Loyo E, Toloza S, Li M, Ahmed Abdel Atty Mohamed W,<br />
Cobankara V, Olas J, Salsano F, Oksel F, Tanaseanu CM, Foti R, Ancuta C,<br />
Vonk M, Caramashi P, Beretta L, Balbir A, Chiàla A, Pasalic Simic K, Ghio M,<br />
Stamenkovic B, Rednic S, Host N, Pellerito R, Hachulla E, Furst DE.<br />
Characteristics of joint involvement and relationships with systemic<br />
inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial<br />
and <strong>Research</strong> Group (EUSTAR) database. J Rheumatol. 2010 Jul;37(7):1488-<br />
501. Epub 2010 Jun 15.<br />
12. Dieudé P, Guedj M, Wipff J, Ruiz B, Riemekasten G, Matucci-Cerinic M,<br />
Melchers I, Hachulla E, Airo P, Diot E, Hunzelmann N, Cabane J, Mouthon L,<br />
Cracowski JL, Riccieri V, Distler J, Meyer O, Kahan A, Boileau C, Allanore Y.<br />
Association of the TNFAIP3 rs5029939 variant with systemic sclerosis in the<br />
European Caucasian population. Ann Rheum Dis. 2010 May 28.<br />
87
13. Krönke G, Uderhardt S, Kim KA, Stock M, Scholtysek C, Zaiss MM, Surmann-<br />
Schmitt C, Luther J, Katzenbeisser J, David JP, Abdollahi-Roodsaz S, Tran K,<br />
Bright JM, Binnerts ME, Akhmetshina A, Böhm C, Distler JH, Joosten LA,<br />
Schett G, Abo A. R-spondin1 protects against inflammatory bone damage<br />
during murine arthritis by modulating the wnt pathway. Arthritis Rheum. 2010<br />
Apr 6.<br />
14. Reich N, Beyer C, Gelse K, Akhmetshina A, Dees C, Zwerina J, Schett G,<br />
Distler O, Distler JH. Microparticles stimulate angiogenesis by inducing ELR(+)<br />
CXC-chemokines in synovial fibroblasts. J Cell Mol Med. 2010 Mar 8.<br />
15. Maurer B, Stanczyk J, Jüngel A, Akhmetshina A, Trenkmann M, Brock M,<br />
Kowal-Bielecka O, Gay RE, Michel BA, Distler JH, Gay S, Distler O. miR-29 is<br />
a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum.<br />
2010 Mar 3.<br />
16. Akhmetshina A, Beer J, Polzer K, Englbrecht M, Palumbo K, Dees C, Reich N,<br />
Zwerina J, Szucs G, Gusinde J, Nevskaya T, Distler O, Kerjaschki D, Schett<br />
G, Distler JH. Decreased lymphatic vessel counts in systemic sclerosis -<br />
Association with fingertip ulcers. Arthritis Rheum. 2010 Feb 12.<br />
17. Reich N, Maurer B, Akhmetshina A, Venalis P, Dees C, Zwerina J, Nevskaja<br />
T, Schett G, Distler JH. The transcription factor fos-related antigen-2 (Fra-2)<br />
regulates the production of extracellular matrix in systemic sclerosis. Arthritis<br />
Rheum 2010 Jan;62(1):280-90.<br />
18. Functional autoantibodies against serpin E2 in rheumatoid arthritis.<br />
Maciejewska-Rodrigues H, Al-Shamisi M, Hemmatazad H, Ospelt C, Bouton<br />
MC, Jäger D, Cope AP, Charles P, Plant D, Distler JH, Gay RE, Michel BA,<br />
Knuth A, Neidhart M, Gay S, Jüngel A.. Arthritis Rheum. 2010 Jan;62(1):93-<br />
104.<br />
19. Maurer B, Busch N, Jüngel A, Pileckyte M, Gay RE, Michel BA, Schett G, Gay<br />
S, Distler JH, Distler O. Fra-2 induces progressive peripheral vasculopathy in<br />
mice closely resembling human systemic sclerosis. Circulation. 2009 Nov 23.<br />
20. Kurowska-Stolarska M, Distler JH, Jüngel A, Rudnicka W, Neumann E, Pap T,<br />
Wenger RH, Michel BA, Müller-Ladner U, Gay RE, Maslinski W, Gay S and<br />
Distler O. Id-2 induced by hypoxia promotes synovial fibroblast-dependent<br />
osteoclastogenesis. Arthritis Rheum. 2009 Nov 30;60(12):3663-3675.<br />
21. Ruiz Heiland G, Aigner E, Dallos T, Sahinbegovic E, Krenn V, Thaler C, Weiss<br />
G, Distler JH, Datz C, Schett G, Zwerina J. Synovial immunopathology in<br />
hemochromatosis arthropathy. Ann Rheum Dis. 2009 Nov 23.<br />
22. Dieudé P, Wipff J, Guedj M, Ruiz B, Melchers I, Hachulla E, Riemekasten G,<br />
Diot E, Hunzelmann N, Sibilia J, Tiev K, Mouthon L, Cracowski JL, Carpentier<br />
PH, Distler J, Amoura Z, Tarner I, Avouac J, Meyer O, Kahan A, Boileau C,<br />
Allanore Y. BANK1 is a genetic risk factor for diffuse cutaneous systemic<br />
sclerosis and has additive effects with IRF5 and STAT4. Arthritis Rheum. 2009<br />
Nov;60(11):3447-54.<br />
88
23. Mieliauskaite D, Venalis P, Dumalakiene I, Venalis A, Distler J. Relationship<br />
between serum levels of TGF-beta1 and clinical parameters in patients with<br />
rheumatoid arthritis and Sjögren's syndrome secondary to rheumatoid arthritis.<br />
Autoimmunity. 2009 May;42(4):356-8.<br />
24. Guiducci S, Distler JH, Milia AF, Miniati I, Rogai V, Manetti M, Falcini F, Ibba-<br />
Manneschi L, Gay S, Distler O, Matucci-Cerinic M. Stiff skin syndrome:<br />
evidence for an inflammation-independent fibrosis? Rheumatology (Oxford).<br />
2009 May 25.<br />
25. Hemmatazad H, Rodrigues HM, Maurer B, Brentano F, Pileckyte M, Distler<br />
JH, Gay RE, Michel BA, Gay S, Huber LC, Distler O, Jüngel A. Histone<br />
deacetylase 7, a potential target for the antifibrotic treatment of systemic<br />
sclerosis. Arthritis Rheum. 2009 May;60(5):1519-29.<br />
26. Akhmetshina A, Dees C, Busch N, Beer J, Zimmer A, Distler O, Schett G,<br />
Distler JH. The cannabinoid receptor CB2 exerts anti-fibrotic effects in<br />
experimental dermal fibrosis. Arthritis Rheum, 2009 Apr;60(4):1129-36.<br />
27. Polzer K, Joosten L, Gasser J, Distler JH, Ruiz G, Baum W, Redlich K,<br />
Bobacz K, Smolen JS, van den Berg W, Schett G, Zwerina J. IL-1 is essential<br />
for systemic inflammatory bone loss. Ann Rheum Dis. 2009 Feb 5.<br />
28. Akhmetshina A, Venalis P, Dees C, Busch N, Zwerina J, Jüngel A, Schett G,<br />
Distler O, Distler JH. Treatment with imatinib does not only prevent fibrosis in<br />
different preclinical models of SSc, but also induces regression of established<br />
fibrosis. Arthritis Rheum 2009 Jan;60(1):219-24.<br />
29. Hanitsch LG, Burmester GR, Witt C, Hunzelmann N, Genth E, Krieg T,<br />
Lehmacher W, Melchers I, Meurer M, Müller-Ladner U, Schulze-Lohoff E,<br />
Becker M, Sunderkoetter C; Worm M, Klaus P, Rubbert A, Steinbrink K,<br />
Grundt B, Hein R, Scharffetter-Kochanek K, Hinrichs R, Walker K, Szeimies<br />
RM, Karrer S, Müller A, Seitz C, Schmidt E, Lehmann P, Foeldvári I,<br />
Reichenberger F, Gross L, Kuhn A, Haust M, Reich K, Böhm M, Saar P,<br />
Fierlbeck G, Kötter I, Lorenz HM, Blank N, Gräfenstein K, Juche A, Aberer E,<br />
Bali G, Fiehn C, Stadler R, Bartels V, Buslau M, Distler J, Sticherling M,<br />
Riemekasten G. Skin sclerosis is only of limited value to identify SSc patients<br />
with severe manifestations--an analysis of a distinct patient subgroup of the<br />
German Systemic Sclerosis Network (DNSS) Register. Rheumatology<br />
(Oxford). 2009 Jan;48(1):70-3.<br />
89
Reviews<br />
1. Iwamoto N, Distler JH, Distler O. Tyrosine Kinase Inhibitors in the Treatment<br />
of Systemic Sclerosis: From Animal Models to Clinical Trials. Curr Rheumatol<br />
Rep. 2010 Nov 2.<br />
2. Beyer C, Schett G, Distler O, Distler JH. Animal Models of Systemic Sclerosis:<br />
Prospects and Limitations. Arthritis Rheum. 2010 Jul 8.<br />
3. Beyer C, Distler JH, Distler O. Are tyrosine kinase inhibitors promising for the<br />
treatment of systemic sclerosis and other fibrotic diseases? Swiss Med Wkly.<br />
2010 Apr 26.<br />
4. Distler JH and Distler O. Tyrosine kinase inhibitors for the treatment of fibrotic<br />
diseases such as systemic sclerosis: towards molecular targeted therapies.<br />
Ann Rheum Dis. 2010 Jan;69 Suppl 1:i48-51.<br />
5. Beyer C and Distler JH. The scientific basis for novel treatments of systemic<br />
sclerosis. f1000 Medicine <strong>Report</strong>s 2009, 1:95.<br />
6. Distler JH, Beyer C, Schett G, Lüscher TF, Gay S, Distler O. Endothelial<br />
Progenitor Cells - Novel players in the pathogenesis of rheumatic diseases.<br />
Arthritis Rheum. 2009 Nov;60(11):3168-79.<br />
7. Abraham DJ, Krieg T, Distler J, Distler O. Overview of pathogenesis of<br />
systemic sclerosis. Rheumatology (Oxford). 2009 Jun;48 Suppl 3:iii3-7.<br />
8. Beyer C, Schett G, Gay S, Distler O, Distler JH. Hypoxia in the pathogenesis<br />
of systemic sclerosis. Arthritis Res Ther. 2009;11(2):220. Epub 2009 Apr 21.<br />
TRAINING OF GRADUATE AND MEDICAL STUDENTS<br />
Doctoral theses (Biology)<br />
Alfiya Akhmetshina, Nicole Busch, Michal Tomcik (PhD part time in Erlangen),<br />
Jerome Avouac (PhD part time in Erlangen)<br />
Doctoral theses (Molecular Medicine)<br />
Sieglinde Marquart, Constantin Huhn, Tobias Strapatsas, Christina Bergmann, Michael<br />
Balzer<br />
90
Laboratory of Dendritic Cell Biology<br />
(Department of Dermatology)<br />
Head: Diana Dudziak, Dr. rer. nat.<br />
Professor of Dendritic Cell Biology<br />
Address: Laboratory of Dendritic Cell Biology<br />
Department of Dermatology<br />
Hartmannstr. 14<br />
D-91052 Erlangen<br />
Telephone: + 49 (9131) 85 39346<br />
Fax: + 49 (9131) 85 39347<br />
E-mail: diana.dudziak@uk-erlangen.de<br />
Homepage: http://www.hautklinik.ukerlangen.de/e1585/e1893/e2171/index_ger.html<br />
Head<br />
Diana Dudziak, Prof. Dr. rer. nat.<br />
Professor of Dendritic Cell Biology<br />
Postdoctoral Fellows<br />
Kirsten Neubert, Dr. rer. nat.<br />
Nathalie Eissing, Dr. med. vet.<br />
Doctoral Students (Biology)<br />
Gordon Heidkamp<br />
Christian Lehmann<br />
Anna Baranska<br />
Lukas Heger<br />
91
* PhD received<br />
Doctoral Students (Medicine)<br />
Kirsten Ehrenspeck<br />
Nathalie Eissing*<br />
Yang Jiao<br />
Technicians<br />
Simone Beck<br />
Christina Weiss<br />
92
<strong>Research</strong><br />
Our research is focussed on the function of Dendritic cell subpopulations in the<br />
process of induction of immunity and maintenance of peripheral tolerance. Dendritic<br />
cells are very important antigen presenting cells. We are especially interested in the<br />
analysis of antigen uptake, antigen processing and antigen presentation by Dendritic<br />
cells, if and how Dendritic cell subpopulations differ in antigen processing and<br />
presentation, and how Dendritic cell subpopulations migrate in the lymphoid tissues<br />
when they have encountered their antigens under immunizing and tolerizing<br />
conditions. Moreover, to understand antigen processing and presentation<br />
mechanisms we focus on the responding T cells. Depending on the Dendritic cell<br />
subpopulation we found that different Dendritic cell subpopulations can induce<br />
different T cell responses in vivo (Dudziak et al., 2007). These findings will have<br />
important implications in the development of new therapeutic vaccines.<br />
Dendritic cells and antigen targeting<br />
Dendritic cells maintain peripheral tolerance and induce immunity<br />
The immune system controls invading pathogenic organisms by innate and adaptive<br />
immune mechanisms. To enable recognition of virtually any antigen, developing B<br />
and T cells randomly rearrange their receptors to produce unique clones with a wide<br />
variety of specificities. It is well accepted that this also leads to the generation of<br />
receptors that can recognize ‘self’ antigens. By central tolerance mechanisms at<br />
several checkpoints self reactive B cells are deleted in the bone marrow whereas self<br />
reactive T cells undergo negative selection mechanisms in the thymus where they<br />
are either deleted or undergo anergic mechanisms. As some of the T cells can<br />
escape negative selection in the thymus, checkpoints in the periphery have to exist to<br />
prevent autoimmune reactions by those potentially self-reactive T cells. Only recently<br />
it became clear that DCs which are essential for the induction of adaptive immune<br />
responses are also key players not only for the maintenance of central tolerance but<br />
also for the maintenance of peripheral tolerance.<br />
Dendritic cells (DCs) are the most important antigen presenting cells in the immune<br />
system. In non-lymphoid organs DCs act as sentinels and take up and process<br />
antigens from the periphery (skin, airways, intestine, interstitial spaces of various<br />
organs). Antigen loaded DCs migrate to the lymphoid tissues and interact with<br />
antigen-specific T cells. Besides the uptake of soluble antigens, DCs are also able to<br />
ingest apoptotic cells, tumor cells, or infected cells to present their antigen. The<br />
induction of peripheral tolerance or immunity depends on the DC differentiation state.<br />
In the steady-state immature DCs express low levels of CD80, CD86 or MHC class II<br />
molecules on their cell surface. Recognition of the MHC peptide complex by a T cell<br />
in the steady-state causes deletion or anergy of self reactive T cells after an initial<br />
phase of proliferation. This process is resulting in peripheral tolerance (Dudziak et al.,<br />
2007, Dudziak, 2009).<br />
In contrast, during a microbial or viral infection antigen uptake is paralleled by DC<br />
activation and maturation. In this process pattern-recognition receptors (PRRs)<br />
expressed on DCs, such as Toll-like receptors (TLRs) and proteins of the C-type<br />
lectin receptor family, recognize conserved parts of pathogens such as lipids, sugar<br />
93
esidues, or nucleic acids. This stimulation causes upregulation of cell surface<br />
activation markers (e.g. CD80, CD83, and CD86) and expression of cytokines and<br />
chemokines such as TNFα, IL6, IL12 or Rantes 9 (Dudziak et al., 2005, Dudziak,<br />
2009). Under these circumstances T cells that recognize bacterial or viral antigens<br />
become activated, clonally expand and develop into memory T cells (Dudziak et al.,<br />
2007; Dudziak, 2009).<br />
Production of antigen carrying recombinant antibodies against different<br />
Dendritic cell subpopulations<br />
Diana Dudziak, Gordon Heidkamp, Nathalie Eissing, Kirsten Ehrenspeck<br />
At least 6 different subtypes of murine DCs can be distinguished based on their<br />
localization and expression of cell surface molecules (Fig. 1, Dudziak, 2009). We are<br />
only just beginning to understand why such a great variety of DC subtypes has<br />
evolved and what their precise role is in the maintenance of peripheral tolerance or in<br />
the induction of immunity. The two main subpopulations of conventional DCs in the<br />
spleen can be distinguished by the expression of CD11c and CD8 as CD11c + CD8 -<br />
(myeloid) and CD11c + CD8 + (lymphoid) DCs (Dudziak, 2009). We found that these<br />
DC subpopulations express different endocytosis receptors and C-type lectin<br />
receptors on their cell surface, e.g. CD11c + CD8 - DCs express DCIR2 whereas<br />
CD11c + CD8 + DCs express DEC205 (CD205) (Fig. 1, Dudziak et al., 2007; Soares et<br />
al., 2007; Yamazaki et al., 2008; Do et al., 2010, O’Kamphorst et al., 2010; Loschko<br />
et al., 2011(1); Loschko et al., 2011(2)). We could show that DCIR2 and DEC205<br />
were rapidly internalized after interaction with antibodies against these endocytosis<br />
receptors (Dudziak et al., 2007). In addition to the internalization of the receptors we<br />
found that also the bound antibodies were internalized into the DCs. These findings<br />
let us to the idea of producing recombinant endocytosis receptor antibodies that are<br />
genetically fused with an antigen of choice.<br />
94<br />
Figure 1. Murine splenic<br />
DCs. A) Overview of<br />
different murine DC subpopulations<br />
and their localization.<br />
B) Immunofluorescence<br />
of murine spleen<br />
showing B cells (B220),<br />
CD11c + CD8 - (DCIR2/<br />
33D1 + ) in the bridging area<br />
and red pulp and<br />
CD11c + CD8 + (DEC205 + )<br />
DCs in the T cell area. C)<br />
FACS analysis of CD11c +<br />
DCs in murine spleen and<br />
the expression of CD8,<br />
DEC205 and DCIR2/33D1.<br />
(Dudziak et al., 2009)
We cloned the variable regions of the DEC205 and the 33D1 rat antibodies (the latter<br />
we identified by microarray analysis and expression cloning to be DCIR2) and fused<br />
them by overlap PCR to the constant regions of the heavy and light chain of murine<br />
IgG1. The Fc region of the murine IgG1 was mutated and therefore binding to Fc<br />
receptors is inhibited. In the heavy chain we inserted the Ovalbumin antigen (and for<br />
some experiments Hen egg lysozyme) as model antigen of choice. The light and<br />
Ovalbumin carrying heavy chains of DEC205 and 33D1 antibodies were transiently<br />
transfected into 293T cells and recombinant antibody containing supernatants were<br />
enriched with protein G. We found that the recombinant antibodies DEC205-Ova and<br />
33D1/DCIR2-Ova were binding to the DC subsets CD11c + CD8 + or CD11c + CD8 - ,<br />
respectively, in vivo and in vitro, were internalized and thus were therefore ready for<br />
antigen targeting experiments (Dudziak et al., 2007). Currently we are producing new<br />
antibodies for future targeting of other DC subpopulations in vivo.<br />
Differential Antigen processing and presentation by Dendritic cell<br />
subpopulations<br />
Diana Dudziak, Anna Baranska, Gordon Heidkamp, Kirsten Ehrenspeck<br />
To analyze if DC subpopulations can be targeted with our recombinant Ovalbumin<br />
carrying antibodies we injected C57BL/6 mice with 33D1-Ova and DEC205-Ova<br />
antibodies to analyze how the different DC subpopulations uptake, process and<br />
present the antigens to T cells. In our experiments we are using transgenic mice that<br />
contain T cells that express either a T cell receptor that recognizes Ovalbumin<br />
peptide when it is presented as peptide MHCI complex or transgenic mice whose T<br />
cell receptor recognizes Ovalbumin antigen when it is presented as peptide MHCII<br />
complex on the surface of antigen presenting DCs. Therefore, both cytotoxic and T<br />
helper cell responses can be analyzed in vivo. First, we performed in vivo antigen<br />
targeting and in vitro T cell stimulation experiments with transgenic Ovalbumin<br />
specific T cells. After antigen targeting of only 10μg DEC205-Ova, or 33D1/DCIR2-<br />
Ova (normally, uncoupled Ovalbumin-protein needs to be injected as 1000-5000<br />
μg/mouse to receive T cell responses) we found, that delivering Ovalbumin antigens<br />
with DEC205-Ova to CD11c + CD8 + DCs induces a strong CD8 T cell response and<br />
antigen targeting with 33D1/DCIR2-Ova to CD11c + CD8 - DCs induced a more<br />
prominent CD4 T cell response in vitro.<br />
Further, we analyzed how T cells respond to antigen loaded DC subpopulations in<br />
vivo. Within 3 days we found that CD4 or CD8 transgenic T cells showed a<br />
proliferative response after interaction with antigen loaded DCs in vivo. We found that<br />
with less than 30 ng of the recombinant antibodies we were able to induce a CD8 T<br />
cell response when DEC205-Ova antibodies were targeted to CD11c + CD8 + DCs,<br />
whereas when we targeted 33D1-Ova to CD11c + CD8 - DCs in vivo we were able to<br />
induce a strong CD4 T cell response in vivo. By microarray analysis and the use of<br />
transgenic mice that express human DEC205 on all DC subpopulations in vivo we<br />
were able to demonstrate that the DC subpopulations were different in antigen<br />
processing and presentation and that the differences were not due to the receptors<br />
we have had targeted in vivo. Thus, we can conclude that CD11c + CD8 + DCs excel in<br />
antigen presentation as peptide MHCI complexes whereas CD11c + CD8 - DCs excel in<br />
antigen presentation on MHCII in the steady state.<br />
95
Targeting antigens under immunizing conditions induced a strong prolonged<br />
proliferative response in either CD4 transgenic T cells (targeting CD11c + CD8 - with<br />
33D1-Ova) or CD8 transgenic T cells (targeting of CD11c + CD8 + DCs with DEC205-<br />
Ova). On the other hand when we targeted antigens under tolerizing conditions<br />
transgenic T cells started to proliferate till day 3, but were deleted afterwards. Left T<br />
cells clearly were of regulatory T cell phenotype (Yamazaki et al., 2008). We further<br />
could show by 2-Photon microscopy that T cells that were interacting with DCs that<br />
presented the antigen under tolerizing conditions or presented the antigen under<br />
immunizing conditions were behaving very similar in dependency on interaction time,<br />
velocity and activation markers expressed on the T cells (Lindquist et al., 2004;<br />
Shakhar et al., 2005). Regarding the induced immune responses we induced under<br />
immunizing conditions with anti CD40 antibody, as gold standard activation stimulus,<br />
we found that targeting antigens to CD11c + CD8 - DCs predominantly induced a TH2 T<br />
cell response when we analyzed Balb/c mice but on the other hand a TH1 T cell<br />
response when CD11c + CD8 + DCs were targeted (Soares et al., 2007).<br />
Altogether, our data indicate that targeting of CD11c + CD8 + DCs by anti-<br />
DEC205 antibody seems to be an efficient way to induce cross presentation in the<br />
classical MHCI pathway. In contrast, CD11c + CD8 - DCs preferentially processed and<br />
presented antigens in the traditional MHCII pathway. Currentlc we are investigating<br />
the antigen processing machineries when DCs were activated with TLR ligands.<br />
Analysis of early T cell tolerance and T cell immunity<br />
Diana Dudziak, Kirsten Neubert<br />
We and others could show that antigen targeted DCs elicited a peripheral tolerance<br />
in antigen-specific T cells under non-inflammatory conditions. In contrast, delivery of<br />
recombinant antigen-carrying antibodies together with a stimulatory anti CD40<br />
antibody established an antigen-specific immune response. Because of severe side<br />
effects such as systemic inflammation and the non-specific activation of all immune<br />
cells that express CD40 on their cell surface the usage of systemic anti CD40<br />
antibody cannot be a feasible costimulatory strategy for human therapy.<br />
As TLR stimulation is an approach already used in clinical trials we believe that TLR<br />
stimulation in combination with our antibody targeting strategy might be an alternative<br />
approach to induce protective immune responses in vivo. TLRs are very well<br />
characterized class of pattern-recognition-receptors (PRRs) in mammalian species.<br />
The TLRs are differentially expressed on various cells of the immune system<br />
including DCs. TLRs 1, 2, 4, 5, and 6 are expressed on the cell surface and seem to<br />
have evolved to recognize bacterial products. In contrast TLRs 3, 7, 8, and 9 are<br />
expressed intracellularly in endosomes and lysosomes and recognize nucleic acids.<br />
Several pathogen-associated molecules such as double stranded RNA (poly(I:C) =<br />
pIC), bacterial or viral double stranded DNA (CpG), bacterial lipopolysaccharides<br />
(LPS), lipoproteins (Pam3Cys = Pam3), lipoteichoide acids, zymosan, or flagellin<br />
have been identified to bind to TLR receptors resulting in a strong inflammatory and<br />
protective immune response.<br />
96
To determine if TLR agonists are able to support the initiation of an immune response<br />
in combination of in vivo antigen targeting of C-type lectin receptors we are analyzing<br />
the early T cell activation and proliferation after interaction of the T cells with antigen<br />
loaded DC subsets in vivo to identify 1) if T cells can respond to TLR ligands similar<br />
to anti CD40 stimulating antibody, 2) to analyze different pathways of TLR stimulation<br />
(MyD88 dependent versus MyD88 independent), 3) to identify which kind of T cell<br />
subset emerged after antigen targeting and TLR stimulation, and 4) to analyze what<br />
type of antibody response can be induced.<br />
To investigate if T cells can respond to antigen loaded and TLR ligand activated DCs<br />
in vivo, we perform T cell transfer experiments in antibody targeted mice. To target<br />
DC subsets in vivo we use the recombinant chimeric antibody DEC205, which<br />
recognizes predominantly CD11c + CD8 + splenic DCs and the 33D1 antibody which<br />
binds uniquely to the molecule DCIR2 on CD11c + CD8 - splenic DCs. For the<br />
phenotypical and functional analysis of the emerged T cells it is planned to reisolate<br />
CD4 + or CD8 + transgenic T cells after activation with TLR-ligands and targeting<br />
antibody in vivo. By CBA-cytokine bead array, FACS-analysis, Western blots and<br />
microarray analyses we will be able to identify important transcription factors,<br />
cytokines, and genes involved in establishing immunity or tolerance in T cells. With<br />
these data we will be able to identify which stimulus needs to be given to induce a<br />
strong and long lasting immune response in vivo.<br />
Analysis of cell migration in steady state und immunity in lymphoid<br />
organs<br />
Anna Baranska; Christina Weiss<br />
In this project we focus on the role of DC migration for the induction of efficient and<br />
life long memory T cell responses. Therefore, we inject mice with different TLR<br />
ligands or anti CD40 antibody to analyze the expression of activation markers by<br />
FACS-analysis, DC migration by confocal microscopy, and the produced cytokines by<br />
CBA-assay at different time points after activation. We found that the C-type lectin<br />
receptor DCIR2 was not influenced by the DC activation, whereas DEC205 was up<br />
regulated by diverse TLR ligands. In addition, we found that the upregulation of<br />
MHCII and the activation markers CD80 and CD86 were different dependent on the<br />
TLR stimulus as well as the DC subpopulation (Baranska et al., in preparation). We<br />
further established a 6 color confocal microscopy analysis to identify where the<br />
different DC subsets localize after activation. Our next steps will be the simultaneous<br />
targeting of antigens to either CD11c + CD8 - or CD11c + CD8 + DCs under stimulating or<br />
tolerizing conditions to analyze when and were DCs interact with T cells in vivo.<br />
These data will help to understand the important role of DCs in initiation of an<br />
immune response.<br />
New molecules for Antigen targeting in vivo<br />
Targeting inhibitory and activating Fc-receptors in vivo<br />
Christian Lehmann<br />
Fc-receptors are widely accepted as key mediators of specific, antibody-dependent<br />
reactions of the immune system against pathogens (Biburger et al., 2011,<br />
97
Baerenwald et al., 2011; Nimmerjahn et al., 2010). In the last couple of years it<br />
became clear, that antibodies can also down-regulate immune-responses by acting<br />
on inhibitory Fc-receptors like Fc-gamma-RIIb (which contains an inhibitory signaling<br />
motif, ITIM). The Fc-gamma-RIIB is an Fc-receptor expressed on B cells, and<br />
therefore gives a negative feed-back to the antibody producing B cells. On the other<br />
hand all other Fc-receptors e.g. Fc-gamma RIV (which interacts with the common<br />
gamma chain and therefore induces an activating signal, ITAM), activate the cells<br />
after binding antibodies. As we are interested to understand how the immune system<br />
maintains peripheral tolerance and induces immunity, we would like to study the role<br />
of intrinsic signaling properties of the targeted receptors. As Fc receptors have a<br />
strong endocytosis capacity, and as they are expressed on a variety of antigen<br />
presenting cells, Fc receptors seem to be ideal molecules for targeting antigens in<br />
vivo. Targeting these molecules can model reactions to antigens bound by<br />
antibodies. In our studies we concentrate on the activating Fc-gamma-RIV and the<br />
inhibitory Fc-gamma-RIIb. We already know from literature that monocytes, but not B<br />
cells express Fc-gamma-RIV, whereas Fc-gamma-RIIb is expressed on both cell<br />
types.<br />
For addressing these questions we have cloned the variable regions of the antibodies<br />
directed against the two mentioned Fc-gamma receptors as mouse IgG1 isotype.<br />
Since the constant region is mutated these antibodies are only able to bind the Fc<br />
receptors via their variable regions and not via their Fc part. In addition, we<br />
genetically fused the model antigen Ovalbumin to the heavy chains, which has been<br />
widely used for investigating specific CD4 and CD8 T cell responses in vivo (Dudziak<br />
et al., 2007, Soares et al., 2007; Do et al., 2010, O’Kamphorst et al., 2010). We are<br />
currently producing these antibodies in HEK293T cells by transient transfection.<br />
Afterwards they will be used to compare T cell responses after targeting different<br />
cells (e.g. CD11c + CD8 + DCs, CD11c + CD8 - DCs, B cells, monocytes) and receptors for<br />
the induction of CD4 and CD8 T cells responses. In future, we are planning to use<br />
our antibodies against the inhibitory Fc-gamma-RIIb to protect mice prone to diabetes<br />
from the disease.<br />
Functional characterization of human Dendritic cell<br />
subpopulations<br />
Characterization of Dendritic cell subpopulations in human tissues<br />
Gordon Heidkamp; Nathalie Eissing, Lukas Heger; Simone Beck, Yang Jiao<br />
As everything we know about immune responses is restricted to the murine system,<br />
we are investigating the function of DC subpopulations in human lymphoid organs. In<br />
order to obtain single cell suspensions, a method to efficiently process human splenic<br />
tissue needed to be established (Heidkamp et al., manuscript in preparation).<br />
Extensive multi-colour FACS analysis was used to identify Dendritic cell<br />
subpopulations. Here, Dendritic cells in the human spleen, tonsils, thymus, bone<br />
marrow, blood and cord blood was analyzed according to the already described<br />
expression profiles of blood DCs. So far, two major human blood DC lineages are<br />
defined: myeloid DCs and plasmacytoid DCs. The latter is characterized by the coexpression<br />
of BDCA-2, BDCA-4, CD123 and HLA-DR, whereas myeloid DCs can be<br />
further subdivided into mDC type 1 (BDCA-1 + , CD14 + , CD11c hi ) and mDC type 2<br />
98
(BDCA-3 + , CD14 + , CD11c lo ). These subpopulations have now been characterized for<br />
the expression profil of their cell surface receptors, by their RNA-expression profile in<br />
genearray analyses and by the localization of the DC subpopulations in the tissue on<br />
the tissues mentioned above with the focus on antigen targeting receptors and<br />
antigen processing machinery in the human DC subpopulations.<br />
Antigen targeting of human DCs with anti C-type lectin antibodies<br />
Gordon Heidkamp, Nathalie Eissing, Kirsten Ehrenspeck,<br />
As 33D1 antibody targeting induced a strong CD4 T cell response in mice and<br />
antigen targeting by DEC205 antibody induced a strong CD8 T cell response in vivo<br />
we wanted to investigate the role of the human counterpart of DCIR2 (33D1-antigen)<br />
and DEC205 in peripheral blood and human organs. As the human DEC205 antibody<br />
already existed, we concentrated on the production of an antibody against human<br />
DCIR. ClecSF6/DCIR/LLIR is the counterpart of the murine DCIR2. The antibodies<br />
were first tested by ELISA, FACS, immunofluorescence, Western blot, and<br />
immunoprecipitations if they bind specifically to the C-type lectin hDCIR (Heidkamp et<br />
al., 2010). Later we have chosen the clone 15E12 which showed the best binding<br />
specificities. We cloned the variable regions of the antibody and produced<br />
recombinant hDCIR antibodies in the tissue culture. In addition, our recombinant<br />
antibodies contained the Hemagglutinin antigen of Influenza virus as model antigen.<br />
With the recombinant HA-conjugated hDCIR-HA and hDEC205-HA antibodies we<br />
were able to target human monocyte derived DCs in the tissue culture and to induce<br />
a restimulation of Influenza-specific CD4 and CD8 T cells (Heidkamp et al.,<br />
manuscript submitted). New antibodies are currently produced against newly<br />
identified endocytic receptors specifically expressed in human tissue DCs for future<br />
antigen targeting as therapeutic option.<br />
2011/2012<br />
Publications (2006-2008)<br />
Original Articles<br />
Heidkamp GF, Eissing N, Heger L, Schmitt V, Neubert K, Baranska A, Bozzacco F,<br />
Trumpfheller C, Zebroski H, Schuler G, Nimmerjahn F, Nussenzweig MC, , Dudziak<br />
D. Differential and directed antigen presentation after targeting of DEC205 and DCIR<br />
on human dendritic cells. manuscript submitted<br />
Biburger M, Albert H, Woigk M, Dudziak D, Mack M, Ravetch JV, Nimmerjahn F.<br />
Monocyte subsets involved in immunoglobulin G mediated effector functions in vivo.<br />
Immunity. 2011 Dec 23;35(6):932-44<br />
Loschko J, Heink S, Hackl D, Dudziak D, Reindl W, Korn T, Krug AB. Antigen<br />
Targeting to Plasmacytoid Dendritic Cells via Siglec-H Inhibits Th Cell-Dependent<br />
Autoimmunity. J Immunol. 2011 Dec 15;187(12):6346-56.<br />
Baerenwaldt A, Lux A, Danzer H, Spriewald BM, Ullrich E, Heidkamp G, Dudziak D,<br />
Nimmerjahn F. Fcγ receptor IIB (FcγRIIB) maintains humoral tolerance in the human<br />
immune system in vivo. Proc Natl Acad Sci U S A. 2011 Nov 15;108(46):18772-<br />
18777.<br />
99
Loschko J, Hackl D, Dudziak D, Reindl W, Krug A. Tuning T cell responses by<br />
antigen targeting to plasmacytoid dendritic cells in vivo. J Immunol. 2011 Jun<br />
15;186(12):6718-25<br />
2010<br />
Nimmerjahn F, Lux A, Albert H, Woigk M, Lehmann C, Dudziak D, Smith P, Ravetch<br />
JV. FcγRIV deletion reveals its central role in mediating IgG2a and IgG2b activity in<br />
vivo. Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19396-401.<br />
Kamphorst, AO, Guermonprez P, Dudziak D, Nussenzweig MC. Route of antigen<br />
uptake differentially impacts presentation by dendritic cells and activated monocytes.<br />
J Immunol. 2010 Sep 15;185(6):3426-35. Epub 2010 Aug 20.<br />
Do Y, Koh H, Park CG, Dudziak D, Seo P, Mehandru S, Choi JH, Cheong C, Park S,<br />
Perlin DS, Powell BS, Steinman RM. Targeting of LcrV virulence protein from<br />
Yersinia pestis to dendritic cells protects mice against pneumonic plague. Eur J<br />
Immunol. 2010 Oct;40(10):2791-6.<br />
Heidkamp GF, Neubert K, Haertel E, Nimmerjahn F, Nussenzweig MC, Dudziak D*.<br />
Efficient generation of a monoclonal antibody against the C-type Lectin receptor<br />
DCIR by targeting murine dendritic cells. Immunol Lett. 2010 Aug 16;132(1-2):69-78.<br />
Epub 2010 Jun 8.<br />
2009-2011/2012<br />
Review Articles<br />
Ullrich E, Bosch J, Aigner M, Voelkl S, Kroeger I, Hoffmann P, Kreutz M, Dudziak D,<br />
Gerbitz A. Advances in cellular therapy: 6th international symposium on the clinical<br />
use of cellular products, March 24 and 25, 2011, Erlangen, Germany. Cancer<br />
Immunol Immunother. 2011 Dec 27.<br />
Ullrich E, Bosch J, Aigner M, Völkl S, Dudziak D, Spriewald B, Schuler G, Andreesen<br />
R, Mackensen R. Advances in Cellular Therapy: 5th International Symposium on the<br />
Clinical Use of Cellular Products, March 19 and 20, 2009, Nürnberg, Germany.<br />
Cancer Immunology Immunotherapy. 2010.<br />
Dudziak D, Dendritic cells as Master regulators of T cell responses. BioForum<br />
Europe. 2009.<br />
100
TRAINING OF GRADUATE AND MEDICAL STUDENTS<br />
Doctoral theses (Biology, Dr. rer. nat.)<br />
Gordon Heidkamp (Dipl. Biol.)<br />
Characterization of human Dendritic cell subpopulations<br />
Anna Baranska (Dipl. Biol.)<br />
Antigen targeting and antigen processing in maturing Dendritic cell subpopulations<br />
Christian Lehmann (Dipl. Chem.)<br />
Antigen targeting to inhibitory and activating Fc-receptors in vivo<br />
Doctoral theses (Molecular Medicine, Dr. rer. nat.)<br />
Lukas Heger<br />
Chemotactic characterization of human DC subpopulations in lymphoid and nonlymphoid<br />
tissues<br />
Doctoral theses (Medicine, Dr. med.)<br />
Yang Jiao<br />
Characterization of pDC subpopulations in human tissues<br />
Doctoral theses (Veterinarian Medicine, Dr. med. vet.)<br />
Nathalie Eissing (maiden name: Nathalie Bleny)<br />
Characterization of Dendritic cell subpopulations and their expression of C-type lectin<br />
receptors in human tissues by immunofluorescence microscopy<br />
Kirsten Ehrenspeck<br />
Characterization of stem cells in human tissues and their differentiation into Dendritic<br />
cells<br />
101
Experimental Immunology and Immunotherapy<br />
(Medical Department III) until March 2010<br />
Head: Falk Nimmerjahn, Dr. rer. nat.<br />
Associate Professor of Experimental Immunology and<br />
Immunotherapy (until March 2010)<br />
Since April 2010:<br />
Professor and Chairman of the Institute of Genetics at<br />
the Department of Biology<br />
Address: Chair of Genetics<br />
Erwin-Rommelstr. 5<br />
D-91058 Erlangen<br />
Telefone: + 49 (9131) 85 25050<br />
Fax: + 49 (9131) 85 28526<br />
E-mail: fnimmerj@biologie.uni-erlangen.de<br />
Markus Biburger, Dr. rer. nat.<br />
Anne Bärenwaldt (PhD<br />
received in 2011)<br />
Susanne Aschermann<br />
(PhD received in 2012)<br />
Head<br />
Falk Nimmerjahn, Prof. Dr. rer. nat.<br />
Professor of Genetics<br />
Postdoctoral Fellows<br />
Doctoral Students<br />
Technicians<br />
102<br />
Anja Lux, Dr. rer. nat.<br />
Inessa Schwab<br />
Birgit Lehmann<br />
Sybille Böhm
<strong>Research</strong><br />
Heike Albert Melissa Woigk<br />
Heike Danzer<br />
The research of our laboratory focuses on understanding the mechanisms that underlie the<br />
different activities of immunoglobulin G (IgG) antibodies in vivo. IgG antibodies are the<br />
primary mediators of protective humoral immunity against pathogens and have been used<br />
therapeutically for over a century. They were first used as antitoxins for the treatment of<br />
infectious diseases in the pre-antibiotic era. Today, hyperimmune sera from human donors<br />
recovering from infection with specific viruses, such as hepatitis B, cytomegalovirus, and<br />
varicella zoster, are used to provide protective immunity to susceptible populations.<br />
Moreover, tumor specific antibodies have been successfully used in human cancer therapy<br />
and have been included in standard therapeutic regimens in lymphoma and breast cancer.<br />
Besides these protective activities, IgG autoantibodies are the principal mediators of<br />
autoimmune diseases such as immune thrombocytopenia (ITP), autoimmune haemolytic<br />
anemia (AHA), and systemic lupus erythematosus (SLE). In addition to this pro-inflammatory<br />
activity antibodies also are known to have an anti-inflammatory activity. If infused at high<br />
doses, IgG can effectively suppress autoimmune mediated inflammation (IVIG therapy).<br />
Recent evidence suggests that both the pro- and anti-inflammatory activity of IgG is<br />
regulated by the sugar side chain that is attached to the CH2-domain of all IgG subclasses.<br />
Subtle variations in the composition of this sugar moiety will either enhance or decrease the<br />
pro-inflammatory activity. Using a variety of in vivo model systems of autoimmune diseases<br />
and syngeneic tumor models we are trying to delineate which effector mechanisms the<br />
different IgG subclasses depend on and which effector cell populations are involved in this<br />
process.<br />
Focus I: Effector cells responsible for IgG activity (Biburger,<br />
Aschermann, Lehmann, Schwab)<br />
Immunoglobulins (Ig) are important mediators of the immunological defence against<br />
pathogens, however, autoantigen-specific antibodies may elicit autoimmunediseases.<br />
Due to these double-edged effects, immunoglobulin-mediated responses<br />
are strictly regulated. This is achieved by the existence of both activating and<br />
inhibitory receptors recognizing these antibodies (Fc receptors). Such Fc receptors<br />
are present in different combinations on the cell surface of various cell types and are<br />
characterized by different affinities for the respective IgG subclasses. In spite of the<br />
physiological importance of the interactions between immunoglobulins and their<br />
103
activating or inhibitory Fc receptors, there are still many unresolved questions. In this<br />
project we aim to understand how antibody-dependent cell-mediated cytotoxicity<br />
(ADCC) reactions work in vivo using a model of autoantibody mediated<br />
thrombocytopenia (ITP). During the last funding period we were able to show that a<br />
certain activating Fc-receptor, FcγRIV, which is crucial for autoantibody mediated<br />
platelet depletion is selectively expressed on tissue macrophages, neutrophils and on<br />
resident monocytes. By using a variety of cell depletion strategies we could<br />
demonstrate that neither neutrophils nor macrophages but resident monocytes were<br />
responsible for IgG dependent platelet removal (Figure 1).<br />
Figure 1: (A) Quantification of cell numbers of Ly6C hi and Ly6C lo monocytes in mice that were either<br />
left untreated, injected with PBS or with 10μl of clodronate liposomes to deplete the Ly6C lo monocyte<br />
subset. (B) Shown are liver sections stained with an F4/80 antibody specific for liver resident<br />
macrophages two hours after injection of 10µl clodronate liposomes or PBS. (C) Blood neutrophil<br />
counts in mice left either untreated or injected with PBS or 10µl of clodronate liposomes two hours<br />
after injection. (D) Platelet depletion activity of the 6A6-IgG2a antibody in mice either left untreated or<br />
pretreated with PBS or clodronate liposomes 2 hours before antibody injection. (E) Platelet depleting<br />
activity of the 6A6-IgG2a antibody in the indicated mouse strains twenty four hours after pretreatment<br />
with diphtheria toxin (+DT) or PBS (-DT). (F) Residual platelet count in C57BL/6 and Fcgr1 -/- Fcgr4 -/-<br />
mice four hours after injection of the 6A6-IgG2a anti-platelet antibody. * indicates p< 0.05.<br />
104
In addition to these passive models of autoimmunity we are also investigating more<br />
complex spontaneous mouse models of chronic autoimmune diseases. Specifically<br />
we are trying to elucidate which parts of the immune system contribute to the severe<br />
systemic autoimmune disease in Scurfy mice, which have a mutation in the<br />
transcription factor Foxp3, the master regulator of CD4+ CD25+ regulatory T cell<br />
development and function. As a member of the forkhead/winged-helix family of<br />
transcriptional regulators Foxp3 is essential for normal immune homeostasis. Mice<br />
hemizygous for the X-linked (Xsf/Y) mutation (scurfy mice) suffer from a fatal<br />
lymphoproliferative disorder caused by an impaired development of regulatory T cells<br />
(CD4+ CD25+ Foxp3+). Mice develop multi-organ lymphocytic infiltrates, resulting in<br />
lethal autoimmunity 3-6 weeks after birth. In our studies during the last years, we<br />
could identify autoantibody specificities associated with arthritis as well as murine<br />
lupus, which is the prototype of immune complex (IC)-mediated autoimmune disease.<br />
In addition, renal function was severely impaired. Interestingly, depletion of B cells<br />
either with a monoclonal antibody or by crossing Scurfy mice to B cell deficient<br />
mouse strains resulted in a prolonged survival of mice, suggesting that B cells and<br />
the respective autoantibodies play a critical role in the systemic inflammatory<br />
response.<br />
Focus II: Humanized mouse models to understand human IgG<br />
activity and pathways of humoral tolerance (Lux, Bärenwaldt,<br />
Böhm)<br />
Mice and humans differ in several aspects of IgG and FcγR biology. Therefore, one<br />
aim of our group is to establish in vivo models that allow studying the mechanism of<br />
human IgG activity and checkpoints of humoral tolerance in the setting of a human<br />
immune system in vivo. Humanized mice are generated by reconstitution of<br />
immunodeficient, irradiated mice (e.g. NOD/SCID/gamma-chain -/- ) with human CD34 +<br />
hematopoetic stem cells (HSC) purified from umbilical cord blood. Following<br />
reconstitution, the development of the human immune system is confirmed by flow<br />
cytometry and immunofluorescence staining. Human immune cells such as B, T, NK<br />
and dendritic cells are present in peripheral blood, spleen and bone marrow and<br />
human haematopoetic stem cells are able to persist in the bone marrow for months<br />
after reconstitution ensuring an ongoing human hematopoesis. As a model for human<br />
IgG activity we study B cell depletion in the peripheral blood, spleen, lymph nodes<br />
and bone marrow by IgG subclass variants of the CD20 specific antibody rituximab.<br />
In the second major project we investigated how impaired FcγRIIB alleles associated<br />
with the development of SLE in humans are involved in the maintenance of humoral<br />
tolerance. For this, humanized mouse colonies were generated that carried either the<br />
functionally normal FcγRIIB-232I allele or the functionally impaired FcγRIIB-232T<br />
allele. By following the development of the human immune system in these mouse<br />
cohorts we were able to show that mice carrying a human immune system with<br />
impaired FcγRIIB function showed a more rapid production of serum immunoglobulin<br />
105
M and G levels. This was mirrored by a higher number of late B cell developmental<br />
stages including memory B cells and plasma cells, consistent with previous data<br />
obtained in classical mouse models. More importantly, however, we could also show<br />
that human B cells in mice with impaired human FcγRIIB function started to produce<br />
autoantibodies (Figure 2). These findings establish an important function of human<br />
FcγRIIB as a late checkpoint in the human humoral immune system, preventing the<br />
expansion of autoantibody producing B cells.<br />
Figure 2: Development of autoantibodies in humanized mice. (A-B) The levels of serum IgM and<br />
serum IgG were analyzed in humanized mice carrying the different FcγRIIB allelic variants at 4 and 6<br />
months of age. (C-F) Detection of IgM autoantibody responses to double stranded DNA (anti-DNA),<br />
glucose 6-phosphate-isomerase (anti-GPI), rheumatoid factor (RF) and cyclic citrullinated peptides<br />
(anti-CCP) in humanized mice at 16 and 24 weeks of age. The level of autoantibody production is<br />
shown as arbitrary units (AU) for anti-DNA, -GPI, and –RF responses and as optical density (OD) for<br />
anti-CCP responses. Statistical significance was calculated with the Mann-Whitney U test. *P < 0.05.<br />
Data points of mice that received human hematopoetic stem cells from the same donor are depicted in<br />
the same color.<br />
106
Publications (2009-2012)<br />
Original Articles<br />
2012<br />
Biburger, M., and Nimmerjahn, F. (2012). Low level of FcgammaRIII expression on<br />
murine natural killer cells. Immunol Lett 143, 53-59.<br />
Bohm, S., Schwab, I., Lux, A., and Nimmerjahn, F. (2012). The role of sialic acid as a<br />
modulator of the anti-inflammatory activity of IgG. Semin Immunopathol.<br />
Harre, U., Georgess, D., Bang, H., Bozec, A., Axmann, R., Ossipova, E., Jakobsson,<br />
P.J., Baum, W., Nimmerjahn, F., Szarka, E., et al. (2012). Induction of<br />
osteoclastogenesis and bone loss by human autoantibodies against citrullinated<br />
vimentin. J Clin Invest 122, 1791-1802.<br />
Kasperkiewicz, M., Nimmerjahn, F., Wende, S., Hirose, M., Iwata, H., Jonkman, M.F.,<br />
Samavedam, U., Gupta, Y., Moller, S., Rentz, E., et al. (2012). Genetic identification<br />
and functional validation of FcgammaRIV as key molecule in autoantibody-induced<br />
tissue injury. J Pathol.<br />
Lehmann, B., Schwab, I., Bohm, S., Lux, A., Biburger, M., and Nimmerjahn, F.<br />
(2012). FcgammaRIIB: a modulator of cell activation and humoral tolerance. Expert<br />
Rev Clin Immunol 8, 243-254.<br />
Moldt, B., Shibata-Koyama, M., Rakasz, E.G., Schultz, N., Kanda, Y., Dunlop, D.C.,<br />
Finstad, S.L., Jin, C., Landucci, G., Alpert, M.D., et al. (2012). A Nonfucosylated<br />
Variant of the anti-HIV-1 Monoclonal Antibody b12 Has Enhanced FcgammaRIIIa-<br />
Mediated Antiviral Activity In Vitro but Does Not Improve Protection against Mucosal<br />
SHIV Challenge in Macaques. J Virol 86, 6189-6196.<br />
Ruiz-Heiland, G., Horn, A., Zerr, P., Hofstetter, W., Baum, W., Stock, M., Distler, J.H.,<br />
Nimmerjahn, F., Schett, G., and Zwerina, J. (2012). Blockade of the hedgehog<br />
pathway inhibits osteophyte formation in arthritis. Ann Rheum Dis 71, 400-407.<br />
Schwab, I., Biburger, M., Kronke, G., Schett, G., and Nimmerjahn, F. (2012). IVIgmediated<br />
amelioration of ITP in mice is dependent on sialic acid and SIGNR1. Eur J<br />
Immunol 42, 826-830.<br />
Uderhardt, S., Herrmann, M., Oskolkova, O.V., Aschermann, S., Bicker, W., Ipseiz,<br />
N., Sarter, K., Frey, B., Rothe, T., Voll, R., et al. (2012). 12/15-lipoxygenase<br />
107
orchestrates the clearance of apoptotic cells and maintains immunologic tolerance.<br />
Immunity 36, 834-846.<br />
2011<br />
Baerenwaldt, A., Lux, A., Danzer, H., Spriewald, B.M., Ullrich, E., Heidkamp, G.,<br />
Dudziak, D., and Nimmerjahn, F. (2011). Fcgamma receptor IIB (FcgammaRIIB)<br />
maintains humoral tolerance in the human immune system in vivo. Proc Natl Acad<br />
Sci U S A 108, 18772-18777.<br />
Biburger, M., Aschermann, S., Schwab, I., Lux, A., Albert, H., Danzer, H., Woigk, M.,<br />
Dudziak, D., and Nimmerjahn, F. (2011). Monocyte subsets responsible for<br />
immunoglobulin G-dependent effector functions in vivo. Immunity 35, 932-944.<br />
Lux, A., and Nimmerjahn, F. (2011). Impact of differential glycosylation on IgG<br />
activity. Adv Exp Med Biol 780, 113-124.<br />
Nimmerjahn, F., and Lunemann, J.D. (2011). Expression and function of the<br />
inhibitory Fcgamma-receptor in CIDP. J Peripher Nerv Syst 16 Suppl 1, 41-44.<br />
Nimmerjahn, F., and Ravetch, J.V. (2011). FcgammaRs in health and disease. Curr<br />
Top Microbiol Immunol 350, 105-125.<br />
Santiago-Raber, M.L., Baudino, L., Alvarez, M., van Rooijen, N., Nimmerjahn, F., and<br />
Izui, S. (2011). TLR7/9-mediated monocytosis and maturation of Gr-1(hi)<br />
inflammatory monocytes towards Gr-1(lo) resting monocytes implicated in murine<br />
lupus. J Autoimmun 37, 171-179.<br />
2010<br />
Anthony, R.M., and Nimmerjahn, F. (2010). The role of differential IgG glycosylation<br />
in the interaction of antibodies with FcgammaRs in vivo. Curr Opin Organ Transplant.<br />
Aschermann, S., Lux, A., Baerenwaldt, A., Biburger, M., and Nimmerjahn, F. (2010).<br />
The other side of immunoglobulin G: suppressor of inflammation. Clin Exp Immunol<br />
160, 161-167.<br />
Baerenwaldt, A., Biburger, M., and Nimmerjahn, F. (2010). Mechanisms of action of<br />
intravenous immunoglobulins. Expert Rev Clin Immunol 6, 425-434.<br />
Comabella, M., Montalban, X., Kakalacheva, K., Osman, D., Nimmerjahn, F., Tintore,<br />
M., and Lunemann, J.D. (2010). B cell expression of the inhibitory Fc gamma<br />
receptor is unchanged in early MS. J Neuroimmunol 223, 135-137.<br />
Heidkamp, G.F., Neubert, K., Haertel, E., Nimmerjahn, F., Nussenzweig, M.C., and<br />
Dudziak, D. (2010). Efficient generation of a monoclonal antibody against the human<br />
108
C-type lectin receptor DCIR by targeting murine dendritic cells. Immunol Lett 132, 69-<br />
78.<br />
Lux, A., Aschermann, S., Biburger, M., and Nimmerjahn, F. (2010). The pro and antiinflammatory<br />
activities of immunoglobulin G. Ann Rheum Dis 69 Suppl 1, i92-96.<br />
Najjar, I., Deglesne, P.A., Schischmanoff, P.O., Fabre, E.E., Boisson-Dupuis, S.,<br />
Nimmerjahn, F., Bornkamm, G.W., Dusanter-Fourt, I., and Fagard, R. (2010).<br />
STAT1-dependent IgG cell-surface expression in a human B cell line derived from a<br />
STAT1-deficient patient. J Leukoc Biol 87, 1145-1152.<br />
Nimmerjahn, F., Lux, A., Albert, H., Woigk, M., Lehmann, C., Dudziak, D., Smith, P.,<br />
and Ravetch, J.V. (2010). FcgammaRIV deletion reveals its central role for IgG2a<br />
and IgG2b activity in vivo. Proc Natl Acad Sci U S A 107, 19396-19401.<br />
Nimmerjahn, F., and Ravetch, J.V. (2010). Antibody-mediated modulation of immune<br />
responses. Immunol Rev 236, 265-275.<br />
Ritter, M., Gross, O., Kays, S., Ruland, J., Nimmerjahn, F., Saijo, S., Tschopp, J.,<br />
Layland, L.E., and Prazeres da Costa, C. (2010). Schistosoma mansoni triggers<br />
Dectin-2, which activates the Nlrp3 inflammasome and alters adaptive immune<br />
responses. Proc Natl Acad Sci U S A 107, 20459-20464.<br />
Schoenen, H., Bodendorfer, B., Hitchens, K., Manzanero, S., Werninghaus, K.,<br />
Nimmerjahn, F., Agger, E.M., Stenger, S., Andersen, P., Ruland, J., et al. (2010).<br />
Cutting edge: Mincle is essential for recognition and adjuvanticity of the<br />
mycobacterial cord factor and its synthetic analog trehalose-dibehenate. J Immunol<br />
184, 2756-2760.<br />
Tackenberg, B., Nimmerjahn, F., and Lunemann, J.D. (2010). Mechanisms of IVIG<br />
efficacy in chronic inflammatory demyelinating polyneuropathy. J Clin Immunol 30<br />
Suppl 1, S65-69.<br />
Zaiss, M.M., Frey, B., Hess, A., Zwerina, J., Luther, J., Nimmerjahn, F., Engelke, K.,<br />
Kollias, G., Hunig, T., Schett, G., et al. (2010). Regulatory T cells protect from local<br />
and systemic bone destruction in arthritis. J Immunol 184, 7238-7246.<br />
Zaiss, M.M., Sarter, K., Hess, A., Engelke, K., Bohm, C., Nimmerjahn, F., Voll, R.,<br />
Schett, G., and David, J.P. (2010). Increased bone density and resistance to<br />
ovariectomy-induced bone loss in FoxP3-transgenic mice based on impaired<br />
osteoclast differentiation. Arthritis Rheum 62, 2328-2338.<br />
2009<br />
109
Grevers, L.C., van Lent, P.L., Koenders, M.I., Walgreen, B., Sloetjes, A.W.,<br />
Nimmerjahn, F., Sjef Verbeek, J., and van den Berg, W.B. (2009). Different<br />
amplifying mechanisms of interleukin-17 and interferon-gamma in Fcgamma<br />
receptor-mediated cartilage destruction in murine immune complex-mediated<br />
arthritis. Arthritis Rheum 60, 396-407.<br />
Guo, S., Muhlfeld, A.S., Wietecha, T.A., Peutz-Kootstra, C.J., Kowalewska, J., Yi, K.,<br />
Spencer, M., Pichaiwong, W., Nimmerjahn, F., Hudkins, K.L., et al. (2009). Deletion<br />
of activating Fcgamma receptors does not confer protection in murine<br />
cryoglobulinemia-associated membranoproliferative glomerulonephritis. Am J Pathol<br />
175, 107-118.<br />
Santiago-Raber, M.L., Amano, H., Amano, E., Baudino, L., Otani, M., Lin, Q.,<br />
Nimmerjahn, F., Verbeek, J.S., Ravetch, J.V., Takasaki, Y., et al. (2009). Fcgamma<br />
receptor-dependent expansion of a hyperactive monocyte subset in lupus-prone<br />
mice. Arthritis Rheum 60, 2408-2417.<br />
Syed, S.N., Konrad, S., Wiege, K., Nieswandt, B., Nimmerjahn, F., Schmidt, R.E.,<br />
and Gessner, J.E. (2009). Both FcgammaRIV and FcgammaRIII are essential<br />
receptors mediating type II and type III autoimmune responses via FcRgamma-LATdependent<br />
generation of C5a. Eur J Immunol 39, 3343-3356.<br />
Tackenberg, B., Jelcic, I., Baerenwaldt, A., Oertel, W.H., Sommer, N., Nimmerjahn,<br />
F., and Lunemann, J.D. (2009). Impaired inhibitory Fcgamma receptor IIB expression<br />
on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Natl Acad Sci<br />
U S A 106, 4788-4792.<br />
Werninghaus, K., Babiak, A., Gross, O., Holscher, C., Dietrich, H., Agger, E.M.,<br />
Mages, J., Mocsai, A., Schoenen, H., Finger, K., et al. (2009). Adjuvanticity of a<br />
synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination<br />
requires FcRgamma-Syk-Card9-dependent innate immune activation. J Exp Med<br />
206, 89-97.<br />
Current <strong>Research</strong> Funding<br />
2007-2012 Bayerisches Genomforschungsnetzwerk<br />
2009-2012 DFG Forschergruppe 832: Regulatoren der humoralen Immunität<br />
2008-2012 SFB 643: Strategien zur zellulären Immunintervention<br />
2010-2013 SPP 1468: Immunobone<br />
110
2011-2015 GK1660: Schlüsselsignale der adaptiven Immunität<br />
2011-2013 Bill and Melinda Gates Foundation<br />
TRAINING OF GRADUATE AND MEDICAL STUDENTS<br />
Doctoral theses<br />
Anja Lux (PhD in 2011)<br />
Anne Bärenwaldt (PhD in 2011)<br />
Susanne Aschermann (PhD in 2012)<br />
Inessa Schwab<br />
Birgit Lehmann<br />
Sybille Böhm<br />
111
Clinical <strong>Research</strong> Group<br />
(Reinhard Voll, Med.3)<br />
Head: Reinhard Voll, Dr. med.<br />
Professor of Rheumatology and Clinical Immunology<br />
(Since Dec. 2010 director of the Division Rheumatology<br />
and Clinical Immunology, University Medical Center<br />
Freiburg)<br />
Address: Clinical <strong>Research</strong> Group<br />
Glückstr. 6<br />
D-91054 Erlangen<br />
Telefone: + 49 (9131) 85 39303<br />
Fax: + 49 (9131) 85 39311<br />
E-mail: reinhard.voll@uniklinik-freiburg.de<br />
Head<br />
Reinhard Voll, Prof. Dr. med.<br />
Professor of Rheumatolgy and Clinical Immunology<br />
Vilma Urbonaviciute, Dr. rer. nat.*<br />
Silke Meister, Dr. rer. nat. *<br />
* part of the time reported<br />
Supporting Staff<br />
Postdoctoral Fellows<br />
112<br />
Bettina Sehnert, Dr. rer. nat. *
Charlotte Starke<br />
° PhD received<br />
Sandy Pohle<br />
° PhD received<br />
Doctoral Students (Biology)<br />
Eva Gückel°<br />
Doctoral Students (Molecular Medicine)<br />
Daniela Graef *<br />
* part of the time reported<br />
<strong>Research</strong><br />
Technicians<br />
Guest Scientists<br />
The clinical research group is mainly interested in the etiology and pathogenesis of<br />
autoimmune diseases, especially systemic lupus erythematosus and rheumatoid<br />
arthritis. Based on the insights into the pathogenesis, new treatment strategies are<br />
going to be developed, initially in mouse models and, eventually, transferred to<br />
clinics. Targeting plasma cells for the treatment of autoantibody-mediated diseases<br />
and selective inhibition of the transcription factor NF-κB within activated endothelial<br />
cells represent such novel treatment strategies.<br />
113
From the immunopathogenesis of systemic lupus erythematosus to<br />
new treatment strategies<br />
Autoantibodies against nuclear antigens, especially double stranded (ds) DNA and<br />
nucleosomes represent a hallmark of SLE. However, the mechanisms involved in<br />
breaking the immunological tolerance against these normally poorly immunogenic<br />
nuclear components are not understood yet. We have shown previously that impaired<br />
phagocytosis of apoptotic cells with consecutive release of nuclear antigens may<br />
critically contribute to the immune pathogenesis of SLE. The architectural<br />
chromosomal protein and alarmin high mobility group box protein 1 (HMGB1) is<br />
tightly attached to the chromatin of apoptotic cells. Our results demonstrate that<br />
HMGB1 remains bound to nucleosomes released from late apoptotic cells in vitro. In<br />
addition, HMGB1-nucleosome complexes were also detected in the blood of SLE<br />
patients. Biochemically purified HMGB1-containing nucleosomes from apoptotic cells<br />
induced secretion of proinflammatory cytokines from monocytes/macrophages and<br />
maturation as well as activation of dendrtic cells. Immunizaton of non-autoimmune<br />
mice with nucleosomes from apoptotic cells, but not with those from living cells,<br />
induced autoantibodies to dsDNA. Further investigations are focused on the<br />
characterization of receptors for HMGB1-nucleosome complexes such as TLR2 and<br />
their roles in the pathogenesis of SLE. In addition, we are investigating if TLR2 and<br />
HMGB1 are suitable therapeutic targets in SLE.<br />
Refractory disease courses of SLE might be caused by long-lived plasma cells<br />
producing pathogenic autoantibodies. Hence, the elimination of long-lived plasma<br />
cells appears to represent an important treatment goal. However, long-lived plasma<br />
cells are resistant toward conventional therapies. We found that proteasome<br />
inhibitors can efficiently eliminate plasma cells including long-lived ones in murine<br />
SLE models.<br />
Recently, we described that long-lived plasma cells can be also found within the<br />
inflamed kidneys of diseased NZB/W F1 lupus mice. Interestingly, the frequency of<br />
autoreactive antibody-producing cells in the kidneys was markedly higher than in<br />
bone marrow and spleen (Starke et al., 2011). Currently we try to characterize these<br />
pathogenic plasma cells within kidneys and explore ways of their efficient elimination.<br />
Selective inhibition of NF-kB in activated endothelium as<br />
treatment strategy in immune-mediated diseases<br />
One research focus of our group is the investigation of the role of the transcription<br />
factor NF-κB in the pathogenesis of inflammatory diseases and the exploration of<br />
new strategies for therapeutic NF-κB inhibition. NF-κB represents a master switch of<br />
the inflammatory and immune responses. Most pro-inflammatory cytokines, tissue<br />
degrading enzymes, and several adhesion molecules are expressed in an NF-κB-<br />
114
dependent manner. Due to its central position in the inflammatory process<br />
interference with NF-κB activation represents a promising target for the treatment of<br />
inflammatory and autoimmune diseases. However, NF-κB plays also an important<br />
role in function and survival of several cell types, tissues, and organs. Therefore, we<br />
explore also the physiological function of NF-κB in lymphocyte development and the<br />
consequences of NF-κB inhibition for developing and mature lymphocytes.<br />
In collaboration with Stefan Dübel (Braunschweig), Harald Burkhardt (Frankfurt),<br />
Alexander Steinkasserer (Erlangen), Falk Nimmerjahn (Erlangen), Georg Schett<br />
(Erlangen) we developed a strategy for cell-type specific interference with NF-κB<br />
activation. Prototypic “sneaking ligand constructs” (SLC) were designed to target<br />
selectively activated endothelial cells via E selectin-binding peptides. The second<br />
domain of the fusion protein contains an endosomal release sequence, which<br />
translocates the IKK2 inhibiting NEMO-binding peptide into the cytoplasm. We could<br />
demonstrate that SLC1 efficiently ameliorates immune-mediated diseases such as<br />
murine arthritis models and experimental autoimmune encephalomyelitis (Sehnert et<br />
al. submitted).<br />
2011/12<br />
Publications (2009-2012)<br />
Original Articles<br />
Hainz N, Thomas S, Neubert K, Meister S, Benz K, Rauh M, Daniel C, Wiesener M, Voll RE,<br />
Amann K. The Proteasome Inhibitor Bortezomib Prevents Lupus Nephritis in the NZB/W F1<br />
Mouse Model by Preservation of Glomerular and Tubulointerstitial Architecture. Nephron<br />
Exp Nephrol. 2012;120(2):e47-58. Epub 2012 Jan 26.<br />
Pullerits R, Urbonaviciute V, Voll RE, Forsblad-D'Elia H, Carlsten H. Serum Levels of<br />
HMGB1 in Postmenopausal Patients with Rheumatoid Arthritis: Associations with<br />
Proinflammatory Cytokines, Acute-phase Reactants, and Clinical Disease Characteristics. J<br />
Rheumatol. 2011 Jul;38(7):1523-5.<br />
Starke C, Frey S, Wellmann U, Urbonaviciute V,Herrmann M, Amann K, Schett G, Winkler ,<br />
Voll RE High frequency of autoantibody-secreting cells and long-lived plasma cells within<br />
inflamed kidneys of NZB/W F1 lupus mice. Eur J 2011 Jul;41(7):2107-12<br />
Gückel E, Frey S, Zaiss MM, Schett G, Ghosh S, Voll RE. Cell-Intrinsic NF-kappaB Activation<br />
Is Critical for the Development of Natural Regulatory T Cells in Mice. PLoS One<br />
2011;6(5):e20003. Epub 2011 May 18<br />
Polzer K, Neubert K, Meister S, Frey B, Baum W, Distler JH, Gückel E, Schett G, Voll RE,<br />
Zwerina J.Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption<br />
in a mouse model of inflammatory arthritis.Arthritis Rheum. 2011 Mar;63(3):670-80.<br />
Gomez AM, Vrolix K, Martínez-Martínez P, Molenaar PC, Phernambucq M, van der Esch E,<br />
Duimel H, Verheyen F, Voll RE, Manz RA, De Baets MH, Losen M. Proteasome inhibition<br />
115
with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune<br />
myasthenia gravis. J Immunol. 2011 Feb 15;186(4):2503-13.<br />
Mosca M, Govoni M, Tomietto P, Aringer M, Boumpas D, Cervera R, Conti F, D'Cruz D,<br />
Doria A, De La Fuente D, Galeazzi M, Houssiau F, Huizinga TW, Khamashta MA, Ines L,<br />
Duarte C, Couto M, Meroni P, Montecucco C, Norkuviene E, Riemekasten G, Rios V,<br />
Schneider M, Shoenfeld Y, Steup-Beekman GM, Szmyrka-Kaczmarek M, Tani C, Tincani A,<br />
Tzioufas AG, Voll R, Bencivelli W, Salaffi F, Bombardieri S. The development of a simple<br />
questionnaire to screen patients with SLE for the presence of neuropsychiatric symptoms in<br />
routine clinical practice. Lupus. 2011;20(5):485-92.<br />
2010<br />
Lang VR, Mielenz D, Neubert K, Böhm C, Schett G, Jäck HM, Voll RE, Meister S. The early<br />
marginal zone B cell-initiated T-independent type 2 response resists the proteasome inhibitor<br />
bortezomib. J Immunol. 2010 Nov 1;185(9):5637-47.<br />
Jellusova J, Düber S, Gückel E, Binder CJ, Weiss S, Voll R, Nitschke L.: Siglec-g regulates<br />
B1 cell survival and selection. J Immunol. 2010 Sep, 15;185(6):3277-84.<br />
Weber CK, Haslbeck M, Englbrecht M, Sehnert B, Mielenz D, Graef D, Distler JH, Mueller<br />
RB, Burkhardt H, Schett G, Voll RE, Fürnrohr BG. Antibodies to the endoplasmic reticulumresident<br />
chaperones calnexin, BiP and Grp94 in patients with rheumatoid arthritis and<br />
systemic lupus erythematosus. Rheumatology (Oxford). 2010 Aug 27. [Epub ahead of print]<br />
van Bavel CC, Dieker JW, Kroeze Y, Tamboer WP, Voll R, Muller S, Berden JH, van der<br />
Vlag J. Apoptosis-induced histone H3 methylation is targeted by autoantibodies in systemic<br />
lupus erythematosus. Ann Rheum Dis. 2010 Aug 10. [Epubahead of print]<br />
Meister S, Frey B, Lang VR, Gaipl US, Schett G, Schlötzer-Schrehardt U, Voll RE. Calcium<br />
channel blocker verapamil enhances endoplasmic reticulum stress and cell death induced by<br />
proteasome inhibition in myeloma cells. Neoplasia. 2010, Jul;12(7):550-61.<br />
Zaiss MM, Sarter K, Hess A, Engelke K, Böhm C, Nimmerjahn F, Voll R, Schett G, David JP.<br />
Increased bone density and resistance to ovariectomy-induced bone loss in FoxP3transgenic<br />
mice based on impaired osteoclast differentiation. Arthritis Rheum. 2010<br />
Aug;62(8):2328-38.<br />
Fürnrohr BG, Wach S, Kelly JA, Haslbeck M, Weber CK, Stach CM, Hueber AJ, Graef D,<br />
Spriewald BM, Manger K, Herrmann M, Kaufman KM, Frank SG, Goodmon E, James JA,<br />
Schett G, Winkler TH, Harley JB, Voll RE. Polymorphisms in the Hsp70 gene locus are<br />
genetically associated with systemic lupus erythematosus. Ann Rheum Dis. 2010 May 24.<br />
[Epub ahead of print]<br />
Vogelbacher R, Meister S, Gückel E, Starke C, Wittmann S, Stief A, Voll R, Daniel C, Hugo<br />
C. Bortezomib and sirolimus inhibit the chronic active antibody-mediated rejection in<br />
experimental renal transplantation in the rat. Nephrol Dial Transplant. 2010 Apr 28. [Epub<br />
ahead of print]<br />
Hakkim A, Fürnrohr BG, Amann K, Laube B, Abed UA, Brinkmann V, Herrmann M, Voll RE,<br />
Zychlinsky A. Impairment of neutrophil extracellular trap degradation is associated with lupus<br />
nephritis. Proc Natl Acad Sci U S A. 2010 May, 25;107(21):9813-8. Epub 2010 May 3.<br />
Kruse K, Janko C, Urbonaviciute V, Mierke CT, Winkler TH, Voll RE, Schett G, Muñoz LE,<br />
Herrmann M. Inefficient clearance of dying cells in patients with SLE: anti-dsDNA<br />
autoantibodies, MFG-E8, HMGB-1 and other players. Apoptosis. 2010, Sep;15(9):1098-<br />
113.<br />
116
Rödel F, Frey B, Capalbo G, Gaipl U, Keilholz L, Voll R, Hildebrandt G, Rödel, C.<br />
Discontinuous induction of X-linked inhibitor of apoptosis in EA.hy.926 endothelial cells is<br />
linked to NF-kappaB activation and mediates the anti-inflammatory properties of low-dose<br />
ionising-radiation. Radiother Oncol. 2010 Feb 17. [Epub ahead of print]<br />
2009<br />
Rödel F, Keilholz L, Herrmann M, Weiss C, Frey B, Voll R, Gaipl U, Rödel C. Activator<br />
protein 1 shows a biphasic induction and transcriptional activity after low dose X-irradiation in<br />
EA.hy.926 endothelial cells. Autoimmunity. 2009, May;42(4):343-5.<br />
Krönke G, Katzenbeisser J, Uderhardt S, Zaiss MM, Scholtysek C, Schabbauer G, Zarbock<br />
A, Koenders MI, Axmann R, Zwerina J, Baenckler HW, van den Berg W, Voll RE, Kühn H,<br />
Joosten LA, Schett G. 12/15-lipoxygenase counteracts inflammation and tissue damage in<br />
arthritis. J Immunol. 2009 Sep 1;183(5):3383-9.<br />
Rödel F, Keilholz L, Herrmann M, Weiss C, Frey B, Voll R, Gaipl U, Rödel C. Activator<br />
protein 1 shows a biphasic induction and transcriptional activity after low dose X-irradiation in<br />
EA.hy.926 endothelial cells. Autoimmunity. 2009 May;42(4):343-5.<br />
Urbonaviciute V, Meister S, Fürnrohr BG, Frey B, Gückel E, Schett G, Herrmann M, Voll RE.<br />
Oxidation of the alarmin high-mobility group box 1 protein (HMGB1) during apoptosis.<br />
Autoimmunity. 2009 May;42(4):305-7.<br />
Muñoz LE, Janko C, Grossmayer GE, Frey B, Voll RE, Kern P, Kalden JR, Schett G, Fietkau<br />
R, Herrmann M, Gaipl US. Remnants of secondarily necrotic cells fuel inflammation in<br />
systemic lupus erythematosus. Arthritis Rheum. 2009 Jun;60(6):1733-42.<br />
Raaz D, Herrmann M, Ekici AB, Klinghammer L, Lausen B, Voll RE, Leusen JH, van de<br />
Winkel JG, Daniel WG, Reis A, Garlichs CD. FcgammaRIIa genotype is associated with<br />
acute coronary syndromes as first manifestation of coronary artery disease.<br />
Atherosclerosis. 2009 Jan 21 [Epub ahead of print].<br />
Books and Reviews<br />
Urbonaviciute V, Voll RE: HMGB1 represents a potential marker of disease activity and novel<br />
therapeutic target in SLE. J Intern Med. 2011 Jul 27. doi: 10.1111/j.1365-<br />
2796.2011.02432.x. [Epub ahead of print]<br />
Feuchtenberger M, Voll RE, Kneitz C.: Impfungen in der Rheumatologie. Z Rheumatol. 2010<br />
Nov;69(9):803-812.<br />
Nikolova KA, Mihaylova NM, Voynova EN, Tchorbanov AI, Voll RE, Vassilev TL. Selective<br />
silencing of autoreactive B lymphocytes-Following the Nature's way. Autoimmun Rev. 2010<br />
Sep;9(11):775-9. Epub 2010 Jul 1.<br />
Weiss EM, Frey B, Rödel F, Herrmann M, Schlücker E, Voll RE, Fietkau R, Gaipl US.: Ex<br />
vivo- and in vivo-induced dead tumor cells as modulators of antitumor responses. Ann N Y<br />
Acad Sci. 2010 Oct;1209:109-17.<br />
Muñoz LE, Lauber K, Schiller M, Manfredi AA, Schett G, Voll RE, Herrmann M.[The role of<br />
incomplete clearance of apoptotic cells in the etiology and pathogenesis of SLE]. Z<br />
Rheumatol. 2010 Mar;69(2):152, 154-6.<br />
117
Voll R, Hiepe F. [Depletion of plasma cells - a novel strategy in the therapy of systemic lupus<br />
erythematosus in mice and man.]. Z Rheumatol. 2009, Mar;68(2):150-3.<br />
TRAINING OF GRADUATE AND MEDICAL STUDENTS<br />
Doctoral theses (Biology)<br />
Eva Gückel<br />
Die Rolle des Transkriptionsfaktors NF-kB <strong>für</strong> die Entwicklung und Funktion natürlich<br />
vorkommender regulatorischer T-Zellen<br />
Charlotte Starkte<br />
Charakterisierung von Antikörper-sezernierenden Zellen in der entzündeten Niere im<br />
NZB/W-F1 Lupusmausmodell.<br />
Doctoral theses (Molecular Medicine)<br />
Sandy Pohle<br />
Influence of dietary salt intake on the immune response and inflammatory diseases<br />
Doctoral theses (Medicine)<br />
Veronika Lang<br />
Resistenz der von Marginalzonen B- Zellen initiierten frühen Phase der T-Zellunabhängigen<br />
Immunantwort Typ 2 gegenüber dem Proteasominhibitor Bortezomib<br />
Ramona Peukert<br />
Proteasominhibition zur Therapie des SLE<br />
Christian Weber<br />
ER-Chaperone als Autoantigene bei der chronischen Polyarthritis<br />
118
DEPARTMENT OF ORTHOPAEDIC TRAUMA<br />
SURGERY<br />
(Molecular Cartilage <strong>Research</strong>)<br />
Head: Prof. Dr. med. F.F. Hennig<br />
(Head of Department of Orthopaedic Trauma Surgery)<br />
Priv.-Doz. Dr. med. K. Gelse<br />
(Leader of <strong>Research</strong> Group)<br />
Address: Department of Orthopaedic Trauma Surgery, Molecular<br />
Cartilage <strong>Research</strong> Group)<br />
Glückstr. 6<br />
D-91054 Erlangen<br />
Telefone: + 49 (9131) 85 42121<br />
Fax: + 49 (9131) 85 33300<br />
E-mail: kolja.gelse@uk-erlangen.de<br />
Patricia Klinger, Dr. rer. nat.<br />
Head<br />
Friedrich F. Hennig, Prof. Dr. med.<br />
Professor of Orthopaedic Trauma Surgery<br />
Leader of <strong>Research</strong> Group<br />
Kolja Gelse, Priv.-Doz. Dr. med.<br />
Postdoctoral Fellows<br />
119
Matthias Koch<br />
Franziska Cipa<br />
Melanie Pflügner<br />
<strong>Research</strong><br />
Doctoral Students (Medicine)<br />
Simon Obier<br />
Technicians<br />
Our group analyses molecular mechanisms that control cartilage and bone biology<br />
focussing on the mechanisms of chondrogenesis and terminal chondrocyte<br />
differentiation. The investigations further include the role of hypoxia and epigenetic<br />
mechanisms on the differentiation of chondroprogenitor cells and mesenchymal stem<br />
cells.<br />
Role of HIF-1α for the chondrogenic phenotype<br />
The aim of this project was to investigate the chondrogenic potential of growth factorstimulated<br />
periosteal cells with respect to the activity of Hypoxia-inducible Factor 1a<br />
(HIF-1a). In this project, scaffold-bound autologous periosteal cells, which had been<br />
activated by Insulin-like Growth Factor 1 (IGF-1) or Bone Morphogenetic Protein 2<br />
(BMP-2) gene transfer using both adeno-associated virus (AAV) and adenoviral (Ad)<br />
vectors, were applied to chondral lesions in the knee joints of miniature pigs. Six<br />
weeks after transplantation, the repair tissues were investigated for collagen type I<br />
and type II content as well as for HIF-1a expression. The functional role of<br />
phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) and<br />
mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK)<br />
signaling on BMP-2/IGF-1-induced HIF-1a expression was assessed in vitro by<br />
employing specific inhibitors.<br />
Unstimulated periosteal cells formed a fibrous extracellular matrix in the superficial<br />
zone and a fibrocartilaginous matrix in deep zones of the repair tissue. This zonal<br />
difference was reflected by the absence of HIF-1a staining in superficial areas, but<br />
moderate HIF-1a expression in deep zones. In contrast, Ad/AAVBMP-2-stimulated<br />
periosteal cells, and to a lesser degree Ad/AAVIGF-1-infected cells, adopted a<br />
120
chondrocyte-like phenotype with strong intracellular HIF-1a staining throughout all<br />
zones of the repair tissue and formed a hyaline-like matrix. In vitro, BMP-2 and IGF-1<br />
supplementation increased HIF-1a protein levels in periosteal cells, which was based<br />
on posttranscriptional mechanisms rather than de novo mRNA synthesis, involving<br />
predominantly the MEK/ERK pathway. The data of this project indicated that<br />
chondrogenesis by chondrogenic precursor cells is facilitated in deeper hypoxic<br />
zones of cartilage repair tissue and is stimulated by growth factors which enhance<br />
HIF-1a activity.<br />
Fig. 1.<br />
O2<br />
Toluidine<br />
blue<br />
Hypoxia<br />
HIF-1α<br />
Hypoxia facilitates<br />
chondrogenesis.<br />
Mesenchymal stem<br />
cells overexpressing<br />
BMP-2 were<br />
transplanted into<br />
cartilage defects in<br />
the knee joints of a<br />
minipig model.<br />
Chondrogenesis was<br />
facilitated in deep<br />
hypoxic tissue layers.<br />
The role of anti-angiogenic factors for stabilizing the<br />
chondrocyte phenotype<br />
This study investigated the effect of the anti-angiogenic factors Thrombospondin-1<br />
(TSP-1) and Chondromodulin-I (Chm-I) on the formation of cartilage repair tissue in<br />
combination with stimulation by osteogenic protein-1 (OP-1). In miniature pigs,<br />
articular cartilage lesions in the femoral trochlea were treated by the microfracture<br />
technique and either received no further treatment (MFX), or were treated by<br />
additional application of recombinant osteogenic protein-1 (MFX+OP1), recombinant<br />
TSP-1 (MFX+TSP1), or a combination of both proteins (MFX+TSP1+OP1). Since<br />
Chm-I is not available as a recombinant protein, we applied self-complementary<br />
Adeno-Associated-Virus (AAV) vectors carrying the Chm-I cDNA to achieve<br />
overexpression of Chm-I within the defects. Six and 26 weeks after surgery, the<br />
repair tissue and the degree of endochondral ossification were assessed by<br />
histochemical and immunohistochemical methods detecting collagen types I, II, X,<br />
TSP-1 and CD31. Microfracture treatment merely induced the formation of inferior<br />
fibrocartilaginous repair tissue. OP-1 stimulated chondrogenesis, but also induced<br />
chondrocyte hypertrophy, characterized by synthesis of collagen type X, and<br />
excessive bone formation. Application of TSP-1 inhibited inadvertant endochondral<br />
ossification, but failed to induce chondrogenesis. In contrast, the simultaneous<br />
121
application of both TSP-1 and OP-1 induced and maintained a permanent, nonhypertrophic<br />
chondrocyte-like phenotype within cartilage repair tissue. Similar<br />
favourable results were observed following Chm-I gene transfer. Overexpression of<br />
Chm-I stabilized the chondrocyte phenotype within the repair tissue and prevented<br />
excessive endochondral ossification. Gene expression analyses in vitro revealed the<br />
cell cycle inhibitor p21 cip1/waf1 as one target upregulated by AAVChm-I. The data of<br />
this study demonstrate that treatment by a combination of OP-1 and TSP-1, as well<br />
as overexpression of Chm-I stabilizes the chondrocyte phenotype by supporting<br />
chondrogenesis but inhibiting chondrocyte hypertrophy and endochondral<br />
ossification.<br />
Molecular differentiation between transient osteophytic and<br />
permanent articular cartilage<br />
The aim of this project to identify the molecular differences between the transient and<br />
permanent chondrocyte phenotype in osteophytic and articular cartilage. Total RNA<br />
was isolated from the cartilaginous layer of osteophytes and from intact articular<br />
cartilage from knee joints of 15 adult human donors and subjected to cDNA<br />
microarray analysis. The differential expression of relevant genes between these two<br />
cartilaginous tissues was additionally validated by quantitative RT-PCR and by<br />
immunohistochemistry. Among 47,000 screened transcripts, 600 transcripts were<br />
differentially expressed between osteophytic and articular chondrocytes. Osteophytic<br />
chondrocytes were characterized by increased expression of genes involved in the<br />
endochondral ossification process (BGLAP, BMP8B, COL1A2, SOST, GADD45ß,<br />
Runx2), and genes encoding tissue remodelling enzymes (MMP-9, -13, HAS1).<br />
Articular chondrocytes expressed increased transcript levels of antagonists and<br />
inhibitors of the BMP- and Wnt-signalling pathways (GREM1, FRZP, WISP3), as well<br />
as factors that inhibit terminal chondrocyte differentiation and endochondral bone<br />
formation (PTHLH, SOX9, STC2, S100A1, S100B). Immunohistochemistry of tissue<br />
sections for GREM1 and BGLAP, the two most prominent differentially expressed<br />
genes, confirmed selective detection of GREM1 in articular chondrocytes and that of<br />
BGLAP in osteophytic chondrocytes and bone.<br />
As a conclusion, osteophytic and articular chondrocytes significantly differ in their<br />
gene expression pattern. In articular cartilage, a prominent expression of antagonists<br />
inhibiting the BMP- and Wnt-pathway may serve to lock and stabilize the permanent<br />
chondrocyte phenotype and thus prevent their terminal differentiation. In contrast,<br />
osteophytic chondrocytes express genes with roles in the endochondral ossification<br />
process, which may account for their transient phenotype.<br />
Epigenetic mechanisms for stabilizing the chondrocyte<br />
phenotype<br />
This study investigates the differences in epigenetic mechanisms between transient<br />
and permanent cartilage. We performed a Methylation Array which demonstrated<br />
distinct differences in the epigenetic pattern of articular chondrocytes and<br />
chondrocytic differentiated mesenchymal stem cells. The promotor region of FoxS1<br />
was one of the most striking regions with a high degree of methylation in articular<br />
chondrocytes. The hypothesis of this study is that an epigenetic suppression of<br />
122
FoxS1 increases the transcriptional activity of Foxo3a which stabilizes the postmitotic<br />
chondrocyte phenotype. Currently, we further analyse the promotor region of Foxs1<br />
by Pyrosequencing and the role of DNA-methyltransferases. The aim of this project is<br />
to evaluate the methylation status as tool for screening the potency of chondrogenic<br />
differentiation of mesenchymal stem cells.<br />
Publications (2009-2011)<br />
Original Articles<br />
Gelse K, Ekici, AB, Cipa F, Swoboda B, Carl HD, Olk A, Hennig FF, Klinger P.<br />
Molecular differentiation between osteophytic and articular cartilage – clues for a<br />
transient and permanent chondrocyte phenotype. Osteoarthritis Cartilage.<br />
2012;20(2) :162-71.<br />
Gelse K, Klinger P, Koch M, Surmann-Schmitt C, von der Mark K, Swoboda B,<br />
Hennig FF, Gusinde J. Thrombospondin-1 prevents excessive ossification in cartilage<br />
repair tissue induced by osteogenic protein-1. Tissue Eng Part A. 2011 Aug;17(15-<br />
16):2101-12.<br />
Klinger P, Schietke RE, Warnecke C, Swoboda B, Wiesener M, Hennig FF, Gelse K.<br />
Deletion of the oxygen-dependent degradation domain results in impaired<br />
transcriptional activity of hypoxia-inducible factors. Transcription. 2011 Nov<br />
1;2(6):269-75.<br />
Klinger P, Surmann-Schmitt C, Brem M, Swoboda B, Distler JH, Carl HD, von der<br />
Mark K, Hennig FF, Gelse K. Chondromodulin 1 stabilizes the chondrocyte<br />
phenotype and inhibits endochondral ossification of porcine cartilage repair tissue.<br />
Arthritis Rheum. 2011 Sep;63(9):2721-31.<br />
Gelse K, Olk A, Eichhorn S, Swoboda B, Schoene M, Raum K. Quantitative<br />
ultrasound biomicroscopy for the analysis of healthy and repair cartilage tissue. Eur<br />
Cell Mater. 2010;19:58-71.<br />
Blanke M, Carl HD, Klinger P, Swoboda B, Hennig F, Gelse K. Transplanted<br />
chondrocytes inhibit endochondral ossification within cartilage repair tissue. Calcif<br />
Tissue Int. 2009;85(5):421-33.<br />
Gelse K, Brem M, Klinger P, Hess A, Swoboda B, Hennig F, Olk A. Paracrine effect<br />
of transplanted rib chondrocyte spheroids supports formation of secondary cartilage<br />
repair tissue. J Orthop Res. 2009;27(9):1216-25.<br />
123
Books and Reviews<br />
Gelse K, Beyer C. The prostaglandin E(2) system: a toolbox for skeletal repair?<br />
Arthritis Rheum. 2011 Apr;63(4):871-3.<br />
Gelse K, Schneider H. In vivo evaluation of gene transfer into mesenchymal cells (in<br />
view of cartilage repair). Methods Mol Biol. 2011;737:391-405.<br />
Linke R, Gelse K, Schuch F. The indication for radiosynoviorthesis. From the<br />
perspective of the nuclear medicine expert, rheumatic orthopedist and internist. Z<br />
Rheumatol. 2011 Jan;70(1):34-44.<br />
Gelse K, Swoboda B. Zell- und Gentherapie – eine kurative Therapieoption bei<br />
Arthrose? Der Internist 2009;50:73.<br />
Gelse K, Swoboda B. Therapie der Arthrose. Der Allgemeinarzt 2009;5:36-40.<br />
TRAINING OF GRADUATE AND MEDICAL STUDENTS<br />
Doctoral theses (Medicine)<br />
Simon Obier<br />
Die Rolle des Transkriptionsfaktors HIF-1a <strong>für</strong> die Integrität des murinen<br />
Gelenkknorpels<br />
Matthias Koch<br />
Die Rolle von Thrombospondin-1 <strong>für</strong> die Stabilität des Knorpelzellphänotyps<br />
Franziska Cipa<br />
<strong>Molekulare</strong>r Vergleich von „transienten“ Osteophytenknorpel und „permanenten“<br />
Gelenkknorpel<br />
124
DEPARTMENT OF PLASTIC AND HAND SURGERY<br />
(Tissue Engineering)<br />
Dr. Subha N. Rath<br />
Leonie Strobel<br />
Daniel Hiller<br />
Head: Raymund E. Horch, Prof. Dr. med.<br />
Vice chairman: Ulrich Kneser, PD Dr. med.<br />
Amelie Balzer<br />
Jennifer Covi<br />
Address: Department of Hand and Plastic Surgery<br />
Krankenhausstraße 12<br />
D-91054 Erlangen<br />
E-mail: ulrich.kneser@uk-erlangen.de<br />
Postdoctoral Fellows<br />
Dr. Andreas Brandl<br />
Doctoral Students (Medicine)<br />
Quan Yuan<br />
Johannes Hilgert<br />
Gregor Bührer<br />
Doctoral Students (Veterinary Medicine)<br />
125
Stefan Fleischer<br />
Technicians<br />
Marina Milde<br />
Guest Scientists<br />
126<br />
Ilse Arnold
<strong>Research</strong><br />
Since the late 1980s, Tissue Engineering has been one of the key technologies in<br />
regenerative medicine. Regarding bone tissue, an approach based on scaffolds as<br />
carriers for patient’s own cells and suitable growth factors has been proposed. Our<br />
group focuses on engineering bioartificial bone tissues and vascularisation models.<br />
The combination of smart biomaterials, osteoinductive factors and osteogenic cells<br />
lead to new perspectives in bone regeneration therapy. Endothelial cell (EC) culture,<br />
osteoblast (OB) culture and marrow stromal cell (MSC) culture are utilised in vitro.<br />
Furthermore, we use in vivo subcutaneous models and vascularisation models (e.g.<br />
arteriovenous loop model) in rats (in cooperation with Franz-Penzoldt-<strong>Zentrum</strong>).<br />
Bone Tissue Engineering<br />
Bone defects and impaired bone healing represent substantial challenges in<br />
reconstructive surgery. By bone tissue engineering it may be possible to heal<br />
complex bone defects in the future. Our group works on the application of novel<br />
biomaterials, innovative cell culture models and co-cultures.<br />
Induction of bone formation in biphasic calcium phosphate ceramics<br />
Subha N. Rath, Leonie Strobel, Ulrich Kneser<br />
In cooperation with the Institute of Materials Science (Prof. P. Greil), Erlangen<br />
Novel biphasic calcium phosphate (BCP) matrices were generated by 3D printing and<br />
high porosity was achieved by starch consolidation (Department of Materials Science<br />
(Glass and Ceramics), FAU Erlangen). This project aimed to characterise the porous<br />
BCP scaffold’s properties and the interaction of osteogenic cells and growth factors<br />
under in vitro and in vivo conditions.<br />
Bioreactors are advised for improved cell survival, as they are able to provide a<br />
controlled flow through the scaffold. Osteogenic cells (rat primary osteoblasts (OB)<br />
and bone marrow stromal cells (MSCs)) were isolated, cultured and seeded onto 3D<br />
scaffolds. Samples in static culture without osteoinduction, static culture with<br />
osteoinduction and dynamic culture with osteoinduction were compared over 6<br />
weeks. Analyses showed that a continuous flow bioreactor not only preserves the<br />
number of osteogenic cells, but also keeps their differentiation ability in balance<br />
providing a suitable cell-seeded scaffold product for applications in regenerative<br />
medicine (Rath, Strobel et al. 2012).<br />
Furthermore, these very BCP scaffolds were evaluated in vivo. Five differently<br />
treated constructs were implanted subcutaneously in syngeneic male Lewis rats:<br />
127
plain BCP constructs, constructs pre-treated with BMP-2, seeded with osteoblasts<br />
(OB), seeded with OB and BMP-2 and constructs with OB that were pre-cultivated in<br />
a flow bioreactor for 6 weeks. Specimens were explanted and subjected to histology<br />
and molecular biological analysis after 2, 4 and 6 weeks.<br />
All explanted constructs were invaded by fibrovascular tissue. Samples with both OB<br />
and BMP-2 demonstrated higher osteogenic gene expression and significantly<br />
increased bone formation compared to all other groups. Pre-cultivation in the flow<br />
bioreactor induced bone formation comparable with the freshly seeded group. In<br />
summary, the combination of OB and BMP-2 enhanced bone formation in the novel<br />
ceramic scaffolds (Strobel, Rath et al. 2012).<br />
This work was supported by the German <strong>Research</strong> Foundation (DFG).<br />
Rath SN, Strobel LA, Meier AK. 2012, Osteoinduction of osteoblasts and bone marrow stromal cells in<br />
3D BCP scaffolds: the effect of bioreactor on cell survival and differentiation, Journal of<br />
Cellular and Molecular Medicine; 2012 Feb 3. doi: 10.1111/j.1582-4934.2012.01545.x.<br />
Strobel LA, Rath SN, Maier AK. 2012, Induction of Bone Formation in Biphasic Calcium Phosphate<br />
Scaffolds by Bone Morphogenetic Protein-2 and Primary Osteoblasts Journal of Tissue<br />
Engineering and Regenerative Medicine; (accepted)<br />
Haematoxylin-eosin (HE) staining of an explanted biphasic calcium phosphate (BCP) scaffold at 6<br />
weeks after subcutaneous implantation. The scaffold was seeded with primary osteoblasts previous to<br />
implantation. Newly formed bone areas (arrows) are visible in the pores of the BCP construct.<br />
Human marrow stromal cells (hMSCs) on innovative bioglass scaffolds*<br />
Subha N. Rath, Daniel Hiller, Ulrich Kneser<br />
In cooperation with the Institute of Biomaterials (Prof. A. Boccaccini), Erlangen<br />
The aim of this study is to analyse hMSCs response to new bioactive copper-doped<br />
glass scaffolds. 45S5 bioglass scaffolds containing different concentrations of copper<br />
are provided by the Institute of Biomaterials. First, these scaffolds were evaluated<br />
regarding copper and bioactive ion release in vitro. For this purpose, we observed 2dimensional<br />
cell culture in vicinity to bioactive glass. The constructs proved non-toxic<br />
and provided continuous release of copper (depending on the initial copperconcentration).<br />
Furthermore, scaffolds are seeded with hMSCs and evaluated under<br />
128
different culture conditions. This will provide the basis for further in vivo studies with<br />
bioactive glass materials.<br />
Bioglass scaffolds in the arteriovenous (AV) loop model*<br />
Amelie Balzer, Gregor Bührer, Andreas Arkudas<br />
Generation of axially vascularised bone tissue engineering constructs in vivo is<br />
performed using an arteriovenous (AV) loop model. After bioactive glass scaffolds<br />
proved biocompatible in vitro, scaffolds are evaluated in the AV loop model in rats.<br />
Different scaffold materials, osteogenic cells and bioactive molecules such as bone<br />
morphogenetic protein-2 (BMP-2) can be incorporated in the matrix that is inserted in<br />
the AV-loop (in cooperation with Franz-Penzoldt-<strong>Zentrum</strong>, Erlangen).<br />
Co-cultures of human marrow stromal cells (hMSCs) and endothelial cells<br />
(hECs) in vitro*<br />
Subha N. Rath, Andreas Brandl, Oliver Bleiziffer, Ulrich Kneser<br />
Previous reports have shown that hMSCs can be osteo-differentiated into boneforming<br />
cells and thus can be used for bone tissue engineering. However, when<br />
applied in vivo in larger dimensions, the lack of development of neovascularization<br />
into the defect substantially limits their survival. It was also reported that hECs when<br />
cultured in vitro forms endothelial tube like structures, which vascularizes upon in<br />
vivo implantation to host blood vessels to supply blood relatively quicker than without<br />
hECs.<br />
Therefore, the combined co-culture of hMSCs and hECs can be attempted for a bone<br />
tissue engineered product which can later be vascularized upon in vivo implantation.<br />
A perfect scaffold material to study the effect is in bioactive glass, which not only<br />
have osteoconductive property, but also have vascularization inducing ability. To<br />
study this effect, our group developes co-culture models to investigate the<br />
interactions and influences of these cells upon each other and the effect of bio-active<br />
glass in inducing VEGF from hMSCs.<br />
*These projects are supported by the Emerging Fields Initiative, FAU Erlangen.<br />
Neovascularization of bioartificial tissues<br />
Neovascularization of tissues and organs is based upon two distinct processes: de<br />
novo formation of blood vessels via the assembly of progenitor cells (vasculogenesis)<br />
and expansion of pre-existing vascular networks by endothelial cell sprouting<br />
(angiogenesis). The latter one is the main mechanism in postnatal life. Evidence exist<br />
that bone marrow-derived progenitor cells can contribute to the formation of new<br />
vessels by incorporation into sites of active angiogenesis (Rüger et al.; 2008). The<br />
discovery of putative endothelial progenitor cells (EPC) gave rise to a new era of<br />
vascular biology to use their highly promising multipotent character for therapeutic<br />
angiogenesis equally with regard to tissue engineering where they could be used as<br />
129
a source to establish a reliable perfusion of bioartificial tissues and organs. Bone<br />
marrow-derived progenitors are known to be heterogenous. Therefore it is absolutely<br />
necessary to clearly characterize isolated populations from bone marrow that are<br />
designated to be EPCs, with regard to their morphology and performance in<br />
endothelial-specific functional assays in vitro prior to using them in in vivo studies.<br />
Effect of rat primary EPCs on neovascularization using the (AV) loop model*<br />
Andreas Brandl, Quan Yuan, Oliver Bleiziffer<br />
Previous studies used a mouse endothelial progenitor cell (EPC) line (T17b) to study<br />
vascularization in a highly standardarized (AV) loop model in rat. One aim of this<br />
project is to isolate and characterize a bone marrow-derived EPC-population from rat<br />
to obtain an allogenic cell population to study angiogenesis in this well-established in<br />
vivo system.<br />
First results show that rat bone marrow-derived mononuclear cells can be<br />
differentiated into E(P)Cs in vitro. MNCs (mononuclear cells) from rat bone marrow<br />
were isolated using density gradient centrifugation and a differential adhesion<br />
method as described in Kähler et al., 2007. Cells were followed up concerning their<br />
morphology for several weeks and they exhibit the typical “cobblestone”-shape after<br />
about two to three weeks in culture (Fig.1).<br />
a) b)<br />
Fig.1: Mononuclear cells from rat bone marrow ( a) day of isolation) can be differentiated<br />
into endothelial cells ( b) 3 weeks post isolation) in vitro using special differentiation<br />
medium.<br />
The cells were also characterized with regard to their surface marker expression<br />
using flow cytometric analyses and their ability to form tube-like structures on<br />
Matrigel. The flow cytometry analyses showed that the cultivated cells gain<br />
endothelial-specific surface marker expression like CD31, VEGFR-2 and CD146 in<br />
culture. Four weeks old EPC are able to form tube-like structures and sprouts on the<br />
130
specialized extracellular matrix (ECM) Matrigel as potent as pure endothelial cell<br />
lines (HDMECs and EC52) do (Fig. 2).<br />
a) b)<br />
Fig.2: Isolated primary endothelial cells ( a) 4 weeks after isolation) perform just as pure<br />
commercially available cell lines ( b) HDMECs) in sprouting experiments on the<br />
specialized extracellular matrix (ECM) Matrigel.<br />
Future experiments will investigate the ability of these primary endothelial cells to<br />
efficiently support or promote neovascularization in bioartificial tissues using the wellestablished<br />
AV-loop model.<br />
Distribution and Impact of Hypoxia on blood vessel formation in a developing<br />
three-dimensional vascular network in the AV-Loop HIF investigated by<br />
detection of hypoxia-inducible factor 1 alpha (HIF-1 α)<br />
Hypoxia inducible factor (HIF) is a transcriptional factor that is the master regulator of<br />
oxygen homeostasis and plays an essential role in angiogenesis. In normoxic<br />
conditions, HIF could be degraded by prolyl hydroxylases (PHDs). Suppression of<br />
PHD activity increases endogenous HIF levels, which is probably able to promote the<br />
angiogenesis. Dimethyloxallyl Glycine (DMOG) is a cell permeable, competitive<br />
inhibitor of prolyl hydroxylase domain-containing proteins (PHDs and HIF-PHs).<br />
Future experiments will apply DMOG in Lewis rats with AV-loop systemically; detect<br />
the angiogenesis-related target genes such as HIF-1a, HIF-2a, VEGFA, eNOS, Flt-1,<br />
VE-Cadherin, KDR and vWF at transcription level in the loop at certain time points,<br />
and evaluate the outgrowth of the capillary network with morphology methods.<br />
* These projects are supported by the Else-Kröner-Fresenius-Stiftung.<br />
131
Original Articles<br />
Rath SN, Strobel LA, Meier AK. 2012, Osteoinduction of osteoblasts and bone marrow stromal cells in<br />
3D BCP scaffolds: the effect of bioreactor on cell survival and differentiation, Journal of<br />
Cellular and Molecular Medicine; 2012 Feb 3. doi: 10.1111/j.1582-4934.2012.01545.x.<br />
Strobel LA, Rath SN, Maier AK. 2012, Induction of Bone Formation in Biphasic Calcium Phosphate<br />
Scaffolds by Bone Morphogenetic Protein-2 and Primary Osteoblasts Journal of Tissue<br />
Engineering and Regenerative Medicine; (accepted)<br />
Bleiziffer O, Horch RE, Hammon M, Arkudas A, Naschberger E, Rath S, Pryymachuk G, Beier JP,<br />
Hatzopoulos AK, Stürzl M, Kneser U, T17b murine embryonal endothelial progenitor cells can<br />
be induced towards both proliferation and differentiation in a fibrin matrix. J Cell Mol Med.<br />
2009; 13: 926-35.<br />
Bleiziffer O, Hammon M, Naschberger E, et al. Endothelial Progenitor Cells are integrated in newly<br />
formed capillaries and alter adjacent fibrovascular tissue after subcutaneous implantation in a<br />
fibrin matrix. J Cell Mol Med 2010; doi: 10.1111/j.1582-4934.2010.01247.x.<br />
Arkudas A, Tjiawi J, Saumweber A, Beier JP, Polykandriotis E, Bleiziffer O, Horch RE, Kneser U.<br />
Evaluation of blood vessel ingrowth in fibrin gel subject to type and concentration of growth<br />
factors. J Cell Mol Med. 2009; 13: 2864-74<br />
Arkudas A, Pryymachuk G, Hoereth T, Beier JP, Polykandriotis E, Bleiziffer O, Horch RE, Kneser U.<br />
Dose-finding study of fibrin gel-immobilized vascular endothelial growth factor 165 and basic<br />
fibroblast growth factor in the arteriovenous loop rat model. Tissue Eng Part A. 2009; 15:<br />
2501-11.<br />
Fiegel HC, Pryymachuk G, Rath S, Bleiziffer O, Beier JP, Bruns H, Kluth D, Metzger R, Horch RE, Till<br />
H, Kneser U. Foetal hepatocyte transplantation in a vascularized AV-Loop transplantation<br />
model in the rat. J Cell Mol Med. 2010; 14: 267-74.<br />
Arkudas A, Beier JP, Pryymachuk G, Hoereth T, Bleiziffer O, Polykandriotis E, Hess A, Gulle H, Horch<br />
RE, Kneser U. Automatic quantitative micro-computed tomography evaluation of angiogenesis<br />
in an axially vascularized tissue-engineered bone construct. Tissue Eng Part C Methods.<br />
2010; 16: 1503-14.<br />
132
AG Krönke<br />
(Department of Internal Medicine 3)<br />
Principal Investigator: Gerhard Krönke, Dr. med.<br />
Address: AG Krönke<br />
Glückstr. 6<br />
D-91054 Erlangen<br />
Telefone: + 49 (9131) 85 43012<br />
E-mail: gerhard.kroenke@uk-erlangen.de<br />
Homepage: www..medizin3.ukerlangen.de/e1846/e741/e614/index_ger.html<br />
Carina Scholtysek<br />
Tobias Rothe<br />
StefanUderhardt°<br />
Arnd Kleyer<br />
Susanne Weig<br />
°MD received<br />
Cornelia Stoll<br />
Martin Steffen<br />
Doctoral Students (Biology)<br />
Natacha Ipseiz<br />
Réne Pfeifle<br />
Students (Medicine)<br />
Tobias Fillep<br />
Technicians<br />
Isabell Schmidt<br />
133<br />
Edith Bottesch
<strong>Research</strong><br />
Our group is interested in common mechanisms regulating the initiation and<br />
resolution of the inflammatory and adaptive immune response. Our aim is to<br />
elucidate the pathogenesis of inflammatory and autoimmune diseases and the<br />
consequences of chronic inflammation on tissue homeostasis. To answer these<br />
questions, we focus on the role and function of cells of the monocytic lineage such as<br />
macrophages, dendritic cells and osteoclasts as well as on the contribution of lipid<br />
mediators and lipid-activated nuclear receptors to inflammation, immunity and<br />
regulation of tissue homeostasis.<br />
Regulation of the immune response by lipid mediators<br />
Lipids such as fatty acids, phospholipids and triglycerides are not only an integral<br />
component of cellular membranes and essential for energy homeostasis, but are also<br />
involved in the regulation of inflammation and the adaptive immune response.<br />
Multiple enzymes including different cyclooxygenases and lipoxygenases metabolize<br />
lipids such as free and esterified polyunsaturated fatty acids and thereby generate<br />
bioactive lipid mediators including prostaglandins, leukotriens and lipoxins as well as<br />
less well characterized species of distinct phospholipid oxidation products. Such lipid<br />
mediators act via multiple mechanisms, which include both activation and inhibition of<br />
different cell-surface receptors and of nuclear receptors that are involved in the<br />
modulation of the innate and adaptive immune response.<br />
Enzymatic lipid oxidation orchestrates the resolution of inflammation<br />
Gerhard Krönke<br />
Inflammation is the physiologic response to infection and tissue damage,<br />
respectively. The inflammatory response, however, has to be tightly regulated and<br />
controlled, since overwhelming and prolonged inflammation would exacerbate tissue<br />
damage and prevent the healing process. Typically, different mechanisms cooperate<br />
to initiate the resolution of inflammation. Interestingly, different lipid oxidation<br />
products such as lipoxin A4 have been recognized as major factors driving this<br />
resolving process.<br />
To study the role of lipoxin A4 during the pathogenesis of chronic inflammatory<br />
diseases, we are analyzing mice with a targeted deletion in the gene for 12/15lipoxygenase<br />
(12/15-LO) as the major enzyme involved in the generation of this proresolving<br />
mediator. These mice display a defect in the resolution of inflammation as<br />
well as a dramatic exacerbation of the inflammatory response as observed in two<br />
models of inflammatory arthritis (Fig. 1; Krönke et al., 2009). Likewise, 12/15-LO<br />
deficiency results in increased inflammation-associated tissue damage, in an altered<br />
healing response and overwhelming post-inflammatory fibrosis (Krönke et al., 2012).<br />
Interestingly additional data indicate that 12/15-LO is also involved in the<br />
pathogenesis of acute lung injury (Zarbock et al., 2009) as well as in the process of<br />
osteoclast differentiation (Krönke et al., 2009).<br />
134
Fig. 1 Experimental Arthritis in TNF-transgenic (TNFtg) mice exacerbates in the absence of 12/15-<br />
LO. (A) survival, (B) weight gain, (C) histological analysis of paws, (D) mRNA expression in joints and<br />
(E) clinical score of arthritis in TNFtg mice in the presence and absence of 12/15-LO.<br />
12/15-lipoxygenase orchestrates the clearance of apoptotic cells<br />
Stefan Uderhardt<br />
During the inflammatory response and the resolution of inflammation, the immune<br />
system is confronted with both pathogens and self-antigens in the form of necrotic<br />
and apoptotic cells (AC). Uptake and processing of AC by inflammatory monocytes<br />
and dendritic cells would eventually result in an immune response to self antigens.<br />
Therefore, the non-inflammatory removal and clearance of AC is essential to<br />
maintain immunologic tolerance. To study the clearance of AC in an inflammatory<br />
setting, we performed phagocytosis assays with monocytes that were isolated from<br />
murine peritonitis. Here we observed that, during inflammation, uptake of ACs is<br />
confined to a population of 12/15-LO-expressing, alternatively activated resident<br />
macrophages (resMΦ), which actively block uptake of ACs into freshly recruited<br />
inflammatory Ly6C high monocytes in a 12/15-LO-dependent manner (Fig. 2). On a<br />
mechanistic basis, we could identify novel 12/15-LO-derived oxidation-products of<br />
phosphatidylethanolamine, which are exposed on the plasma membranes of resMΦ.<br />
Thereby these cells generate a sink for distinct soluble receptors for ACs such as<br />
milk fat globule-EGF factor 8, which are essential for the uptake of ACs into<br />
inflammatory monocytes. Loss of 12/15-LO-activity, in turn, results in an aberrant<br />
phagocytosis of ACs by inflammatory monocytes, subsequent antigen-presentation of<br />
AC-derived antigens, and a lupus-like autoimmune disease (Fig. 2; Uderhardt et al.,<br />
2012). These data indicate that enzymatic phospholipid oxidation products are<br />
135
essential regulatory mediators during the clearance of AC and in the maintenance of<br />
self-tolerance.<br />
Fig. 2 12/15-LO orchestrates the clearance of apoptotic cells. (A and B) Macrophages isolated from<br />
a thioglycollate-induced peritonitis of WT and 12/15-LO-deficient mice were incubated with apoptotic<br />
cells (AC; green) and analysed by immunofluorescence. Alternatively activated resident macrophages,<br />
which ingest most of the AC in WT mice, were identified by their expression of 12/15-LO (blue in A) or<br />
Tim4 (red in B). (C) FACS-based analysis of the uptake of CFSE-labelled AC by Ly6Chigh<br />
inflammatory monocytes during a thioglycollate-induced peritonitis in vivo. (D and E) 12/15-LOdeficient<br />
mice develop a systemic autoimmune disease with signs of glomerulonephritis and different<br />
classes of autoantibodies.<br />
Oxidized phospholipids control the maturation of dendritic cells<br />
Tobias Rothe<br />
The analysis of murine bone marrow-derived dendritic cells (DC) revealed a high<br />
expression of 12/15-LO in these cells. Likewise we could identify different 12/15-LOderived<br />
phospholipid oxidation products in these cells. Our data demonstrates that<br />
this enzyme and its oxidation products critically modulate the maturation status and<br />
gene expression profile of DC. Absence of 12/15-LO results in an enhanced DC<br />
maturation, whereas addition of 12/!5-LO-specific phospholipid oxidation products<br />
interfered with the maturation process of DC. As a consequence, 12/15-LO-dficient<br />
mice show an altered activation of T-cells and an exacerbation of T-cell-driven<br />
autoimmune diseases such as experimental autoimmune encephalomyelitis (Rothe<br />
et al.; in preperation).<br />
136
Nuclear receptors as modulators of tissue homeostasis<br />
Nuclear receptors comprise a superfamily of ligand-activated transcription factors and<br />
regulate multiple homeostatic processes. Different nuclear receptors such as PPARγ<br />
have been identified as key regulators of fat and glucose metabolism as well as<br />
crucial factors influencing inflammation and the adaptive immune response.<br />
The nuclear receptor NR4A1 mediates anti-inflammatory effects of apoptotic<br />
cells<br />
Natacha Ipseiz<br />
The non-inflammatory clearance of apoptotic cells (AC) is essential to dispose selfantigens<br />
and to maintain immunologic tolerance. Mechanisms and factors<br />
contributing to this process are poorly understood, though. We observed a rapid<br />
induction of the expression of the nuclear receptor NR4A1 in macrophages ingesting<br />
AC. This induction of NR4A1 was critically involved in the anti-inflammatory effects<br />
AC exerted on macrophages. Indeed, AC efficiently blocked the inflammatory<br />
response in WT, but not NR4A1-deficient macrophages. Moreover, we observed a<br />
critical role of NR4A1 during the modulation of the activity of the pro-inflammatory<br />
transcription factor NFκB and the expression of different sets of pro-inflammatory<br />
genes such as IL12 and TNF. In line with these results, NR4A-/- mice display a break<br />
in self-tolerance in a model of murine lupus erythematodes (Ipseiz et al. in<br />
preperation).<br />
The nuclear receptor PPARβ acts as a key regulator of bone homeostasis<br />
Carina Scholtysek, Edith Bottesch and Arnd Kleyer,<br />
The nuclear receptor PPARγ acts as a master regulator of adipocyte differentiation.<br />
In contrast, PPARγ negatively affects Wnt-signalling in osteoblasts and thereby<br />
interferes with osteoblast differentiation and bone formation. The role of its family<br />
member PPARβ during bone homeostasis has not been studied, though. To address<br />
the role of PPARβ during bone homeostasis, we analyzed its role in osteoblasts and<br />
observed that this nuclear receptor acted in a permissive manner on Wnt-signaling in<br />
these cells. Activation of PPARβ by specific ligands induced expression of the Wntco-receptor<br />
LRP5, promoted nuclear accumulation of β-catenin and consequently<br />
enhanced TCF-driven transcriptional activity. Thereby, PPARβ augmented<br />
expression of different Wnt-dependent genes, such as osterix and osteoprotegerin<br />
(opg), in osteoblasts. Consequently, activation of PPARβ in osteoblasts blocked the<br />
differentiation of bone- resorbing osteoclasts. Mice deficient in PPARβ, displayed<br />
reduced Wnt-signaling activity and low serum levels of OPG resulting in an increased<br />
differentiation of osteoclasts and osteopenia. Conversely, pharmacological treatment<br />
with a PPARβ-specific agonist blocked the formation of osteoclasts in vivo and<br />
protected mice from ovariectomy-induced bone loss in a therapeutic manner. These<br />
data reveal a so far unrecognized role for PPARβ in the crosstalk between energy<br />
metabolism and bone homeostasis and highlights its potential to serve as a target for<br />
the treatment of osteoporosis (Fig. 3; Scholtysek et al., in revision).<br />
137
Fig. 3 The nuclear receptor PPARβ acts as key regulator of bone homeostasis. (A) Gene expression<br />
analysis in primary osteoblasts after stimulation with specific agonists for PPARα, PPARβ or PPARγ in<br />
the absence or presence of the Wnt agonist Wnt3a. (B) Analysis of the mineralization of primary<br />
osteoblasts after treatment with the indicated concentrations of the PPARβ agonist GW501516. (C)<br />
Measurement of the transcriptional activity of a TCF-luciferase reporter after overexpression of PPARβ<br />
and stimulation with Wnt3a or a vehicle, respectively. (D) In vitro quantification of osteoclast<br />
differentiation in osteoblast/osteoclast co-cultures after stimulation with the indicated concentration of<br />
the PPAR β agonist GW501516 and Wnt3a. (E) Micro-CT analysis of the bone structure and (F)<br />
determination of the mineral apposition in sham-trated mice and mice after ovariectomy (OVX), which<br />
have been treated with a vehicle or the PPARβ agonist GW501516 over a period of 6 weeks.<br />
Publications (2009-2012)<br />
2011/12<br />
Uderhardt S, Herrmann M, Oskolkova O, Aschermann S, Bicker W, Ipseiz N, Sarter<br />
K, Frey B, Rothe T, Voll R, Nimmerjahn F, Bochkov VN, Schett G, Krönke G. 12/15-<br />
Lipoxygenase Orchestrates the Clearance of Apoptotic Cells and Maintains<br />
Immunologic Tolerance, Immunity (2012), doi:10.1016/j.immuni.2012.03.010. [Epub<br />
ahead of print]<br />
Schwab I, Biburger M, Krönke G, Schett G, Nimmerjahn F. IVIg-mediated<br />
amelioration of ITP in mice is dependent on sialic acid and SIGNR1. Eur J Immunol.<br />
2012 Jan 26. doi: 10.1002/eji.201142260. [Epub ahead of print]<br />
Krönke G, Reich N, Scholtysek C, Akhmetshina A, Uderhardt S, Zerr P, Palumbo K,<br />
Lang V, Dees C, Distler O, Schett G, Distler JH. The 12/15-lipoxygenase pathway<br />
138
counteracts fibroblast activation and experimental fibrosis. Ann Rheum Dis. 2012<br />
Jan 20.<br />
Dees C, Akhmetshina A, Zerr P, Reich N, Palumbo K, Horn A, Jüngel A, Beyer C,<br />
Krönke G, Zwerina J, Reiter R, Alenina N, Maroteaux L, Gay S, Schett G, Distler O,<br />
Distler JH. Platelet-derived serotonin links vascular disease and tissue fibrosis.<br />
J Exp Med. 2011 May 9;208(5):961-72.<br />
2010<br />
Krönke G, Uderhardt S, Kim KY, Zaiss MM, Katzenbeisser J, Schett G, Abo A. R-<br />
Spondin-1 protects against inflammatory bone damage during murine arthritis by<br />
modulating the Wnt pathway. Arthritis Rheum. 2010 Aug;62(8):2303-12.<br />
Uderhardt S, Diarra D, Katzenbeisser J, David JP, Zwerina J, Richards WG, Krönke<br />
G, Schett G. Blockade of Dickkopf-1 induces fusion of sacroiliac joints.<br />
Ann Rheum Dis. 2010 Mar;69(3):592-7<br />
Stach CM, Bäuerle M, Englbrecht M, Krönke G, Engelke K, Manger B, Schett G.<br />
Periarticular bone structure in rheumatoid arthritis patients and healthy individuals<br />
assessed by high-resolution computed tomography.<br />
Arthritis Rheum. 2010 Feb;62(2):330-9.<br />
2009<br />
Böhm C, Hayer S, Kilian A, Zaiss MM, Finger S, Hess A, Engelke K, Kollias G,<br />
Krönke G, Zwerina J, Schett G, David JP. The {alpha}-Isoform of p38 MAPK<br />
Specifically Regulates Arthritic Bone Loss.<br />
J Immunol. 2009 Oct 14. [Epub ahead of print]<br />
Zarbock A, Distasi MR, Smith E, Sanders JM, Krönke G, Harry BL, von Vietinghoff S,<br />
Buscher K, Nadler JL, Ley K. Improved Survival and Reduced Vascular Permeability<br />
by Eliminating or Blocking 12/15-Lipoxygenase in Mouse Models of Acute Lung Injury<br />
(ALI).<br />
J Immunol. 2009 Oct 1;183(7):4715-22. Epub 2009 Sep 14.<br />
Schett G, Stolina M, Dwyer D, Zack D, Uderhardt S, Krönke G, Kostenuik P, Feige U.<br />
Tumor necrosis factor alpha and RANKL blockade cannot halt bony spur formation in<br />
experimental inflammatory arthritis.<br />
Arthritis Rheum. 2009 Sep;60(9):2644-54.<br />
Axmann R, Böhm C, Krönke G, Zwerina J, Smolen J, Schett G. . Inhibition of<br />
interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo.<br />
Arthritis Rheum. 2009 Sep;60(9):2747-56.<br />
Krönke G, Katzenbeisser J, Uderhardt S, Zaiss M, Scholtysek C, Schabbauer G,<br />
Zarbock A, Koenders MI, Axmann R, Zwerina J, Baenckler HW, van den Berg W, Voll<br />
RE, Kühn H, Joosten LAB, Georg Schett G. 12/15-lipoxygenase counteracts<br />
inflammation and tissue damage in arthritis.<br />
J Immunol. 2009 Sep 1;183(5):3383-9. Epub 2009 Aug 12.<br />
Krönke G, Uderhardt S, Katzenbeisser J, Schett G. The 12/15-Lipoxygenase-<br />
Pathway Promotes Osteoclast Development and Differentiation.<br />
Autoimmunity. 2009 May;42(4):383-5.<br />
139
Books and Reviews<br />
Scholtysek C, Krönke G, Schett G. Inflammation-associated changes in bone<br />
homeostasis.<br />
Inflamm Allergy Drug Targets. 2012 Jan 20.<br />
140
DEPARTMENT OF UROLOGY<br />
Div. Molecular Urology<br />
Head: Helge Taubert, Dr. rer. nat.<br />
Professor of Molecular Urology<br />
Address: Division of Molecular Urology<br />
Glückstr. 6<br />
D-91054 Erlangen<br />
Telefone: + 49 (9131) 85 23373<br />
Fax: + 49 (9131) 85 23374<br />
E-mail: helge.taubert@uk-erlangen.de<br />
Homepage: www.urologie.uk-erlangen.de<br />
Sven Wach, Dr. rer. nat.<br />
Head<br />
Helge Taubert, Prof. Dr. rer. nat.<br />
Professor of Molecular Urology<br />
Supporting Staff<br />
Postdoctoral Fellows<br />
141
Elke Nolte geb. Löprich,<br />
Dipl. Biologin<br />
Omar Al-Janabi , Dipl.<br />
Biologe<br />
Christine Ellmann<br />
Kathrin Holzer<br />
Katrin Weigelt, MTA<br />
Doctoral Students (Biology)<br />
Doctoral Students (Medicine)<br />
Technicians<br />
Guest Scientists<br />
142<br />
Anne Theil, BTA
<strong>Research</strong><br />
Our group analyses molecular mechanisms that control tumor development and<br />
progression, focusing on microRNA expression and their target genes and gene<br />
expression that is hypoxia- or stem cell-associated in solid tumors (urologic tumors,<br />
soft tissue sarcomas).<br />
Tumor genetic research with focus on identification of biomarkers<br />
Dr. rer. nat. S. Wach<br />
The identification and characterization of specific biological properties of the prostate<br />
carcinoma as well as other malignant tumors like kidney carcinoma is the main focus<br />
of the biological research projects. By assessing changes in microRNA (miRNA)<br />
expression profiles it is already possible to distinguish between samples of tumor and<br />
non-malignant tissue. Furthermore the prognostic value of miRNA expression profiles<br />
is currently examined. MiRNAs directly regulate the expression of numerous other<br />
proteins in cells. Therefore, experimental methods for analyzing protein expression<br />
(Fig.1) are a vital component of our research.<br />
The complete spectrum of molecular cytogenetic techniques including fluorescence<br />
in situ DNA and RNA hybridization is established in the laboratory. The quantification<br />
of micro-RNA and gene expression as well as the determination of gene copy<br />
numbers using real time PCR approaches is a central part of the experimental<br />
methods.<br />
The role of hypoxia and hypoxia-associated signal transduction<br />
pathways in solid tumors<br />
Prof. Dr. rer. nat. Helge Taubert<br />
The lack of oxygen (hypoxia) is a situation seen in many solid tumors. Especially<br />
locally advanced malignancies rapidly outgrow the blood vessels that supported their<br />
growth. By this tumor cells are confronted with a lack of oxygen and nutrition. As a<br />
consequence, more than 70 genes are activated by the HIF-1 transcription factor.<br />
Signal molecules are produced that stimulate the growth of new blood vessels,<br />
enzymes are produced that support a survival of cells under hypoxic conditions and<br />
stem cell-associated genes are expressed. We are mainly interested in the regulation<br />
of miRNA genes by HIF-1. Because miRNAs themselves regulate numerous target<br />
genes, it is obvious that hypoxia has a vital influence on any cell. Using cell culture<br />
models we examine the functional consequences of hypoxia on tumor cells.<br />
Projects<br />
Is the detection of members of the urokinase plasminogen activator<br />
family and of splice variants of survivin suitable as marker for<br />
143
prognosis and metastases of prostate cancer in the Clinic of<br />
Urology?<br />
Rudolf und Irmgard Kleinknecht-Stiftung (Grant No. 01.10.11-30.9.2013)<br />
Prof. Dr. H. Taubert<br />
Although prostate cancer belongs is the most frequent tumor in men there are except<br />
clinical factors no markers that are valid for an evaluation of the individual disease<br />
course ort he individual prognosis. We will investigate members of the urokinase<br />
plasminogen activator family and splice variants of the apoptosis inhibitor survivin on<br />
the mRNA level in prostate cancer retrospectively and prospectively. The molecular<br />
results will be correlated with the clinical parameters and tested for their relevance for<br />
the tumor biological behavior (development of relapses and/or metastases) and the<br />
individual prognosis. We expect to better characterize factors that can improve<br />
individual prognosis evaluation and help to support future therapy decisions.<br />
Alterations of the microRNA expression profile of primary prostate<br />
cancer<br />
Wilhelm Sander-Stiftung (Grant No. 2007.025.01)<br />
Prof. Dr. B. Wullich, Prof. Dr. F. Grässer<br />
MicroRNAs (miRNAs) belong to the family of non-coding RNAs. Their biological role<br />
is the regulation of gene expression on a post-transcriptional level. In every human<br />
tumor entity examined so far, there exists a characteristic pattern of deregulated<br />
miRNAs. Hereby, miRNAs contribute to tumorigenesis by promoting the expression<br />
of oncogenes or suppressing the tumor suppressor genes. In prostate cancer we<br />
were able to establish comprehensive and reliable miRNA expression signatures.<br />
Using these miRNA expression signatures, we were able to distinguish between<br />
tumor- and normal tissue with high accuracy. Therefore, miRNAs have the potential<br />
of being valuable biomarkers for the diagnosis of prostate cancer in the future.<br />
Besides their properties as biomarkers, miRNAs lead the way to the discovery of<br />
novel tumor-relevant genes because miRNA deregulation is not merely a symptom<br />
but a driving force in the process of tumorigenesis. We are currently investigating<br />
several specific target genes of deregulated miRNAs to unravel their intrerplay and<br />
functional relevance in prostate carcinogenesis.<br />
MiRNAs in papillary renal cell carcinoma<br />
ELAN-Funds (Grant No. 09.11.11.1)<br />
Dr. Sven Wach<br />
Papillary renal cell carcinomas (pRCCs) represent the second most common entity of<br />
renal cell carcinomas. According to histopathological criteria, pRCCs can even be<br />
further subdivided into two distinct subtypes. Recent insights point towards the fact,<br />
that pRCCs of type 1 represent a low-malignant phenotype whereas type 2 pRCCs<br />
are high-risk carcinomas associated with a worse clinical outcome. So far, there is<br />
little insight into the molecular basis of the differentiation pattern or the different<br />
clinical behavior of these two subtypes of pRCC. Using our established method of<br />
miRNA expression profiling, we are currently identifying miRNAs that discriminate<br />
144
etween the two pRCC subtypes. When target genes of these miRNAs will be<br />
defined, this may lead to a better understanding of the molecular pathways affected<br />
in both subtypes of pRCC.<br />
2012<br />
Publications (2009-2012)<br />
Original Articles<br />
Wach S, Nolte E, Szczyrba J, Stöhr R, Hartmann A, Orntoft T, Dyrskjøt L, Eltze E, Wieland<br />
W, Keck B, Ekici AB, Grässer F, Wullich B. MicroRNA profiles of prostate carcinoma<br />
detected by multiplat- form microRNA screening. Int J Cancer 2012;130(3):611-21<br />
Greither T, Würl P, Grochola L, Bond G, Bache M, Kappler M, Lautenschläger C,<br />
Holzhausen HJ, Wach S, Eckert AW, Taubert H. Expression of microRNA 210 associates<br />
with poor survival and age of tumor onset of soft-tissue sarcoma patients. Int J Cancer 2012<br />
130:1230-5.<br />
2011<br />
Szczyrba J, Nolte E, Wach S, Kremmer E, Stöhr R, Hartmann A, Wieland W, Wullich B,<br />
Grässer FA. Down-regulation of Sec23A protein by miRNA-375 in prostate carcinoma. Mol<br />
Cancer Res. 2011;9(6):791-800.<br />
Keck B, Stoehr R, Wach S, Rogler A, Hofstaedter F, Lehmann J, Montironi R, Sibonye M,<br />
Fritsche HM, Lopez-Beltran A, Epstein JI, Wullich B, Hartmann A. The plasmacytoid<br />
carcinoma of the bladder- rare variant of aggressive urothelial carcinoma. Int J Cancer.<br />
2011;129(2):346-54.<br />
Eckert AW, Lautner MH, Schütze A, Taubert H, Schubert J, Bilkenroth U. (2011)<br />
Coexpression of hypoxia-inducible factor-1α and glucose transporter-1 is associated with<br />
poor prognosis in oral squamous cell carcinoma patients. Histopathology 2011;58:1136-47.<br />
Kappler M, Taubert H, Eckert AW. Oxygen sensing, homeostasis, and disease. N Engl J<br />
Med. 2011;365(19):1845-6 (letter/author reply).<br />
Rot S1, Taubert H1, Bache M, Greither T, Würl P, Eckert AW, Schubert J, Vordermark D,<br />
Kappler M. A novel splice variant of the stem cell marker LGR5/GPR49 is correlated with the<br />
risk of tumor-related death in soft-tissue sarcoma patients. BMC Cancer. 2011 Oct 6;11:429.<br />
(1equally contributed)<br />
Bache M, Zschornak MP, Passin S, Keßler J, Wichmann H, Kappler M, Paschke R,<br />
Kaluđerović GN, Kommera H, Taubert H, Vordermark D. Increased betulinic acid induced<br />
cytotoxicity and radiosensitivity in glioma cells under hypoxic conditions. Radiat Oncol. 2011<br />
Sep 9;6(1):111.<br />
Kotzsch M, Magdolen V, Greither T, Kappler M, Bache M, Lautenschlager C, Fussel S,<br />
Eckert AW, Luther T, Baretton G, Wurl P, Taubert H. Combined mRNA expression levels of<br />
members of the urokinase plasminogen activator (uPA) system correlate with diseaseassociated<br />
survival of soft-tissue sarcoma patients. BMC Cancer. 2011 Jun 25;11(1):273.<br />
[Epub ahead of print]<br />
145
Grochola LF, Taubert H, Greither T, Bhanot U, Udelnow A, Würl P. Elevated transcript levels<br />
from the MDM2 P1 promoter and low p53 transcript levels are associated with poor<br />
prognosis in human pancreatic ductal adenocarcinoma. Pancreas. 2011 Mar;40(2):265-70.<br />
2010<br />
Szczyrba J, Loprich E, Wach S, Jung V, Unteregger, G, Barth S, Grobholz R, Wieland W,<br />
Stohr R, Hartmann A, Wullich B, Grässer F. The MicroRNA Profile of Prostate Carcinoma<br />
Obtained by Deep Sequencing. Mol Cancer Res. 2010;8(4):529-38.<br />
Goebell PJ, Keck B, Wach S and Wullich B. [Value of biomarkers in urology]. Urologe A<br />
2010, 49, 547-559.<br />
Fürnrohr BG, Wach S, Kelly JA, Haslbeck M, Weber CK., Stach CM, Hueber AJ, Graef, D,<br />
Spriewald BM, Manger K Herrmann M, Kaufman KM, Frank SG, Goodmon E, James JA,<br />
Schett G, Winkler TH, Harley JB, Voll RE. Polymorphisms in the Hsp70 gene locus are<br />
genetically associated with systemic lupus erythematosus. Ann Rheum Dis.<br />
2010;69(11):1983-9.<br />
Taubert H, Heidenreich C, Holzhausen HJ, Schulz A, Bache M, Kappler M, Eckert AW, Wurl<br />
P, Melcher I, Hauptmann K, Hauptmann S, Schaser KD. Expression of survivin detected by<br />
immunohistochemistry in the cytoplasm and in the nucleus is associated with prognosis of<br />
leiomyosarcoma and synovial sarcoma patients. BMC Cancer. 2010,10(1):65.<br />
Taubert H, Würl P, Greither T, Kappler M, Bache M, Lautenschläger C, Füssel S, Meye A,<br />
Eckert AW, Magdolen V, Kotzsch M. Co-detection of members of the urokinase plasminogen<br />
activator system in tumor tissue and in serum correlates with a poor prognosis for soft-tissue<br />
sarcoma patients. Brit J Cancer 2010 Feb 16;102(4):731-7.<br />
Greither T, Grochola L, Udelnow A, Lautenschläger C, Würl P, Taubert H. Elevated<br />
expression of microRNAs 155, 203, 210 and 222 in pancreatic tumours associates with<br />
poorer survival. Int J Cancer. 2010 Jan 1;126(1):73-80.<br />
Vazquez A, Grochola LF, Bond EE, Levine AJ, Taubert H, Müller TH, Würl P, Bond GL.<br />
Chemosensitivity Profiles Identify Polymorphisms in the p53 Network Genes 14-3-3{tau} and<br />
CD44 That Affect Sarcoma Incidence and Survival. Cancer Res. 2010; 70(1):172-80.<br />
Bache M, Kappler M, Wichmann H, Rot S, Hahnel A, Greither T, Said HM, Kotzsch M, Würl<br />
P, Taubert H, Vordermark D. (2010) Elevated tumor and serum levels of the hypoxiaassociated<br />
protein osteopontin are associated with prognosis for soft tissue sarcoma<br />
patients. BMC Cancer. 10:132.<br />
Eckert AW, Schubert J, Taubert H. Optimising the therapeutic ratio in head and neck cancer.<br />
Lancet Oncol. 2010 Jun;11(6):511-2. (letter/author reply)<br />
Eckert AW, Schutze A, Lautner MH, Taubert H, Schubert J, Bilkenroth U. HIF-1a is a<br />
prognostic marker in oral squamous cell carcinomas. Int J Biol Markers. 2010 Apr-<br />
Jun;25(2):87-92.<br />
Eckert AW, Lautner MHW, Schuetze A, Bolte K, Bache M, Kappler M, Schubert J, Taubert H,<br />
Bilkenroth U. (2010) Co-expression of Hif1a and CAIX is associated with poor prognosis in<br />
oral squamous cell carcinoma patients. J Oral Pathol Med. 39(4):313-7.<br />
Hahnel A, Wichmann H, Kappler M, Kotzsch M, Vordermark D, Taubert H, Bache M. Effects<br />
of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cells. Radiat<br />
Oncol. 2010;5:82.<br />
Grochola LF, Müller TH, Bond GL, Taubert H, Udelnow A, Würl P. MDM2 SNP309<br />
Associates With Accelerated Pancreatic Adenocarcinoma Formation. Pancreas. 2010<br />
Jan;39(1):76-80.<br />
146
2009<br />
Hoffman AC, Danenberg KD, Taubert H, Danenberg PV, Wuerl P. A three-gene signature for<br />
outcome in soft tissue sarcoma. Clin Cancer Res. 2009 15(16):5191-8.<br />
Bluemke K, Bilkenroth U, Meye A, Fuessel S, Lautenschlaeger C, Goebel S, Melchior A,<br />
Heynemann H, Fornara P, Taubert H. Detection of circulating tumor cells in peripheral blood<br />
of patients with renal cell carcinoma correlates with prognosis. Cancer Epidemiol Biomarkers<br />
Prev 2009; 2009 Aug;18:2190-4.<br />
Grochola LF, Vazquez A, Bond EE, Würl P, Taubert H, Müller TH, Levine AJ, Bond GL.<br />
Recent Natural Selection Identifies a Genetic Variant in a Regulatory Subunit of Protein<br />
Phosphatase 2A that Associates with Altered Cancer Risk and Survival. Clin Cancer Res.<br />
2009;15(19):6301-8.<br />
Schmidt H, Taubert H, Lange H, Kriese K, Schmitt WD, Hoffmann S, Bartel F, Hauptmann<br />
S.Small polydispersed circular DNA contains strains of mobile genetic elements and occurs<br />
more frequently in permanent cell lines of malignant tumors than in normal lymphocytes.<br />
Oncol Rep. 2009 Aug;22:393-400.<br />
Seifert A, Taubert H, Hombach-Klonisch S, Fischer B, Navarrete Santos A.: TCDD mediates<br />
inhibition of p53 and activation of ERalpha signaling in MCF-7 cells at moderate hypoxic<br />
conditions. Int J Oncol. 2009;35:417-24.<br />
TRAINING OF GRADUATE AND MEDICAL STUDENTS<br />
147
DEPARTMENT OF INTERNAL MEDICINE 5<br />
(Haematology / Oncology)<br />
Head: Andreas Mackensen, Prof. Dr. med.<br />
<strong>Research</strong> Cellular Immunoregulation<br />
Group: Evelyn Ullrich, Prof. Dr. med.<br />
Address: Department of Internal Medicine 5<br />
Ulmenweg 6<br />
D-91054 Erlangen<br />
Telefone: + 49 (9131) 85 43091<br />
Fax: + 49 (9131) 85 35958<br />
E-mail: evelyn.ullrich@uk-erlangen.de<br />
Homepage: http://www.medizin5.uk-erlangen.de<br />
Postdoctoral Fellows<br />
Ruth Bauer, Dr. rer. nat.<br />
Doctoral Students (Biology)<br />
Kathrin Meinhardt<br />
Johanna Rothamer<br />
Doctoral Students (Molecular Medicine)<br />
Stephanie Krieg<br />
148
<strong>Research</strong><br />
Technicians<br />
Julia Schneider<br />
Franziska Ganß<br />
Our group analyses human and murine natural killer cells in different lymphoid and<br />
non-lymphoid organs. NK cells are a heterogeneous population of immune cells with<br />
cytotoxic capacity and multiple immunoregulatory properties. Until recently, studies<br />
on human NK cells have been mainly focused on NK cells from peripheral blood. The<br />
project based in the <strong>Nikolaus</strong>-<strong>Fiebiger</strong>-Center aims to characterize the genomic,<br />
phenotypical and functional profile of human NK cell subsets from different organs<br />
with a special interest in early forms of thymic NK cells in comparison to mature<br />
peripheral blood NK cells from adults and children.<br />
Phenotypical, functional and genomic analyses of human NK cell<br />
subpopulations<br />
Human NK cells can be classified according to the expression of CD56 and CD16<br />
into immunoregulatory, cytokine producing CD56 high CD16 dim and mature cytotoxic<br />
CD56 dim CD16 high NK cells. In contrast to murine NK cell subpopulations that have<br />
been extensively studied in different compartments, studies on human NK cells have<br />
been mainly focused on NK cells from peripheral blood. Little is known about the<br />
functional role of human NK cell subpopulations in different lymphoid organs.<br />
Therefore, a translation of murine studies, mainly performed on splenic NK cells, into<br />
the human system remains quite difficult. In our first analyses of human NK cell<br />
subsets from peripheral blood, spleen, bone marrow, and thymus, we observed<br />
relevant differences concerning the distribution of CD56 high CD16 dim and<br />
CD56 dim CD16 high NK cells. In addition, the expression of functionally relevant surface<br />
molecules varies on the NK cell subsets.<br />
One important observation from our phenotypic analyses was that especially the<br />
composition of NK cell subpopulations in the thymus differs in particular from those in<br />
spleen and peripheral blood. For that reason that thymus is already well-known for<br />
being an organ for immune cell development, we further focused on the<br />
characterization of thymic NK cells. NK cells from thymus have not only a lower<br />
CD56-expression but also a different ratio of CD16 high / CD16 dim NK cells compared<br />
to peripheral blood NK cells (Fig.1). While peripheral blood NK cells from adults have<br />
a ration of 10 / 1, children have a ratio of only 4 / 1 and those of child thymus have an<br />
even lower ratio of < 1 (Fig.2).<br />
149
Fig. 1 FACS analysis of NK cell subpopulations in child PBMC and<br />
thymic MNC. Two populations can be distinguished according to<br />
the expression of CD56 and CD16. CD16 dim thymic NK cells have a<br />
lower CD56-expression compared to peripheral blood NK cells.<br />
Importantly, the NK cell subset ratio shows an age-dependency that differs in<br />
peripheral blood and thymus. Especially the number of CD16 dim immunoregulatory<br />
NK cells increases in thymus, but decreases in peripheral blood with age so that the<br />
ratio of CD16 high / CD16 dim NK cells increases in total (Fig.2). This process might be<br />
explained by acquisition of surface molecules that regulate migration, homing and<br />
differentiation of early forms of NK precursors, immature, immunoregulatory or<br />
mature NK cells.<br />
Fig. 2 Ratio of CD16 high / CD16 dim NK cells in peripheral blood and<br />
thymus of children. This NK subset ratio is lower in thymus and<br />
showed a negative correlation with increasing donor’s age.<br />
To get further insights, we performed microarray analyses that will provide us with<br />
detailed information on the gene expression profile of NK cell populations from<br />
different organs. In addition to the genomic and phenotypical analysis, we<br />
investigated the cytokine production and cytotoxicity of these different NK cell<br />
150
subpopulations. Our data clearly demonstrates that NK cells from thymus as well as<br />
from peripheral blood of young children produce only low amounts of IFN-γ and need<br />
additional IL-2 stimulation to develop an antitumor capacity that is still under<br />
averaged compared to adult NK cells (data not shown).<br />
In summary, this comparative study of NK cell subsets provides important information<br />
on the development and function of NK cells that will be of great value for the<br />
optimization of cellular therapy.<br />
Publications (2006-2011)<br />
Original Articles<br />
Ullrich E, Bosch J, Aigner M, Völkl S, Dudziak D, Spriewald B, Schuler G,<br />
Andreesen R, Mackensen A. Advances in Cellular Therapy: 5th International<br />
Symposium on the Clinical Use of Cellular Products, March 19 and 20, 2009,<br />
Nürnberg, Germany. Cancer Immunol. Immunother. 2009; Oct 28. [Epub ahead of<br />
print]<br />
Terme M, Ullrich E, Delahaye N, Chaput N, Zitvogel L. NK cell-directed<br />
therapies: from unexpected results to successful strategies. Nat.Immunol.<br />
2008;9(5):486-94.<br />
Ullrich E, Bonmort M, Mignot G, Jacobs B, Bosisio D, Sozzani S, et al. Transpresentation<br />
of Interleukin-15 dictates IKDC effector functions. J.Immunol.<br />
2008;180(12):7887-97.<br />
Mignot G, Ullrich E, Bonmort M, Menard C, Apetoh L, Taieb J, et al. The<br />
critical role of IL-15 in the antitumor effects mediated by the combination therapy<br />
imatinib and IL-2. J.Immunol. 2008; 180(10):6477-83.<br />
Ullrich E, Chaput N, Zitvogel L. Killer dendritic cells and their potential role in<br />
immunotherapy. Hormone and Metabolic <strong>Research</strong> 2008;40(2):75-81.<br />
Ullrich E, Bonmort M, Mignot G, Kroemer G, Zitvogel L. Tumor stress, cell<br />
death and the ensuing immune response. Cell Death.Differ. 2008;15(1):21-8.<br />
Ullrich E, Menard C, Flament C, Terme M, Mignot G, Bonmort M, et al.<br />
Dendritic cells and innate defense against tumor cells. Cytokine Growth Factor Rev.<br />
2008; 19(1):79-92.<br />
151
Ullrich E, Bonmort M, Mignot G, Chaput N, Taieb J, Menard C, et al. Therapy-<br />
Induced Tumor Immunosurveillance Involves IFN-Producing Killer Dendritic Cells.<br />
Cancer Res. 2007;67(3):851-3.<br />
Taieb J, Chaput N, Menard C, Apetoh L, Ullrich E, Bonmort M, et al. A novel<br />
dendritic cell subset involved in tumor immunosurveillance. Nat.Med. 2006;12(2):214-<br />
9.<br />
TRAINING OF GRADUATE AND MEDICAL STUDENTS<br />
Doctoral theses (Biology)<br />
Kathrin Meinhardt<br />
Isolation and characterization of murine NK cell subpopulations in vitro und in vivo<br />
Johanna Rothamer<br />
Investigation of the role of TH17 cells in a murine model of GVHD<br />
Doctoral theses (Molecular Medicine)<br />
Stephanie Krieg<br />
Functional, phenotypical und genomic analyses of human NK cells subpopulations<br />
152
AG Wiesener<br />
Department of Nephrology and Hypertension<br />
Group leader: Michael Wiesener, Prof. Dr. med.<br />
Address: Hypoxia <strong>Research</strong> Group<br />
Glückstr. 6<br />
D-91054 Erlangen<br />
Telefone: + 49 (9131) 85 36353<br />
Fax: + 49 (9131) 85 39209<br />
E-mail: michael.wiesener@uk-erlangen.de<br />
Karl Knaup, Dr. rer. nat.<br />
Ruth Schietke, Dr. rer. nat.*<br />
* period of time reported<br />
Head<br />
Michael Wiesener, Prof. Dr. med.<br />
Postdoctoral Fellows<br />
153<br />
Thomas Hackenbeck, Dr. rer. nat.
Tilman Jobst-Schwan<br />
Sina Grupp<br />
* period of time reported<br />
Juliana Monti*<br />
* period of time reported<br />
Doctoral Students (Medicine)<br />
Stefan Thieme<br />
Regina Günther<br />
Technicians<br />
Guest Scientists<br />
154<br />
-<br />
Johanna Stöckert
<strong>Research</strong><br />
The constant availability of molecular oxygen is crucial for function and survival of<br />
any cell and tissue of organisms of higher order. All mammalian cells investigated to<br />
date are capable of utilising an important adaptive mechanism, which is strongly<br />
influenced by oxygen tensions. Hypoxia-Inducible transcription-Factors (HIF) are<br />
activated by a decline of oxygen supply and stimulate numerous target genes that<br />
convey adaptation to hypoxia. This system is probably of great importance for the<br />
growth of solid tumours. Inactivation of the “von Hippel Lindau” tumour suppressor<br />
gene, which is part of the destruction apparatus of HIF, leads to strong upregulation<br />
of HIF in clear cell renal carcinoma. Importantly, early HIF activation may play an<br />
important role in tumorigenesis of VHL associated tumours. These tumours could<br />
therefore function as a model system to study causes and consequences of<br />
pronounced HIF expression.<br />
Our group mainly investigates the role and effect of overexpression of both HIFα<br />
subunits, HIF-1α and HIF-2α, in tumour tissues, cell culture models, as well as rodent<br />
models. The role of selected HIF target genes in tumour growth is being analysed.<br />
Genetically modified mice for HIF overexpression in the kidney have been generated,<br />
to investi-gate whether HIF plays a role in tumorigenesis.<br />
The role of HIF in renal epithelial cells and tumorigenesis<br />
Renal tubular HIF-2α expression requires VHL inactivation and causes fibrosis<br />
and cysts<br />
A number of publications have indicated tumorigenic potential of HIF, which may<br />
primarily concern HIF-2α and particularly for clear cell RCC. We have studied the<br />
expression patterns of HIFα isoforms in the renal tubules in detail. In three different<br />
species (mouse, rat and human) microenvironmental stimulation by hypoxia always<br />
leads to tubular HIF-1α activation, but never to HIF-2α stabilization. Since HIF-2α is<br />
widely expressed in human RCC and may be functionally more important in terms of<br />
tumorigenesis, de novo expression of HIF-2α may indicate an oncogenic switch of<br />
renal tubular cells. In line with this, we have studied two different kidney specific<br />
knockout models for the tumour suppressor VHL, which shows de novo expression of<br />
HIF-2α, next to HIF-1α. Thus, the deletion of VHL may enable expression of HIF-2α,<br />
which may have an oncogenic potential.<br />
We have therefore established transgenic mice for overexpression of HIF-2α in distal<br />
tubuli of the kidney, driven by the Ksp-Cadherin promotor (Schietke and Hackenbeck<br />
et al., PLoSOne 2012). We have not observed any malignant tumors in this model,<br />
but the transgenic HIF-2α animals develop an interesting phenotype at 12 months of<br />
age. The kidneys showed obvious morphological differences on the surface in<br />
155
comparison to the control animals. Control animals displayed a uniform and smooth<br />
kidney surface, whereas the kidneys of HIF-2 expressing mice had an irregular and<br />
rough appearance and a significantly reduced kidney weight as judged by kidney to<br />
body weight ratio.<br />
Histological analysis of the kidneys from the transgenic mice showed a strong<br />
increase of fibrotic tissue in comparison to healthy kidneys and an increase of<br />
fibrosis-associated genes like TGFβ1. We additionally determined plasma<br />
parameters for renal function. Furthermore, transgenic mice had significantly<br />
increased creatinine levels confirming impaired renal function (Fig. 1)<br />
Figure 1: Renal tubular HIF-2α expression induces fibrosis and results in reduced kidney<br />
function. A. Immunohistochemical analysis of HIF-2α and collagen I in a kidney from a transgenic<br />
HIF-2 expressing mouse. B. Blinded analysis of renal fibrosis after SiriusRed (total collagen) staining<br />
C. mRNA expression (RT-PCR) of TGFβ1 from total kidney lysates. D. Kidney function as a<br />
measurement of serum creatinine of transgenic HIF-2α mice (* p < 0.05). All figures: tmHIF-2α.HA(-):<br />
transgen negative; tmHIF-2α-HA(+): transgen positive.<br />
In addition to the fibrotic phenotype, the histological analysis of the tmHIF-2α.HA(+)<br />
transgenic mice revealed frequent formation of cysts in the renal cortex, which was<br />
not observed in the control strain (Fig. 2).<br />
156
Figure 2: Renal cyst development in aged HIF-2α transgenic mice. 12 month and older HIF-2α<br />
expressing mice develop multiple renal cysts, mainly in the kidney cortex. These partly form around<br />
glomeruli, where the glomerular tuft can be seen (arrows in A). Other cysts arise from distal tubular<br />
segments.<br />
In summary we could demonstrate, that continuous transgenic expression of HIF-2α<br />
by the Ksp-Cadherin promotor leads to renal fibrosis and insufficiency, next to<br />
multiple renal cysts. Our data cleary show, that unphysiological activation of HIF<br />
contributes to renal epithelial dedifferentiation.<br />
Differential role of HIFalpha subunits<br />
HIF-1 or HIF-2 induction is sufficient to achieve cell cycle arrest in NIH3T3<br />
mouse fibroblasts independent from hypoxia<br />
Hypoxia is a severe stress which induces physiological and molecular adaptations,<br />
where the latter is dominated by the Hypoxia-inducible transcription Factor (HIF). A<br />
well described response on cellular level upon exposure to hypoxia is a reversible<br />
cell cycle arrest, which probably renders the cells more resistant to the difficult<br />
environment. The individual roles of hypoxia itself and of the isoforms HIF-1α and<br />
HIF-2α in cell cycle regulation are poorly understood and discussed controversially.<br />
In order to characterize the isolated effect of both HIFα isoforms on the cell cycle we<br />
generated tetracycline inducible, HIF-1α and -2α expressing NIH3T3 cells<br />
(Hackenbeck et al., Cell Cycle 2009). The cDNAs for HIFα were mutated to generate<br />
stable and active HIF under normoxia. Upon activation of both HIFα subunits, the<br />
total number of living cells was reduced and long-term stimulation of HIF led to<br />
complete loss of transgene expression, implicating a strong negative selection<br />
pressure. Equally, colony forming activity was reduced by activation of both HIFα<br />
subunits. Cell cycle analyses showed that HIF activation resulted in a prominent cell<br />
cycle arrest in G1-phase, similarly to the hypoxic effect. Both, HIF-1α and HIF-2α<br />
157
were able to induce the expression of the cyclin-dependent kinase inhibitor p27 on<br />
reporter gene and protein level.<br />
Our study shows that HIF-1 and HIF-2 can individually arrest the cell cycle<br />
independent from hypoxia. These findings have implications for the resistance of<br />
tumor cells to the environment and treatment, but also for physiological cells.<br />
Importantly, recent approaches to stabilize HIFα in normoxia could have deleterious<br />
effects on proliferating tissues.<br />
Regulation of HIF by the mammalian target of rapamycin (mTOR)<br />
Consequences of genetic mTOR activation on HIF expression<br />
Stabilisation of the Hypoxia Inducible Transcriptionfactor (HIF) is a global<br />
phenomenon in most solid tumors. The predominant regulation of HIF is controlled<br />
via a prolyl hydroxylase (PHD) mediated oxygen-dependent, posttranslational<br />
degradation. The PI3K/TSC/mTOR pathway is an alternative pathway, which is<br />
capable of enhancing HIF levels. mTOR itself is negatively regulated via the<br />
Tuberous Sclerosis Complex (TSC), which consists of and is only functional in<br />
combination of both subunits (TSC1 and TSC2). In the disease of “Tuberous<br />
Sclerosis” (TS) patients harbour a heterozygous germline mutation of either the<br />
TSC1 or TSC2 gene. Due to a somatic “second hit” these individuals develop a<br />
variety of tumors, including angiomyolipomas of the kidney. Our study aims to<br />
analyze the impact and the consequences of this genetic mTOR activation on HIF<br />
accumulation. We are approaching this by pursuing three experimental avenues:<br />
1. in vitro analysis of the molecular mechanisms with an doxycyclin inducible siTSC2<br />
HeLa cell line (in cooperation with Dr. Kathrin Thedick, Albert-Ludwigs-University of<br />
Freiburg) shows that HIF is stabilized quicker, if there is previous mTOR activation to<br />
hypoxic exposure. (Fig. 3).<br />
158<br />
Fig. 3: Immunoblots of doxycyclin inducible<br />
siTSC2 HeLa cells. TSC2 reduction leads to an<br />
(A) activation of mTOR by increased rpS6<br />
phosphorylation at Ser 235/236 and (B) an<br />
earlier accumulation of HIF-1α under mild<br />
hypoxia (3% O2). ß-actin is implied as a loading<br />
control.
Apart from our previously described interplay of the mTOR and the HIF system<br />
(Knaup et al., Mol Canc Res 2009) this supports the thesis of an oxygen independent<br />
regulation pathway of HIF by mTOR.<br />
2. Immunohistochemical analysis of the mTOR and the HIF pathway in kidney samples<br />
of patients with TS reveals an unphysiological HIF accumulation in the tubules.<br />
This is probably due to the genetic inactivation of TSC and the resulting subsequent<br />
activation of mTOR (Fig. 4). Whether this unphysiological HIF expression in the<br />
healthy kidney directly influences the development and/or the growth of the tumors<br />
(angiomyolipomas) is subject of ongoing analysis.<br />
Figure 4: Immunohistohemical analysis of mTOR activation (P-rpS6) and HIF-1α stabilization in both<br />
angiomyolipoma and adjacent kidney samples from human tuberous sclerosis patients.<br />
HIF and the HIF target gene HIG2 (data not shown) are strongly expressed in angiomyolipomas.<br />
This could be due to either regional hypoxia as well as mTOR<br />
activation, possibly a combination of both scenarios.<br />
3. We are currently analysing the role of HIF activation in the tumor development and<br />
growth in a TSC2 knockout mouse model which was supplied to us by the group of<br />
Prof. T. Noda, Tokyo, Japan (Kobayashi, T. et al, Cancer Res. 1999 Mar<br />
15;59(6):1206-11).<br />
159
Figure 5: A. Kidney of a 7 months old TSC2 knockout mouse (supplied to us from the group of Prof.<br />
T. Noda, Tokyo, Japan), which developed a macroscopically visible tumor on the kidney surface. B.<br />
Morpholgical evaluation classifies this as being a papillary tumor. C and D. mTOR activation in the<br />
tumor can be detected by immunohistochemical staining of P-rpS6 (Ser 235/236).<br />
The knockout mice develop macroscopically visible tumors on the surface of the kidneys<br />
(Fig. 5, A). These tumors have papillary structures (B) and express high levels<br />
of phospho-rpS6 (Ser235/236) (C and D), which is a profound marker of mTOR<br />
activation. Our current data suggests that this genetic mTOR activation can enhance<br />
accumulation of HIF and therefore support tumor development and growth. We are<br />
currently analyzing the kidneys and the developing tumors of these mice in this<br />
context.<br />
In this ongoing study we hope to gain more insight into the molecular mechanisms of<br />
the mTOR-HIF pathway. Further, we are aiming to investigate the impact of<br />
pharmacological mTOR inhibition on tumor development and growth and its<br />
consequences on HIF expression and functionality in vitro and in vivo. Ongoing<br />
clinical studies with TS-patients and mTOR inhibitors are showing promising results,<br />
encouraging us in our effort to dissect the details and mechanisms of the mTOR-HIF<br />
interplay.<br />
Identification and characterisation of new HIF target genes<br />
In order to understand the function and mechanism of action of the HIF transcription<br />
factors it is important to characterise the spectrum of its target genes. We have<br />
previously performed affymetrix arrays to identify novel HIF-1α and HIF-2α targets<br />
(Warnecke et al., Exp. Cell Res. 2008) and selected a number of those for further<br />
analysis with potential functionality in tumor biology.<br />
160
The GTPase Rab20 is a HIF target with mitochondrial localization mediating<br />
apoptosis in hypoxia<br />
We were able to demonstrate that Rab20, which is a member of the Rab family of<br />
small GTP-binding proteins, regulating intracellular trafficking and vesicle formation,<br />
is a new HIF-1 target gene. Rab20 is directly regulated by HIF-1, resulting in rapid<br />
upregulation of Rab20 mRNA as well as protein under hypoxia. Furthermore,<br />
exogenous as well as endogenous Rab20 protein colocalizes with mitochondria.<br />
Knockdown studies revealed that Rab20 is involved in hypoxia induced apoptosis.<br />
Since mitochondria play a key role in the control of cell death, we suggest that<br />
regulating mitochondrial homeostasis in hypoxia is a key function of Rab20.<br />
Furthermore, our study implicates that cellular transport pathways play a role in<br />
oxygen homeostasis. Hypoxia-induced Rab20 may influence tissue homeostasis and<br />
repair during and after hypoxic stress. (Hackenbeck et al., Biochim Biophys Acta<br />
2011).<br />
The lysyl oxidases LOX and LOXL2 are necessary and sufficient to repress Ecadherin<br />
in hypoxia: insights into cellular transformation processes mediated<br />
by HIF-1.<br />
In our array experiments, the lysyl oxidases Lox and LoxL2 showed a very high level<br />
of regulation, where LOX has previously been shown to be a HIF-1 target gene (Erler<br />
et al., Nature 2006). We were able to show that LOXL2 is a direct target as well. Both<br />
genes are very highly expressed in clear cell RCC and are involved in repression of<br />
the epithelial marker E-cadherin – a hallmark of the epithelial to mesenchymal<br />
transformation (EMT). EMT is of great importance for tumour cells to progress into an<br />
increasingly aggressive phenotype, as well as for diseased tissues into fibrosis. Thus,<br />
we believe that the lysyl oxidases represent a relevant mechanism in tumour biology,<br />
possible an effective area for pharmacological intervention (Schietke et al., J Biol<br />
Chem. 2010).<br />
Miscellaneous kidney related research projects<br />
The inhibitor of apoptosis protein surviving accumulates at the apical<br />
membrane of renal proximal tubules, which colocolises with megalin<br />
In the past report period we also analysed the inhibitor of apoptosis protein survivin<br />
and its role in kidney function. Survivin is a bifunctional molecule, which regulates<br />
cellular division and survival. A paradigm of a restricted oncofetal role for survivin has<br />
been formulated, where most of the published work implicates a function merely in<br />
embryonic and malignant tissues. In contrast, we have previously shown that survivin<br />
161
protein is highly expressed in the adult kidney, particularly in the proximal tubules and<br />
to a weaker extent in podocytes (Lechler et al., Am J Pathol 2007).<br />
We were able to confirm and expand our previous work, which identified survivin as<br />
being strongly present in healthy adult kidneys. Survivin predominantly accumulates<br />
at the apical membranes of proximal tubules, demonstrated clearly in vivo by<br />
immunostaining and electron microscopy. The apical localisation at the membrane of<br />
the proximal tubules reveals a pattern, which resembles that of many absorbed<br />
proteins. Survivin is a small protein of approximately 14 kDa which could, if<br />
circulating, be freely filtered by the glomerular apparatus. Many proteins in primary<br />
urine are internalised by megalin, an endocytosis receptor, of which the expression<br />
pattern is in principle comparable to the observed survivin pattern. Therefore, we<br />
generated a hypothesis of an active renal uptake mechanism for survivin, possibly by<br />
a megalin dependent process. We could clearly demonstrate in vitro, that polarised<br />
primary renal tubular cells store survivin at the apical membrane, which is true for<br />
both, endogenous and exogenously added recombinant survivin protein. Finally,<br />
knockout animals for renal megalin showed accumulation of survivin in their urine.<br />
We are currently in the process of preparing a manuscript for submission for these<br />
data (Jobst-Schwan et al.).<br />
Analyses of molecular causes of different genetic renal diseases<br />
We have recently been engaged in attempting to clarify the genetic cause of a<br />
number of hereditary diseases, which lead to end-stage renal disease. A moderate<br />
number of families are treated in our department, where we have undertaken linkage<br />
and locus analyses by next generation sequencing. We have identified families with<br />
medullary cystic kidney disease type 1 (MCKD1), as well as Alport´s disease and<br />
membranoproliferative glomerulonephritis, as well as so far uncharacterised<br />
hereditary diseases. These studies are ongoing. We hope to be able to take some of<br />
these genetic studies on to functional and molecular biology investigations after<br />
identification of the causative genes.<br />
2011/12<br />
Publications (2009-2011/12)<br />
Original Articles<br />
162
Buettner M, Xu H, Böhme R, Seliger B, Jacobi J, Wiesener M, Benz K, Amann K.<br />
Predominance of Th2 cells and plasma cells in polyoma virus nephropathy: a role for<br />
humoral immunity? Hum Pathol. 2012 Mar 8.<br />
Schietke RE, Hackenbeck T, Tran M, Günther R, Klanke B, Warnecke CL, Knaup<br />
KX, Shukla D, Rosenberger C, Koesters R, Bachmann S, Betz P, Schley G, Schödel<br />
J, Willam C, Winkler T, Amann K, Eckardt KU, Maxwell P, Wiesener MS. Renal<br />
tubular HIF-2α expression requires VHL inactivation and causes fibrosis and cysts.<br />
PLoS One. 2012;7(1):e31034.<br />
Hainz N, Thomas S, Neubert K, Meister S, Benz K, Rauh M, Daniel C, Wiesener M,<br />
Voll RE, Amann K. The Proteasome Inhibitor Bortezomib Prevents Lupus Nephritis in<br />
the NZB/W F1 Mouse Model by Preservation of Glomerular and Tubulointerstitial<br />
Architecture. Nephron Exp Nephrol. 2012;120(2):e47-58.<br />
Klinger P, Schietke RE, Warnecke C, Swoboda B, Wiesener M, Hennig FF, Gelse K.<br />
Deletion of the oxygen-dependent degradation domain results in impaired<br />
transcriptional activity of hypoxia-inducible factors. Transcription. 2011 Nov-<br />
Dec;2(6):269-75.<br />
Schley G, Klanke B, Schödel J, Forstreuter F, Shukla D, Kurtz A, Amann K, Wiesener<br />
MS, Rosen S, Eckardt KU, Maxwell PH, Willam C. Hypoxia-inducible transcription<br />
factors stabilization in the thick ascending limb protects against ischemic acute<br />
kidney injury. J Am Soc Nephrol. 2011 Nov;22(11):2004-15.<br />
Hackenbeck T, Huber R, Schietke R, Knaup KX, Monti J, Wu X, Klanke B, Frey B,<br />
Gaipl U, Wullich B, Ferbus D, Goubin G, Warnecke C, Eckardt KU, Wiesener MS.<br />
The GTPase RAB20 is a HIF target with mitochondrial localization mediating<br />
apoptosis in hypoxia. Biochim Biophys Acta. 2011 Jan;1813(1):1-13.<br />
2010<br />
Bernhardt WM, Wiesener MS, Scigalla P, Chou J, Schmieder RE, Günzler V, Eckardt<br />
KU. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J<br />
Am Soc Nephrol. 2010 Dec;21(12):2151-6.<br />
Gimm T, Wiese M, Teschemacher B, Deggerich A, Schödel J, Knaup KX,<br />
Hackenbeck T, Hellerbrand C, Amann K, Wiesener MS, Höning S, Eckardt KU,<br />
Warnecke C. Hypoxia-inducible protein 2 is a novel lipid droplet protein and a specific<br />
target gene of hypoxia-inducible factor-1. FASEB J. 2010 Nov;24(11):4443-58.<br />
Schietke R, Warnecke C, Wacker I, Schödel J, Mole DR, Campean V, Amann K,<br />
Goppelt-Struebe M, Behrens J, Eckardt KU, Wiesener MS. The lysyl oxidases LOX<br />
163
and LOXL2 are necessary and sufficient to repress E-cadherin in hypoxia: insights<br />
into cellular transformation processes mediated by HIF-1. J Biol Chem. 2010 Feb<br />
26;285(9):6658-69.<br />
2009<br />
Morris MR, Hughes DJ, Tian YM, Ricketts CJ, Lau KW, Gentle D, Shuib S, Serrano-<br />
Fernandez P, Lubinski J, Wiesener MS, Pugh CW, Latif F, Ratcliffe PJ, Maher ER.<br />
Mutation analysis of hypoxia-inducible factors HIF1A and HIF2A in renal cell<br />
carcinoma. Anticancer Res. 2009 Nov;29(11):4337-43.<br />
Bernhardt WM, Gottmann U, Doyon F, Buchholz B, Campean V, Schödel J,<br />
Reisenbuechler A, Klaus S, Arend M, Flippin L, Willam C, Wiesener MS, Yard B,<br />
Warnecke C, Eckardt KU. Donor treatment with a PHD-inhibitor activating HIFs<br />
prevents graft injury and prolongs survival in an allogenic kidney transplant model.<br />
Proc Natl Acad Sci U S A. 2009 Dec 15;106(50):21276-81.<br />
Weidemann A, Kerdiles YM, Knaup KX, Rafie CA, Boutin AT, Stockmann C, Takeda<br />
N, Scadeng M, Shih AY, Haase VH, Simon MC, Kleinfeld D, Johnson RS. The glial<br />
cell response is an essential component of hypoxia-induced erythropoiesis in mice. J<br />
Clin Invest. 2009 Nov;119(11):3373-83.<br />
Tanaka T, Wiesener M, Bernhardt W, Eckardt KU, Warnecke C. The human HIF<br />
(hypoxia-inducible factor)-3alpha gene is a HIF-1 target gene and may modulate<br />
hypoxic gene induction. Biochem J. 2009 Oct 23;424(1):143-51.<br />
Kroening S, Neubauer E, Wessel J, Wiesener M, Goppelt-Struebe M. Hypoxia<br />
interferes with connective tissue growth factor (CTGF) gene expression in human<br />
proximal tubular cell lines. Nephrol Dial Transplant. 2009 Nov;24(11):3319-25.<br />
Schödel J, Klanke B, Weidemann A, Buchholz B, Bernhardt W, Bertog M, Amann K,<br />
Korbmacher C, Wiesener M, Warnecke C, Kurtz A, Eckardt KU, Willam C. HIF-prolyl<br />
hydroxylases in the rat kidney: physiologic expression patterns and regulation in<br />
acute kidney injury. Am J Pathol. 2009 May;174(5):1663-74.<br />
Hackenbeck T, Knaup KX, Schietke R, Schödel J, Willam C, Wu X, Warnecke C,<br />
Eckardt KU, Wiesener MS. HIF-1 or HIF-2 induction is sufficient to achieve cell cycle<br />
arrest in NIH3T3 mouse fibroblasts independent from hypoxia. Cell Cycle. 2009 May<br />
1;8(9):1386-95.<br />
164
Wacker I, Sachs M, Knaup K, Wiesener M, Weiske J, Huber O, Akçetin Z, Behrens J.<br />
Key role for activin B in cellular transformation after loss of the von Hippel-Lindau<br />
tumor suppressor. Mol Cell Biol. 2009 Apr;29(7):1707-18.<br />
Knaup KX, Jozefowski K, Schmidt R, Bernhardt WM, Weidemann A, Juergensen JS,<br />
Warnecke C, Eckardt KU, Wiesener MS. Mutual regulation of hypoxia-inducible factor<br />
and mammalian target of rapamycin as a function of oxygen availability. Mol Cancer<br />
Res. 2009 Jan;7(1):88-98.<br />
Books and Reviews<br />
Wiesener MS, Maxwell PH, Eckardt KU. Novel insights into the role of the tumor<br />
suppressor von Hippel Lindau in cellular differentiation, ciliary biology, and cyst<br />
repression. J Mol Med (Berl). 2009 Sep;87(9):871-7.<br />
TRAINING OF GRADUATE AND MEDICAL STUDENTS<br />
Doctoral theses (Biology)<br />
Ruth Schietke (2009)<br />
Thomas Hackenbeck (2009)<br />
Doctoral theses (Medicine)<br />
Stefan Thieme<br />
Tilman Jobst-Schwan<br />
Sina Grupp<br />
Regina Günther<br />
165
TEACHING ACTIVITIES<br />
at the <strong>Nikolaus</strong>-<strong>Fiebiger</strong>-Center<br />
LECTURES, SEMINARS AND PRACTICAL COURSES<br />
Members of the <strong>Nikolaus</strong>-<strong>Fiebiger</strong>-Center participate in courses and lectures that are<br />
currently offered to students enrolled in the Graduate Programs in Biology at the<br />
School of Basic Sciences II (Naturwissenschaftliche Fakultät II) and in Molecular<br />
Medicine at the Medical School as well as to medical students. The focus is on basic<br />
and advanced molecular cell biology (Behrens, von der Mark, Müller) and basic and<br />
clinical immunology (Jäck).<br />
166
SEMINARS AND CONFERENCES<br />
at the <strong>Nikolaus</strong>-<strong>Fiebiger</strong>-Center<br />
Selection of Speakers since January 2009:<br />
NIKOLAUS-FIEBIGER-SEMINAR<br />
K. Förstemann, München<br />
Gene Regulation by Small RNAs- General Principles and Examples from Drosophila<br />
28.01.2009<br />
C. Stocking, Hamburg<br />
Activated FLT3 Tyrosine Receptor Kinase in Acute Lymphoblastic Leukemiea<br />
20.05.2009<br />
H. Urlaub, Göttingen<br />
Quantitative Mass Sepctrometry to Elucidate B Cell Receptor Signaling<br />
29.07.2009<br />
K. Toellner, Birmingham, UK<br />
Imprinting B Cells: Germinal Centres and Plasma Cells – Two sides of the Coin<br />
21.10.2009<br />
E. Izaurralde, Tübigen<br />
Mechansim of miRNA-mediated gene Silencing<br />
31.03.2010<br />
T. Nguyen, Paris<br />
The (pro)renin receptor: important for blood pressure and organ damage or just in<br />
development?<br />
23.02.2011<br />
G. Weidinger, Dresden<br />
Wnt-signaling in Development and Regeneration<br />
11.05.2011<br />
R. Renkawitz-Pohl, Marburg & S. Lindner, Hamburg, D. Mielenz, Erlangen<br />
Interdisciplinary Minisymposium<br />
18.05.2011<br />
R. Obst, München<br />
Timed antigen presentation and T cell responses<br />
25.05.2011<br />
M. Flajnik, Baltimore, USA<br />
Evolution of the Immune System<br />
15.06.2011<br />
167
G. Riemekasten, Berlin<br />
Systemic sclerosis as prototypic disease for functional autoantibodies against vascular<br />
receptors<br />
06.07.2011<br />
H. Bastians, Göttigen<br />
Mechanisms underlying Chromosomal Instability in Human Cancer<br />
12.07.2011<br />
N. Abdalah<br />
The interplay of behavior and adult neurogenesis for cognitive and affective disorders<br />
27.07.2011<br />
B. Blomberg, Miami, USA<br />
Molecular mediators of autonomous B cell deficiencies in aging mice and humans<br />
19.09.2011<br />
R. Blum, Würzburg<br />
The sodium channel Nav1.9 regulates activity-dependent axon growth and might serve as a<br />
target for axon regeneration and maintenance<br />
05.10.2011<br />
S. Herzog, Freiburg<br />
BIOSS – Centre for Biological Signaling Studies<br />
23.05.2012<br />
A. Blesch, Heidelberg<br />
Challenges and Opportunities in Spinal Cord Regeneration<br />
20.06.2012<br />
168